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The metabolic phenotype of cancer cells is dependent on the differential oxygen 
and nutrient distribution in the tumor microenvironment. These diminishing resources 
coupled with increased energetic and biosynthetic demands of tumor cells further 
encourage the upregulation of glycolysis with overexpression of related enzymes and 
transporters. This shift towards a more glycolytic character results in a disruption of the 
intracellular pH as the cell rapidly becomes more acidic. The accumulation of acidic 
byproducts like lactic acid requires new strategies to maintain cellular homeostasis 
resulting in the overexpression of transporters. These extracellular acidic byproducts are 
taken up by neighboring cells and are utilized for oxidative phosphorylation (OxPhos). 
Cancer cells often switch between glycolysis and OxPhos to meet the energy demands, 
termed as metabolic plasticity, which is driven by a necessity to avoid conditions that 
would induce apoptosis. For this reason, cancer cells express proton coupled 
monocarboxylate transporters 1-4 (MCT1-4). Specifically, these transporters have been 
found to be expressed in the most aggressive tumors and ultimately been linked to poor 
patient outcome. Hence, this transporter can be targeted for therapeutic intervention to treat 
a wide variety of cancers. 
 One well known MCT1 inhibitor α-cyano-4-hydroxycinnamic acid (CHC) has 




reduce tumor growth in mouse xenograft models. The therapeutic potential of CHC is 
hindered by its lack of efficacy at low concentrations and very high dose requirement for 
significant anticancer efficacy in vivo. In this regard, we have modified the CHC template 
with alkyl and aryl silyl substitutions and also introduced nitric oxide donors. These 
structural modifications have resulted novel candidate compounds which exhibit potent 
MCT1 and MCT4 inhibition and higher cell proliferation inhibition on several cancer cell 
lines. These drug candidates have also been evaluated for their effects on glycolytic and 
mitochondrial metabolic parameters. These studies have shown that all the lead derivatives 
have significant effects on both metabolic processes. Further in vivo preclinical evaluation 
of lead candidate compounds indicate that these compounds are generally well tolerated in 
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CHAPTER 1: Introduction 
 
CHAPTER 1: Introduction to Cancer Metabolism 
1.1 Cancer Heterogeneity and Hallmarks 
For the pursuit of effective therapeutics in the treatment of cancers, the emerging 
information and potential targets have exponentially expanded. A previously simplistic 
view of cancer progression being based on aberration and uncontrolled growth has 
compounded as the factors driving tumor promoting processes have been expanded upon. 
Now it is understood that tumor progression is a myriad of biochemical exchanges and 
recruitment of both cancerous and neighboring stromal fibroblast cells.1–4 The 
development from aberrant cellular growth to an aggressive malignancy is driven through 
genetic instability, biochemical, and physical signaling and their resulting downstream 
mechanisms. These factors help in the development of the heterogeneity in the tumor 
environment required to persist and overcome many impasses that would prevent such 
aberrant growth of endogenous cells.1,2 The various processes and tumor promoting 
environments have resulted in a need for categorizing and classifying these differences 
between the epithelial cancerous cells and stromal fibroblasts. The need for classification 
and defining these differences was satisfied through the landmark review Hallmarks of 
Cancer.5,6 These hallmarks are important for they represent a classification system that can 
be used to drive therapeutic development. One of the important hallmarks in cellular 
signaling promote dysregulation of cellular energetics making it an attractive target for 




factors are important for maintaining the bioenergetics and biosynthetic demands of rapid 
cellular proliferation. 
1.2 Overcoming energetic impasse 
Cancer progression favors cells that are capable of rapid proliferation, 
outcompeting the slow growing cells. This aberrant metabolic phenotype represents an 
impasse required for cellular progression as ATP production becomes a limiting factor. 
Normal cellular growth favors ATP production using oxidative phosphorylation (OxPhos). 
This is a more efficient process than glycolysis with the production of 32-36 moles of ATP 
for one mole of glucose.9 While efficient, this process requires the usage of a complex 
electron transport system and the establishment of proton gradients which are all contained 
in the mitochondria. Another process that cancer cells extensively utilize for swift ATP 
production is glycolysis. Contrary to OxPhos, the method of ATP production via glycolysis 
is dependent on enzymatic activity and can easily be modified via overexpression of 
glycolytic proteins. The preference for glycolysis in ATP production, even in a well 
oxygenated environment, has led to the identification of a new characteristic of cancer cells 
which is called aerobic glycolysis. One of the main reasons behind the preference of a 
glycolytic phenotype within late stage cancer cells is due to the flexibility and relative ease 
of rapid ATP production via glycolysis when compared to OxPhos.10–14 Previous studies 
have highlighted this preference, as cells were able to produce ATP quicker by 





Preference for glycolysis also addresses another concern of rapidly proliferating 
cells, the development of hypoxic regions. Initial development of solid tumors occurs 
within oxygen and nutrient rich environments provided from the vasculature system. Rapid 
proliferation leads to cells outgrowing the existing blood vessels and the formation of 
hypoxic pockets. Glycolysis imparts a natural advantage for it does not require oxygen for 
ATP production like OxPhos. This advantage leads late stage cells to depend on glycolysis 
as a main ATP productions source.11,16,17 The preference for glycolytic phenotype in cancer 
cells is a well observed phenomenon and has its own demerits that tumors must overcome 
in order to maintain and achieve a rapid proliferative advantage. 
1.3 Warburg Effect and the tumor’s dilemma 
The extracellular acidification was first recorded by Otto Warburg who postulated 
that the reduction of the pH of the culture medium was due to a more glycolytic cell line. 
This insight is why the phenomenon has been termed the Warburg Effect (WE).  The 
metabolic reprogramming that cancer cells undergo favors a dependency on glycolysis for 
most of the ATP production. One fundamental issue with glycolytic dependency is the need 
to maintain cellular homeostasis. The major byproduct of glycolysis is a surplus of lactic 
acid. Accumulation of lactic acid increases as a cell becomes more glycolytic resulting in 
apoptosis via cellular acidosis.18–20 In order to maintain cellular homeostasis, cancer cells 
begin to upregulate glycolytic transport proteins. The proteins of our specific interest are 
proton coupled transporters that export the abundance of lactate to the extracellular 






Figure 1a: The intratumoral symbiotic relationship based on lactate transport between 
aerobic OxPhos cells and glycolytic hypoxic cells.  
Aerobic glycolytic phenotype is an initial response to the ATP deficiency because 
of rapid cellular proliferation and further glycolytic dependency is stimulated by the 
formation of hypoxic regions as the tumor growth outpaces angiogenesis.12,13,21 The next 
problem as a result of increased acidic byproducts which is a rapid decrease in the 
extracellular pH. This represents another impasse as the rapid lowering of pH can result in 
the cellular death. To maintain the tumor microenvironment, aerobic cells import the 
excess lactate converting it into pyruvate and utilize it as an energy source for OxPhos. 
This metabolic symbiosis between hypoxic and aerobic cancer cells results in the optimal 
usage of glucose and maintenance of an acidic microenvironment (Figure 1a). The slight 
acidity of the tumor microenvironment is well documented and has been linked to pro-
oncogenic events like stimulation of angiogenic factors, invasion, metastasis, and reduction 




and out of the cell have been extensively studied and their over expression has been linked 
to treatment failure, relapse, and patient mortality.25 Their role in the maintenance of 
cellular energetics and tumor homeostasis makes them an excellent target for therapeutic 
intervention. 
1.4 Monocarboxylic acid transporters (MCTs) 
The MCTs belong to a family of the SLC16 gene that codes for a wide variety of 
different transporters. All the transporters of this family are proton-linked in the plasma 
membrane. Their role is to shuttle small monocarboxylic acids such as lactate, pyruvate 
and other ketone bodies across the cellular membrane.26,27 Within the SLC16 gene family, 
there are 14 known isoforms of MCT and it is known that MCT1 and MCT4 are critically 
involved in the symbiotic relationship of lactate transport between aerobic and hypoxic 
cells within the tumor.28 The MCT1 is a 40 kDa protein that spans 12 transmembrane 
domains with hydrophobic α-helical segments.29 The transmembrane nature of the protein 
makes it difficult to discern the crystal structure but there have been some good homology 
models created for the design of therapeutic derivatives.30,31 Differences in these 
transporters results in MCT1 favoring the export of lactate and MCT4 favoring the import. 
For this system, glucose is actively being taken up by the hypoxic cells for glycolysis and 
the aerobic cells become dependent on the extracellular lactate for most of their energy 
production. The role that MCT1 and MCT4 play in the maintenance of cellular homeostasis 
makes them attractive target for cancer treatment. MCTs are overexpressed in cancer cells 
due to their glycolytic switch, and only minimally expressed in normal tissues.32–34 




rapid decrease of intracellular and extracellular pH resulting in cellular acidosis and the 
development of intratumoral necrosis.35–38. 
1.5 Previously reported MCT1 and MCT4 inhibitors  
The α-cyano-4-hydroxy cinnamic acid (CHC) is a well-known inhibitor of MCT1 
for more than four decades (Figure 1b). Classically, its function has been reserved to plant 
growth regulation but has been gaining some attention due to its significant in vivo 
anticancer efficacy in various tumor models.12,35,39  
 
Figure 1b: Chemical structure of MCT1 inhibitor CHC. 
Anticancer efficacy studies using CHC were conducted by Sonveaux et al.  CHC 
was used in the treatment of SiHa, a human cervix squamous cell carcinoma, and WiDr, a 
human colorectal adenocarcinoma. It was found that the treatment with MCT1 inhibitor in 
vitro results in the reprogramming of the cells’ metabolic phenotype and cause cell death.39 
Furthermore, intraperitoneal administration in vivo at a concentration of 25 µM showed 
significant reduction in Lewis Lung carcinoma and WiDr xenograft models. A non-MCT1 
expressing cell line hepatocarcinoma TLT conducted in a syngenic Rj:NMRI mice did not 
exhibit any significant anti-cancer efficacy. This study supports the significance of MCT1 
inhibition for therapeutic effect in cancer treatment. The results presented in this study 
warranted further research and development of the potent CHC analogs and MCT 




Our lab synthesized a large library of CHC derivatives and evaluated for their in 
vitro MCT1 inhibitory potential and in vivo efficacy. The simplicity and tolerance of the 
Knoevenagel condensation with cyanoacetic acid allowed for rapid synthesis of novel CHC 
analogs based on a wide variety of benzaldehydes (Scheme 1a).  
 
Scheme 1a: Knoevenagel condensation of substituted benzaldehydes with cyanoacetic 
acid to form CHC based derivatives. 
A myriad of benzaldehydes was condensed with the cyanoacetic acid and the 
resulting products were evaluated for their MCT1 inhibition properties. Initial studies 
indicated that substitution of the p-hydroxyl group in CHC with electron withdrawing 
groups such as halides, CN, and NO2 and electron donating groups such as methoxy, 3,4-
methylenedioxy, alkyl, and N,N-dialkyl improved MCT1 inhibition compared to parent 
CHC. These results from MCT1 inhibition assay highlighted the importance of lipophilic 
alkyl/aryl substitution on the para position of the phenyl ring of CHC.  Especially, the 
MCT1 inhibition activity was enhanced when simple N,N-dialkyl groups such as methyl, 
ethyl, propyl, and butyl groups were introduced. Extending the lipophilicity to more than 
four carbons resulted in reduction of activity. The MCT1 inhibition properties were also 




Our further SAR studies indicated that introduction of a methoxy group at the ortho 
position to the cyano acrylic acid group further enhanced the efficacy of N,N-dialkyl CHC 
template (Scheme 1b). The results of this SAR along with other in vitro assays identified 
compound 1.6 for further preclinical development (Figure 1c).  
 








Studies into various modifications of the cyano (-CN), carboxylic acid (-CO2H) 
resulted in the lowered activity towards MCT1. Reduction of the double bond also lead to 
a complete loss of activity. As previously described, MCT4 plays a vital role in the 
metabolic symbiosis of intratumoral region (Figure 1a). Since the CHC based derivatives 
exhibited significant MCT1 inhibition activity, we envisioned the cyanoacrylic acid unit 
may also play a significant role in the inhibition of similar transporters such as MCT4. In 
this regard the most efficacious derivatives, o-methoxy N,N-dialkyl CHCs described in 
Figure 1c, were evaluated for their inhibition of MCT4. All the tested derivatives showed 
MCT4 inhibition activity similar to that of MCT1.30  
The N,N-diphenyl CHC (1.16) with a methoxy ortho substitution (Figure 1c) and 
the N,N-dibenzyl coumarin carboxylic acid were identified as a lead candidate compounds 
based on their selective inhibitory capacity towards MCT1 and/or MCT4. These 
derivatives have been identified as lead candidate compounds and selected for further 
preclinical development in vivo.  
Another structural analog that was found to have strong MCT1 inhibition was 
coumarin carboxylic acid. Owing to the importance of coumarin in providing 
pharmacological and pharmaceutical properties, our group also explored structurally 
similar but bicyclic aminocarboxy coumarin derivatives as potential MCT inhibitors. 
Modification of this structure started with various dialkyl substitutions to the amino group 
on the amino salicylaldehyde. Condensation of dialkylated salicylaldehydes with diethyl 
malonate followed by base hydrolysis and subsequent acidic workup provided dialkyl 




dialkyl aminocarboxy coumarins had increased specificity to MCT1 inhibition albeit lower 
than the CHC derivatives (Figure 1d). Interestingly, none of the coumarin derivatives have 
any significant MCT4 activity up to 1µM concentration except the lead dibenzyl derivative 
which has an IC50 of ~200nM.
38,40  
 







Figure 1d: List of the N,N-dialkyl aminocoumarin derivatives and their corresponding 
MCT1 inhibition activity. 
The candidate coumarin derivative 1.17 was evaluated in vivo in MCT1 expressing 
glioma cell line GL261-luc2 in C57BL/J6 mice and this compound exhibited significant 









Figure 1e: The in vitro and in vivo activity of the candidate compounds designed in the 
CHC and the coumarin based project.  
Based on the excellent in vitro MCT1 inhibition results from the dialkyl 
aminocarboxy coumarins, Draoui et al. conducted further preclinical development on these 
compounds. Initial evaluation using MCT1 uptake assays identified the most potent MCT1 
inhibitors 1.18 and 1.19 (Figure 1f). Further preclinical development of these derivatives 
via several anticancer efficacy studies on MCT1 expressing tumor models were carried out 










Figure 1f:  Structures of the lead coumarin based MCT1 inhibitors 1.18 and 1.19 
 Candidate compounds 1.18 and 1.19 were tested against SiHa based cervical tumor 
model and the HCT-116 colorectal model. Administration of 1.18 and 1.19 was at a dosage 
of 3 mg/Kg. Even at a low dosage, the candidate compounds exhibited significant 
anticancer efficacy against MCT1 expressing SiHa and HCT-116. As a negative control, 
candidate compounds 1.18 and 1.19 were tested against low MCT1 expressing UM-UC-3 
bladder cancer tumor model. The UM-UC-3 xenograft study did not have any significant 
reduction in the tumor burden highlighting the importance of MCT1 expression as a target 
for chemotherapy.38  
1.6 Competing MCT1 inhibitors for therapeutic applications 
Utilizing MCT1 as a potential target for therapeutic intervention is actively being 
investigated by other labs for the development of chemotherapeutics. The pharmaceutical 
company AstraZeneca has developed a series of MCT1 inhibitors. SAR study on 
thienopyrimidones had identified candidate compounds AZD3965 and ARC155858 
(Figure 1g). Both these inhibitors are selective towards MCT1 inhibition only and do not 
exhibit any MCT4 inhibition properties.41 The MCT1 efficacy was evaluated using L-





Figure 1g: Structures of AZD3965 and ARC158858 
The ARC155858 exhibited significant efficacy towards the transporter in rat 
erythrocytes and xenopus oocytes with Ki values of 2.3nm and 100nM, respectively. To 
evaluate the therapeutic potential of this enhanced efficacy for the transporter, ARC155858 
was screened against 64 different cancer cell lines from NCI. These derivatives were 
especially active against MCT1 expressing cell lines DLBCL, Burkitt’s lymphoma, and 
other haemotological cell lines that predominantly express MCT1. 42 
By carrying out further studies, the derivative AZD3965 was identified as the lead 
candidate compound. Anticancer efficacy studies were conducted with this compound in 
nonobese diabetic scid-γ mice xenografted with COR-L103 which was isolated from 
human lung small cell carcinoma. AZD3965 was administered at a dosage of 100mg/kg 
and the candidate compound exhibited ~60% tumor growth inhibition.43 Furthermore, 
immunohistochemistry studies on whole tumor after treatment found that AZD3965 caused 
increased intracellular lactate accumulation in the COR-L103 cells.  
Another preclinical evaluation of AZD3965 for its potential therapeutic benefits 
against a metastatic model was also carried out using luciferase-expressing CA46 Burkitt 




AZD3965 was administered at 100mg/kg with significant reduction in tumor burden and 
metastatic sites.44 These studies were enough to elevate the lead candidate compound to be 
filed as an investigative new drug. It is now currently in phase-I clinical trials for diffuse 
large B-cell lymphoma, Burkitt lymphoma, and other solid tumors.  
Investigation of substituted pteridine diones and triones  
Another SAR study in the pursuit of a more efficacious and selective MCT1 
inhibitor was conducted by Wang et al. In this SAR study, various substitutions on the 
pteridine diones and triones were employed and their effect on MCT1 activity was 
evaluated. MCT1 evaluation was conducted in MCF7 cell line that have been transfected 
to overexpress the MCT1 transporter. The synthesis of the inhibitors focused the 
importance of hydrophobic side groups to enhance the lipophilic characteristics of the 
derivatives. Furthermore, introduction of strategically placed hydroxyl groups into the 
template were found to have enhanced activity towards MCT1. 
Evaluation of the MCT1 inhibitory activity indicated that trione substitutions 
(MCT1 IC50: 548 nM) resulted in less activity when compared to the dione derivatives 
(MCT1 IC50: 116-192 nM). This was largely attributed to the placement of the hydroxyl 





Figure 1h: Structures of pteridine trione and diones. 
As seen with derivative 1.20, the hydroxyl tether is directed to the C5 nitrogen group. This 
significantly reduced the MCT1 selectivity and a higher IC50 value. When placed on the 
C6 carbon in the dione derivatives 1.21-1.23, there is a significant increase in the activity 
of the derivatives. This degree of selectivity is important for driving a more efficacious 
inhibitor for MCT1 activity. 
 The enhanced potency of the inhibitors also correlated with improved 
antiproliferative activity. These derivatives were tested against an MCT1 expressing cell 
line Raji lymphoma. The MTT assay supported the direct connection between MCT1 
inhibition and antiproliferative activity. The most potent MCT1 inhibitors had major 




candidate compounds and a scaffold for further SAR study for the preclinical development 
of a new therapeutics that could take advantage of the MCT1 transporter inhibition.45  
Pyrazole methylpropanoic acid derivatives as MCT4 inhibitors 
As further studies identify the therapeutic importance of MCT1 inhibitors, 
researchers have begun to conduct SAR studies to identify therapeutics that are selective 
to MCT4 transporter as well. In developing a more efficacy inhibitor for MCT4, a library 
of 2-((1-(2-chlorobenzyl)-5-(3-substituted phenyl)-1H-pyrazol-3-yl)methoxy)-2-
methylpropanoic acids were reported (Figure 1i). These derivatives exhibited excellent 
specificity towards the MCT4 activity.  
 
Figure 1i: Lead MCT4 inhibitor 2-((1-(2-chlorobenzyl)-5-(3-substituted phenyl)-1H-
pyrazol-3-yl)methoxy)-2-methylpropanoic acid 
A library of derivatives was evaluated for their MCT4 inhibition activity against 
the MCT4 expressing cell line MDA-MB-231. The pyrazole derivatives exhibited potent 
MCT4 inhibition in nM range. The pyrazole methylpropanoic acid (Figure 1i) was very 




derivative has excellent specificity as the IC50 for MCT1 was 5600 nM and was evaluated 
in the for MCT1 expressing BT20 cell line.  
1.7 Further development and improvements 
 While the CHC derivatives exhibited a significant reduction in tumor burden in vivo 
there is room for improvement in the PK/PD parameters of the drug. Furthermore, there is 
significant room for increasing the antiproliferative nature of these derivatives. One 
potential route is combining two anti-metabolic derivatives into one molecular aggregate. 
In previous research had hinted at the therapeutic advantage of an MCT inhibitor with 
another derivative causing mitochondrial disfunction. The proposed idea was to take a 
known MCT1 and MCT4 inhibitor syrosingopine and metformin which is a known 
derivative with selective inhibition of mitochondrial activity (Figure 1j). Metformin 
disrupts mitochondrial activity by targeting complex I in the electron transport chain. The 





Figure 1j: Proposed duel mechanism of action for inducing apoptosis in cells. 
The result of the study showed that MCT1 and/or MCT4 inhibition using 
syrosingopine resulted in significant increase in lactate accumulation. This led to inhibition 
of lactate dehydrogenase activity leading to a significant reduction in NAD+ regeneration. 
The inhibition activity of metformin on complex I resulted in a significant reduction in 
NAD+ regeneration via mitochondrial activity. The cumulative decrease in NAD+/NADH 
ratio severely hinders any ATP production within the cell and ultimately leads to cell 
death.46 This study supports the merits of utilizing a dual mechanistic approach in order to 
enhance the therapeutic potential of the MCT inhibitors. The incorporation of a 
mitochondrial disrupting functional group could potentially enhance the activity and 




Using MCT1 and MCT4 as potential targets for therapeutic intervention has been 
supported by successful development of therapeutics for cancer treatment. There are some 
areas for improvement on these inhibitors. The first of which is the pharmacokinetic 
properties of the derivatives. In most cases the inhibitors are found to be 99% protein bound 
and have a relatively quick clearance from the system.40 Furthermore, the derivatives were 
effective at reducing the tumor growth but do not exhibit any tumor elimination. The 
impact of the following projects is the improvement on the well-established MCT1 and 
MCT4 inhibitors by combing various chemical and biological approaches. These strategies 
aim to exploit the tumor microenvironment and over expression of various proteins for 
selective targeting of MCT1 and MCT4 inhibitors and the cytotoxic components coupled 
to them. The hypothesis is to develop derivatives with enhanced pharmacokinetic 





CHAPTER 2: Literature survey on the importance of silyl groups in improving the 
pharmacological and pharmaceutical properties of drug candidates 
2.1 Silicon as an emerging chemical entity for therapeutics development 
Most of the therapeutics created for the treatment of wide variety of diseases 
contain elements such as hydrogen, carbon, nitrogen, oxygen, sulfur etc. Recent therapeutic 
development has focused on expanding upon the classically used elements and 
incorporating other hetero atoms.  Silicon is the 14th element and is located under carbon 
in the periodic table. The proximity to each other help to highlight the chemical similarities 
between the two elements. Both elements have a valency of four and readily form 
tetrahedral compounds (Figure 2a).  
 
Figure 2a: Comparison of the four valance of silicon (purple) and carbon (gray) with 
simple methyl groups attached to the center atom. 
Where the two elements diverge is their ability to form π bonds. Carbon has a 
unique self-linking property called catenation, that allows it to form double and triple 
bounds. Furthermore, C-C bonds are very stable entities while Si-Si bonds are generally 
unstable. The Si-O bond is very stable when compared to the C-O bond and explains why 
silicon is naturally found as silicates instead of Si-Si complexes.47 These differences in 




of the two atoms. While carbon has an electronegativity of 2.55, the electronegativity of 
the silicon atom is 1.99. This difference results in a larger sharing of electrons between the 
silicon atom and those it binds to when compared to the carbon atom.  
Even with some major differences in the electronegativity and radii between the 
two elements, silicon has gained some attention as a bioisosteric replacement of carbon. 
Bioisosteres are elements or groups that exhibit similar physicochemical properties and are 
commonly used to improve pharmacological and pharmaceutical properties of a drug entity 
without changing the mechanism of action.48,49 The replacement of carbon with silicon is 
known as the “silicon switch” and this replacement could provide some therapeutic 
advantages.50 
The most prevalent advantage of the “silicon switch” is a change in the 
pharmacokinetic properties of the drug. Normal enzymatic reactions convert therapeutics 
into more polar metabolites that are water soluble and easily excreted. Enzymatic reactions 
require very specific chemical configurations of the ligands where substrates for metabolic 
clearance commonly involve carbon-oxygen, carbon-nitrogen, carbon-sulfur, nitrogen-
oxygen, and oxygen-hydrogen bonds. In contrast, silicon represents a foreign element that 
does not fit the normal configuration. The silicon atom has a different electronegativity 
resulting in a very different bond polarity because the silicon atom has a larger radius and 
the silicon bond length is almost 20% longer when compared to carbon.47 This change from 
carbon to silicon has been used to create new molecular entities with desired therapeutic 




One example is haloperidol which is commonly used as an antipsychotic drug but 
is metabolized readily into a pyridinium derivative that is a quaternary amine. This 
pyridinium metabolite has been found to cause neurotoxic side effects as it is a structural 
analog of the known neurotoxin 1-methyl-4-phenylpyridinium (MMP+).51 The bioisoteric 
replacement with the silicon atom in silahaloperidol results in a different metabolic 
pathway and metabolites (Figure 2b). The resulting metabolites do not include the 
pyridinium structure and therefore no neurotoxic effects are observed.  
 
Figure 2b: The antipsychotic drug haloperidol and its downstream neurotoxic metabolite.  
The silicon analog silahaloperidol has an alternative metabolic process that lacks 
the neurotoxic pyridinium structure.  Another example of the improved therapeutic 
potential by a “silicon switch” is with loperamide. This therapeutic is an antidiarrheal drug 
with three major metabolites that are stable under physiological conditions and the N-
desmethyl loperamide has been linked to increased cardiomyopathy and QTc 




change in the metabolism of the drug resulting in three new metabolites. One of the 
metabolites is highly water soluble and easily excreted (Figure 2c).51,53,54 The result of this 
high clearance metabolite is an overall reduction of the metabolite burden and potential 
reduction of cardiomyopathy and QTc elongation. 
 
Figure 2c: The two drugs loperamide and its silicon analog silaloperamide along with the 




The introduction of a silicon atom has another added benefit with an increase in the 
lipophilicity of the derivative. The silicon atom is more lipophilic when compared to 
carbon.55 This substitution has been linked to improved cell penetration and a better 
therapeutic potential.56 Furthermore, the blood-brain barrier represents a very difficult 
impasse for majority of anticancer agents. The diffusion of small molecules across this 
barrier is correlated to the lipophilicity of the drug. The replacement with a more lipophilic 
element has been connected to increased permeability of that drug across the blood-brain 
barrier. 57 This strategy was employed to enhance the transport of oxazolidinone antibiotics 
by incorporating the silicon atom (Figure 2d).  
 
Figure 2d: Substitution of the oxygen in linezolid to form the silinezolid. 
One study looked to improve the therapeutic potential of the antibiotic drug 
linezolid by replacing the carbon with silicon atom.58 It was found that replacement of the 
oxygen in the morpholine ring with silicon significantly increased the distribution of the 
compound in the brain when compared to the plasma. This increase in blood-brain barrier 
permeability has been attributed to the increased lipophilicity of the compound.58  
Lipophilicity also enhances the partitioning of drugs in vivo. The anticancer drug 




Incorporation of silicon entity increased the lipophilic nature of camptothecin resulting in 
increased partitioning into the red blood cells (Figure 2e). This increase partitioning in the 
red blood cells resulted in better distribution and a longer half-life of the silyl Camptothecin 
derivatives. 
   
Figure 2e: The difference between the Camptothecin and its more hydrophilic silicon 
analog Karenitecin. 
Furthermore, these derivatives were able to pass the blood-brain barrier more efficiently 







2.2 Silyl ethers-more than just a protecting group 
One of the more interesting properties of silylated derivatives is their usage as a 
prodrug. Silyl ethers can easily be cleaved yielding a hydroxyl group. Silyl ethers represent 
a class of protecting groups commonly used in organic chemistry. These protecting groups 
are used to prevent the undesired reaction of hydroxyl groups. There are many different 
variations of silyl ethers with varying degrees of stability. The general trend in stability is 
tightly correlated with the bulkiness of the functional groups and aromaticity (Figure 2f).61  
 
Figure 2f: Various silyl protecting groups and their relative stabilities under acidic 
conditions (1% HCl in MeOH) when compared to trimethyl silyl ether.  
The ease of reactivity of these derivatives combined with the variety of different 
hydrophobic derivatives have made them an attractive molecular entity to modulate the 
efficacy of chemotherapeutics. The usage of these derivatives led to an increase in the 
metabolic parameters such as stability and lipophilicity.55 Literature reviews indicate that 
silyl ethers incorporated into therapeutic agents such as testosterone and ephedrines which 
were evaluated for their drug latency properties. Drug latency is the selective and timely 
release of the drugs and is known to promote slow release so that the action is apparent 
over a longer period. This native latency was then compared to the latency of their silyl 
ether analogs. In all cases, a strong correlation was observed between the silyl protecting 




testosteroxytrimethylsilane analog extended the drug latency and maximal androgenic 
activity from 10 days to 30 days when administered in mice.62 These results support the 
importance of the silyl ether in enhancing the metabolic stability of a therapeutic (Figure 
2g). 
 
Figure 2g: Incorporation of the silyl ether for enhanced drug latency 
Another study investigated the silyl protection of methylephedrine, ephedrine, and 
norephedrine. Extensive studies were carried out on these silylated derivatives on the 
stability in phosphate-citrate buffers and partition coefficients. These results indicate that 
the selective release and hydrophobicity could be modified by changing the substituents on 
the silicon atom.63  
More recent studies into the practical therapeutic application using a pro-drug 
approach observed the enhancement of the antiproliferative activity of ureidoadenosine 
derivatives (Figure 2h). It is well documented that the hydroxyl ureidoadenosine is a 
potent inhibitor of the kinase BMPR1b but lacks any cytotoxicity in vitro.  This study 
indicated that protection of the hydroxyl groups of the ribose with silyl ethers resulted in 
enhanced antiproliferative effects. This improved activity was attributed to better lipophilic 
character after silyl ether incorporation. This silyl ether derivative also resulted in an 




also enhanced selectivity towards cancerous cells which highlights the potential therapeutic 
application of this group.  
 
Figure 2h: The prodrug silyl ether of ureidoadenosine  
The silyl ether facilitates the membrane penetration of the ureidoadenosine 
resulting in more accumulation of the drug within the cancer cells. Once in the cytoplasm, 
the silyl ether is cleaved yielding the potent hydroxyl ureidoadenosine which inhibits the 
BMPR1b signaling cascade.64  
2.3 Silyl Ethers as a targeted therapy:  
Literature reports show that the acidic microenvironment has been exploited for the 
selective delivery of chemotherapeutics. For example, acid liable functional groups such 
as trityls have been previously used in the selective delivery of a chemotherapeutic 
LY207702 which has acute cardiotoxicity.65 The theory behind the usage of trityls was that 
the linked trityl functional group would allow for the selective release of LY207702. The 
carrier was COL1 which is a murine IgG2a mAb that binds to CEA which is overexpressed 





Figure 2i: The structure of the chemotherapeutic LY207702 using an acid liable linker to 
COL1 for selective delivery to mitigate the cardiotoxicity. 
The trityl linked chemotherapeutic had selective release within acidic conditions of 
6.4-5.4 while relatively stable under physiological conditions with long t1/2 ranging from 
146 hours to 33 days. This derivative maintained its anti-proliferative character in vitro and 
exhibited similar antitumor effects against HCT1 based human colon carcinoma in mice. 
The novelty of this conjugation increased selectivity resulting in a reduction of the 
cardiotoxicity of LY207702. In vivo cardiotoxicity study also showed that the acid labile 
conjugate did not exhibit any cardiotoxicity in mice while the non-conjugated derivative 
exhibited some cardiotoxicity. The issue with this approach is that it is synthetically 
difficult and requires harsh conditions. Furthermore, the release window is longer requiring 
three hours for a significant release with any therapeutic benefit.  
Another example of using acid labile function groups for therapeutic intervention 




therapeutics into cancer cells. It was found that the proposed liposomes exhibited excellent 
stability under physiological conditions, but the resulting PEG vinyl ether was easily 
cleaved under acidic conditions. This acid labile property was integrated into their 
liposome carrier by incorporating it into diplasmalogen (DPPlsC). The new entity would 
result in a liposome of acid-sensitive DPPlsC encapsulating the vinyl ether with the target 
chemotherapeutic (Figure 2j).  
 





The hypothesis behind this modification was that the liposome carrier would 
transport the drug safely under physiological conditions. Upon exposure to the acidic 
microenvironment the drug would be released.  The synthesized vinyl ether PEG 
derivatives exhibited selective release under acidic conditions resulting in increased 
therapeutic uptake within the cancer cells. The resulting cleavage of the pegylated 
plasmalogen led to a lamellar-to-micellular phase transition (Lα-HI). The issue here is the 
difficulty of the chemistry required to form the acid liable lipids. Furthermore, there is a 
lack of flexibility due to limited PEG vinyl ethers67. 
 Another approach for selective delivery of chemotherapeutic via acid liable 
function groups was conducted on an anticancer agent doxorubicin. Previous studies have 
resulted in the synthesis of a doxorubicin pro-drug with an acid labile hydrazine.  
 
Figure 2k: The combination of doxorubicin with the protein L-HSA and the acid liable 




The doxorubicin derivative was linked to lactosaminated human albumin (L-HAS). The 
selectivity of L-HAS was attributed to the over expression of asialoglycoprotein receptors 
in the human hepatocellular carcinomas (HCCs). The result of this study was a selective 
pro-drug of doxorubicin that exhibited very little systemic toxicity when evaluated in mice. 
Furthermore, this study showed that there was selective accumulation of the drug in the 
liver at the site of the carcinoma. These results support the effectiveness of acid liable pro-
drugs, especially when linked to a targeted carrier such as L-HSA (Figure 2k).68   
Using a similar approach, the silylated protecting groups can be employed as acid 
labile groups. There are several advantages of this strategy compared to other acid labile 
groups. First advantage is the ability to “tune” the stability of the protecting group. As 
stated previously, the substituents on the silyl atom have a strong effect on the stability of 
the derivative prodrug under acidic conditions. If a quicker release is required, a prodrug 
that utilizes the TBS group could be used. If a longer and more stable derivative is required, 
the DPS protection group can be attached instead. Another advantage is the release of non-
toxic byproducts. Upon cleavage of the silyl protection group, the resulting silyl oxide by 
itself is not known to be toxic. Finally, the procedures and conditions required for the 
synthesis of the product are simple, mild and amenable to large scale synthesis.  
Previous research studied the incorporation of acid labile silicate groups to 
scaffolds that selectively target the tumor. In all cases, this was accomplished via a 
bifunctional silyl bridge (Figure 2l). Initial synthesis resulted in the coupling of a toxic 
chemotherapeutic such as camptothecin or gemcitabine to a polymerizable monomer like 




could couple the chemotherapeutic to a delivery particle of choice. This selective delivery 
of the chemotherapeutic was dependent on the linker. Various acid liable substitutions were 
incorporated into the linker region with varying results.69,70  
 
Figure 2l: Silyl ether a prodrug approach for selective delivery of toxic therapeutic agents 
to the tumor site for payload delivery of cancer chemotherapeutics.  
This selective releasing mechanism was also tested using mesoporous silica 
nanoparticles. Various silylated linking groups were used to tailor the release of the active 
drug camptothecin under weakly acidic conditions (pH 6.8), while no release was detected 
at a physiological pH of 7.4.69 In both studies, it was found that there was a significant 
increase in drug retention with the increase in bulkiness on the silyl group. The change in 
the R group from simple ethyl group to tButyl (Figure 2l) resulted in the difference in t1/2 
from 1.36 hours to 6995 hours.70  
2.4 Mitochondrial dysfunction via biomineralization of accumulated silyl ether  
A recent report on the therapeutic potential of simple silyl ether supported an 
interesting claim of the silyl ether template. In this study, silyl ether was coupled via a 
simple carbon chain to a quaternary triphenyl phosphonium salt. The triphenyl 
phosphonium salt is well known to act as a selective carrier to the mitochondria within 





Figure 2m: The synthesized triphenylphosphine silicate was transported into the cell and 
the silicate was hydrolyzed followed by biomineralization within the mitochondria 
leading to ROS release. 
Selective accumulation of silicate followed by hydrolysis were shown to result in 
condensation or biomineralization forming aggregates of the hydroxy silyl within the 
mitochondrial matrix. This biomineralization was supported using time dependent light 
scattering and in vitro TEM imaging techniques. Mitochondrial destabilization was also 
supported by mitotracker red imaging which showed fragmentation and membrane 
depolarization of mitochondria after exposure with the silylated derivatives. Translation of 
the study into SCC7 xenograft model yielded excellent therapeutic benefit with a 







CHAPTER 3 Synthesis and Evaluation of Novel Silylated CHC Derivatives as MCT1 
Inhibitors 
3.1 Rationale for proposed synthesis of silyl CHC derivatives 
Our previous SAR studies highlighted the importance of lipophilic functional 
groups in the para position of the CHC template in improving MCT inhibition properties. 
Although our previously reported N,N-dialkyl CHC derivatives exhibited potent and dual 
MCT1 and MCT4 inhibition properties,30,40,72–74 but they suffered from few drawbacks 
such as lack of potent cell proliferation inhibition, metabolic stability and lack of anticancer 
efficacy at low concentrations in highly aggressive tumor models. As reported in the 
literature, introduction of silyl groups has significantly improved pharmaceutical and 
pharmacological properties of several drug candidates. We envisioned that the “silicon 
switch” can enhance the lipophilicity of the inhibitors as the silicon atom is more lipophilic 
when compared to nitrogen of the dialkylamino CHC template. In this regard, we proposed 
to introduce alkyl and aryl silyl groups in place of N,N-dialkyl groups on CHC template 
with the goals to improve the lipophilicity, cytotoxicity, and if possible, selectivity towards 
cancer cells (Figure 3a).  
 





Within the CHC molecule, there is a phenol group at the para position which 
renders it labile for metabolic sulfonation and glucuronidation resulting in quick clearance 
from the system. The introduction of the silyl ether group could provide silyl CHC 
derivatives higher stability and improved pharmacokinetic properties. The proposed 
template represents a small SAR study to evaluate the effects of incorporating silyl groups 
into the para position of CHC and their relation to the MCT inhibition properties.  
Tumor progression and proliferation are highly dependent on metabolic plasticity 
between glycolysis and mitochondrial OxPhos. This ability to reprogram metabolic 
parameters to meet energy demands under unfavorable conditions is vital to survive in a 
dynamic tumor microenvironment. 75 This metabolic switch to a very flexible source of 
ATP production ultimately results in a dependency for cells found in hypoxic regions 
within the tumor. This upregulation of glycolytic enzymes and processes leads to an 
increased rate of lactic acid production. Rapid export of lactate is facilitated by MCT1 and 





Figure 3b: Graphical representation of distribution of oxygen in the tumor mass. The 
larger the tumor gets, the more hypoxic (blue cells) it becomes. This results in a buildup 
of the acidic by product lactic acid (H+) and a lower pH. 
We hypothesize that our proposed silyl derivatives would potently inhibit MCT 
function, enter cytoplasm efficiently, disrupt mitochondrial properties, and affect the 
metabolic plasticity that exists in many solid tumors. This in turn should effectively limit 
the options for ATP production stalling cell growth and inducing apoptosis in tumors.  
Synthesis of the silylated CHC (Scheme 3a) was performed by taking 
commercially available α-cyano-4-hydroxy cinnamic acid and protecting it using TBSCl 
and TBDPSCl in the presence of Hunig’s base. The silyl protected CHC derivatives 3.1a-
b were readily purified via ethyl acetate extraction followed by silica gel column 
chromatography. Attempts to attach the isopropyl protecting group TIPS were 
More hypoxic cells 




unsuccessful due to the low yield of formation and lack of the stability on the silica gel-
based column. The TBDPS 3.1a and TBS 3.1b protected derivatives were stable at room 
temperature and were purified using a base quenched silica gel column chromatography.  
 
Scheme 3 a: The synthesis of the directly attached silylated CHC derivative 3.1a-b 
  Next, we sought to investigate the effect of increased carbon content and 
lipophilicity on the activity of the silyl protected CHC derivatives. In this regard, we 
introduced a carbon linker chain which would increase the carbon content and potentially 
the lipophilicity. Furthermore, this substitution would also change the electron donating 
property in the para position and illustrate the electronic effects on MCT1 inhibition. There 
is a significant change in the electronegative properties associated with the bond of the p-
phenolic oxygen-silyl in compounds 3.1a and 3.1b when compared to p-phenolic oxygen-






Scheme 3b: The synthesis of the extended ethyl linked silylated CHC derivatives 3.5a-c 
and 3.3 
Synthesis of the silylated extended CHC derivatives started with 4-
hydroxybenzaldehyde in excess of chloroethanol (4 equivalent) in the presence of 




This derivative was then protected with TBS, TIPS, and TBDPS chlorides in the presence 
of imidazole yielding various silylated benzaldehydes 3.4a-c, respectively. Knoevenagel 
condensation with the benzaldehydes 2.4a-c in the presence of cyanoacetic acid yielded 
the desired silyl linked CHC derivatives 3.5a-c. The non-silylated CHC derivative 2.3 was 
synthesized by treatment of 11 with cyanoacetic acid under Knoevenagel condensation 
conditions.  
3.2 Evaluation of compounds 3.1a-b, 3.5 a-c, and 3.3 for in vitro antiproliferation 
activity:  
Synthesized CHC derivatives 3.1a-b, 3.5a-c, and 3.3 were evaluated for their 
antiproliferation properties against a MCT4 expressing triple negative breast cancer cell 
line MDA-MB-231. These derivatives were also tested against two MCT1 expressing cell 
lines; murine metastatic breast cancer cell line 4T1 and human colorectal cancer cell line 
WiDr. Furthermore, these five derivatives were tested against a non-cancerous human 
mammary epithelial cell line MCF10A. Cell proliferation was measured using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). The amount of MTT 
converted to formazan is an indication of cell viability which is measured at 570 nm 
wavelength.76 All these test compounds were diluted to a concentration of 500 µM except 
CHC. The lipophilicity of the silyl ether derived cyanocinnamates limits the solubility 
beyond this concentration. The difference in lipophilicity is essential for enhanced 
inhibition activity towards cell proliferation. Due to its polar phenolic hydroxy with 





Table 3a. Cell proliferation inhibition IC50*(µM) properties of compounds 3.1a-b, 3.5a-c, 
and 3.3.  
 MDA-MB-231 4T1 WiDr MCF10A 
3.1a 93±0 56±1 41±2 44±2 
3.1b >500 >500 >500 >500 
3.5a 71±1 22±1 6 ± 1 139 ± 7 
3.5b >500 82 ± 1 123±4 >500 
3.5c 134±5 41 ± 6 5 ± 1 75 ± 5 
3.3 >500 >500 >500 >500 
CHC 5300±130 3600±300 1100±96 >10000 







Figure 3c. Cell proliferation inhibition properties of compounds 3.1a-b, 3.5a-c and the 
non-silylaetd derivative 3.3. Values represent the average IC50 ± SEM (µM) of at least three 
independent experiments in (A) MDA-MB-231, (B) 4T1, (C) WiDr, and (D) MCF10A cell 
lines 
Compound 3.1a exhibited enhanced cell proliferation inibition properties with IC50 
values in the  range of 44-93 µM, which is a 100-fold increase in activity when compared 




seemed to be more effective against the MCT1 expressing cell lines WiDr (41 µM) and 
4T1 (56 µM) when compared to the MCT4 expressing cell line MDA-MB-231 (93 µM). 
The extended derivative 3.5a did provide some enhanced activity lowering the IC50 to 6-
71 µM. These derivatives also have higher potency towards MCT1 expressing cell lines. 
Interestingly, the extended derivative 3.5a exhibited selectivity towards the cancerous cell 
lines as the activity was greatly reduced in non-cancerous MCF10A cell line (139 µM).  
The TBS derivative 3.1b did not exhibit any cell proliferation inhibition even up to its 
maximum concentration of 500 µM. This trend was also seen in its extended derivative 
3.5b which had some enhanced activity against 4T1 (82 µM) and WiDr (123 µM), but was 
comparatively inferior compared to the other silylated CHC derivatives.  The extended 
derivatives 3.5a and 3.5c are similarly active against the MCT1 expressing cell lines 4T1 
and WiDr. Interestingly, there was a marked reduction in the cell proliferation inhibition 
of extended TIPS 3.5c when compared to WiDr (5 µM) to MDA-MB-231 (134 µM). The 
similarties between 3.5a and 3.5c can be extended to the selectivity in antiproliferative 
activity. Similarly, these two derivatives were not as effective against MCF10A cell line. 










3.3 Evaluation of 3.1a-b and 3.5a-b for MCT1 inhibition using 14C-lactate uptake 
assay:  
The incorporation of the silyl group in the para position seemed to greatly enhance 
the antiproliferation activity of the derivatives. We then evaluated these derivatives for 
their MCT1 inhibition properties using 14C-lactate uptake assay. The radiometric assay 
uses 14C-lactate and for the evaluation of MCT1 inhibition activity, an MCT1 expressing 
cell line rat brain endothelial 4 (RBE4) was chosen as previously reported.  
Table 3b. MCT1 IC50 values of compounds 3.1a-b and 3.5a-b.  











Figure 3d. MCT1 inhibition properties of compounds (A) 3.1a, (B) 3.1b, (C) 3.5a, and 
(D) 3.5b. Graphs represent the average IC50 ± SEM (µM) of at least three independent 




The results of the uptake assay highlight the importance of the hydrophobic region 
in the para position as there was a significant improvement on the MCT1 inhibitory 
properties of these derivatives when compared to the native CHC derivative (Table 3b, 
Figure 3c). The extended TBS derivative 3.5b exhibited the highest potency towards 
MCT1 inhibition with an IC50 of 0.01 µM. The more effective antiproliferative agent 3.1a 
expressed the lowest IC50 with 40-times reduction in activity (0.4 µM). In fact, the 
derivative with the lowest antiproliferatie activity, 3.1b (~0.1 µM) had enhanced MCT1 
inhibition properties when compared to 3.1a. The TBDPS linker derivative 3.5a also 
exhibited improved MCT1 inhibition properties compared to parent CHC with an IC50 
value of ~0.1 µM, comparable to 3.1b.  
3.4 Evaluation of the effect on the metabolic profile of WiDr and MDA-MB-231 cell 
lines when exposed to candidate compounds 
As discussed previously, metabolic plasticity is tightly controlled by the expression 
and activity of MCT1. The critical role that MCT1 plays in both glycolytic and 
mitochondrial activity can be understood by using the XFe Seahorse-based flux assays. We 
sought to evaluate cellular effects of compound treatment on these two energy pathways. 
In this regard, we evaluated the ability of compounds 3.1a-b, 3.5a-c, and 3.3 at disrupting 
both glycolysis and mitochondrial respiration. Various metabolic parameters can be 
modeled using the widely employed Seahorse extracellular flux assays. Specifically, due 
to the potential downstream effects of MCT1 inhibition, glycolysis and mitochondrial 




The assay was conducted by seeding MDA-MB-231 or WiDr cells into 96 well 
plates and incubating 16-24 hours before the experiment. Cells are washed with assay 
medium three times before the experiment. Assay medium consists of a base DMEM 
supplemented with L-glutamine and pyruvate. Before the experiments, the cells were 
acclimatized to the glucose free media for 20 minutes in the incubator. Initially the basal 
proton flux effects were recorded in glucose free conditions (Figure 3e). 
 
 
Figure 3e: Glycolytic profile of MCT1 expressing WiDr cell line with (A) 3.1a-b, 3.5a-b 
(B) 3.5c and 3.3. Against the MCT4 expressing cell line MDA-MB-231 with (C) 3.1a-b, 




Following initial reads, the cells were exposed to the test compounds setting a 
control read before induction of glycolysis. Next, glucose was added to the cells at a 
concentration of 10 mM. The introduction of glucose stimulates glycolysis within the cells 
resulting in a spike in the ECAR values. This increase in ECAR is used in the determination 








Figure 3f: Comparison of the glycolysis parameters calculated from glycolysis stress test 
assay in (A) MCT1 expressing WiDr cell line for compounds 3.1a-b, 3.5a-b and (B) 3.5c 
and 3.3. (C) MCT4 expressing cell line MDA-MB-231 for compounds 3.1a-b, 3.5a-b and 
(D) 3.5c and 3.3. Bar graphs represent the average ± SEM of at least three independent 





Interestingly, all silylated derivatives (3.1a-b and 3.5a-c) increased glycolysis 
significantly in WiDr cell line. In MDA-MB-231 cell line, this spike was not as significant 
compared to the control, but there was some significant effect after exposure to 3.1a and 
3.5a-c. Interestingly, the TBS silylated CHC derivative 3.1b did not exhibit any change in 
glycolysis and with the TIPS derivative 3.5c, change was significantly lower when 
compared to the other silylated CHC derivatives. This increase in glycolysis signifies a 
metabolic reprogramming of the cells due to 3.1a and 3.5a-c. This new observed glycolytic 
phenotype could signify mitochondrial dysfunction when treated with test compounds as 
the cells are more dependent on glycolysis after introduction of the compounds to the assay 
media. This could explain why the effect was significant in the WiDr cell line which 
depends more on OxPhos for ATP production when compared to the more glycolytic 
MDA-MB-231 cell line.  
The next drug introduced is the ATP synthase inhibitor oligomycin. This drug shuts 
down the main route of proton flow across the mitochondrial intramembrane space 
resulting in an increase in the proton gradient and subsequent stalling of the electron 





Figure 3g: Comparison of the glycolytic capacity parameters calculated from glycolysis 
stress test assay in (A) MCT1 expressing WiDr cell line for compounds 3.1a-b, 3.5a-b and 
(B) 3.5c and 3.3. (C) MCT4 expressing cell line MDA-MB-231 for compounds 3.1a-b, 
3.5a-b and (D) 3.5c and 3.3. Bar graphs represent the average ± SEM of at least three 
independent experiments. Statistical significance was calculated using repeated measures 




The resulting increase in ECAR is due to the shift away from ATP production 
through mitochondrial respiration. The cell now becomes dependent on glycolysis for most 
of its energy production and reaches its maximum glycolytic activity or the glycolytic 
capacity.  A reduction in the glycolytic capacity could be attributed to the MCT inhibition 
property of these derivatives. Effective inhibition of the efflux of lactate would limit the 
maximum rate of glycolysis as MCT1 is critical for maintenance of cellular homeostasis 
(Figure 1a). 
The apparent reduction in glycolytic capacity was seen in both WiDr and MDA-
MB-231 cell lines with all silylated CHC derivatives except with the TBS derivative 3.1b. 
The extended derivatives TBS (3.5b) and TIPS (3.5c) showed significant inhibition activity 
in both WiDr and MDA-MB-231. Interestingly, the derivative 3.1a had a significant 
reduction in its activity against the MDA-MB-231 cell line. Furthermore, its extended 
derivative 3.5a did exhibit reduction in the glycolytic capacity parameter. This could 
support the lack of MCT1 activity and the reduction in specific to bulkier DPS when 










Figure 3h: Comparison of the glycolytic reserve parameters calculated from glycolysis 
stress test assay in (A) MCT1 expressing WiDr cell line for compounds 3.1a-b, 3.5a-b and 
(B) 3.5c and 3.3. (C) MCT4 expressing cell line MDA-MB-231 for compounds 3.1a-b, 
3.5a-b and (D) 3.5c and 3.3. Bar graphs represent the average ± SEM of at least three 
independent experiments. Statistical significance was calculated using repeated measures 




The final parameter, glycolytic reserve, is the difference between basal glycolysis 
and the glycolytic capacity. It represents a cell’s ability to switch from its dependence on 
ATP production from OxPhos to complete dependence on glycolysis. In both cell lines 
WiDr and MDA-MB-231, there was significant reduction in the glycolytic reserve after 
exposure to 3.1a and 3.5b-c. In the case of 3.5c there was almost a complete elimination 
of the glycolytic reserve in both WiDr and MDA-MB-231 cell lines (Figure 2.1h).  
 
Figure 3i: Glycolytic profile of MCT1 expressing WiDr cell line with (A) 3.1a-b, 3.5a-b 
(B) 3.5c and 3.3. Against the MCT4 expressing cell line MDA-MB-231 with (C) 3.1a-b, 





Based on these results, we next evaluated the state of mitochondrial respiration via 
the mitochondrial stress test. The mitochondrial stress test is conducted in glucose-rich 
media. After initial exposure to the compound, the ATP synthase inhibitor oligomycin is 
added. This inhibition results in the mitochondrial respiration stalling as the main driving 
force of proton movement is ATP synthase. Without the ATP synthase, the electron 
transport chain stalls as the oxidative driving force of the electron transport chain is not 
enough to pump more protons against the steep gradient. This reduction in OCR gives an 













Figure 3j: Comparison of the ATP production parameters calculated from mitochondrial 
stress test assay in (A) MCT1 expressing WiDr cell line for compounds 3.1a-b, 3.5a-b and 
(B) 3.5c and 3.3. (C) MCT4 expressing cell line MDA-MB-231 for compounds 3.1a-b, 
3.5a-b and (D) 3.5c and 3.3. Bar graphs represent the average ± SEM of at least three 
independent experiments. Statistical significance was calculated using repeated measures 




In most of the silylated derivatives, there was a significant reduction in the ATP 
production via mitochondrial respiration in both WiDr and MDA-MB-231 cell lines. The 
DPS CHC derivative 3.1a exhibited significant reduction in ATP production in WiDr cell 
line but had slightly reduced activity in the MDA-MB-231 cell line. Interestingly, the 
extended DPS derivative 3.5a exhibited significant reduction in this parameter only in 
WiDr cell line whereas its activity in MDA-MB-231 was comparably less significant. The 
extended derivatives 3.5b and 3.5c had similar activity in WiDr and MDA-MB-231 cell 
lines. Interestingly, the directly attached TBS derivative 3.1b did not seem to affect the 
ATP production via mitochondrial respiration in either cell line.  
The study of TIPS substituted CHC derivative 3.5c against the unsilylated CHC 
derivative 3.3 clearly indicates that the presence of the lipophilic silylated group as opposed 
to the polar hydroxy group had higher impact on the ATP production. These results were 
true in both the WiDr and MDA-MB-231. TIPS derivative 3.5c had a significant reduction 
in the ATP production while the derivative 3.3 did not exhibit significant reduction in WiDr 
and only minor reduction in the MDA-MB-231 cell line.  
The next activity evaluated was the maximal respiration which can be calculated 
following addition of FCCP. The ionophore FCCP disrupts the intramembrane of the 
mitochondria resulting in the rapid efflux of protons down the gradient. The electron 
transport chain has a spike in activity as it tries to reestablish the proton gradient. The spike 





Figure 3k Comparison of the maximal respiration parameters calculated from 
mitochondrial stress test assay in (A) MCT1 expressing WiDr cell line for compounds 
3.1a-b, 3.5a-b and (B) 3.5c and 3.3. (C) MCT4 expressing cell line MDA-MB-231 for 
compounds 3.1a-b, 3.5a-b and (D) 3.5c and 3.3. Bar graphs represent the average ± SEM 
of at least three independent experiments. Statistical significance was calculated using 




The maximal respiration of both WiDr and MDA-MB-231 cell lines was 
significantly reduced after exposure to all derivatives except the TBS derivative 3.1b. 
When compared to the control, derivatives 3.1a and 3.5a-b where significantly more 
effective in the WiDr cell line when compared to the MDA-MB-231 cell line. There was 
little difference between the reduction in maximal respiration between 3.1a and 3.5a-b in 
both cell lines.  
In the study comparing the TIPS derivative 3.5c and the unsilylated derivative 3.3, 
it is apparent that the activity is enhanced by the presence of the silyl ether group. 
Interestingly, the unsilylated derivative 3.3 exhibited significant reduction in the maximal 
respiratory activity in MDA-MB-231 cell line. In WiDr cell line, there was no observed 
activity after exposure to 3.3.  
The next parameter spare respiratory capacity can be evaluated form the difference 
in maximal respiration and the respiration attributed to ATP production. The spare 
respiratory capacity is used to determine the plasticity of the cell via mitochondrial 





Figure 3l. Comparison of the spare respiratory capacity parameters calculated from 
mitochondrial stress test assay in (A) MCT1 expressing WiDr cell line for compounds 
3.1a-b, 3.5a-b and (B) 3.5c and 3.3. (C) MCT4 expressing cell line MDA-MB-231 for 
compounds 3.1a-b, 3.5a-b and (D) 3.5c and 3.3. Bar graphs represent the average ± SEM 
of at least three independent experiments. Statistical significance was calculated using 




As expected, derivatives that exhibited significant reduction in the maximum level 
of respiration also had a significant effect on the spare respiratory capacity. 3.5c completely 
eliminated the cells’ spare respiratory capacity. This means that the cancer cells had 
reached the maximum level OCR for ATP production. Interestingly, there was a significant 
reduction in the spare respiratory capacity with the unsilylated derivative 3.3 in the MDA-
MB-231 cell line. Outside of this result, there seems to be a strong indication of 
mitochondrial dysfunction within WiDr and MDA-MB-231 cells after exposure to the 













Figure 3m: Comparison of the spare respiratory capacity parameters calculated from 
mitochondrial stress test assay in (A) MCT1 expressing WiDr cell line for compounds 
3.1a-b, 3.5a-b and (B) 3.5c and 3.3. (C) MCT4 expressing cell line MDA-MB-231 for 
compounds 3.1a-b, 3.5a-b and (D) 3.5c and 3.3. Bar graphs represent the average ± SEM 
of at least three independent experiments. Statistical significance was calculated using 




The next parameter measured was the proton leak. This is a measure of the 
mitochondrial membrane structural integrity. The membrane is responsible for the 
establishment of a proton gradient to drive the ATP production via the ATP synthase 
complex. Structural damage to these membranes can result in proton leak. Therefore, this 
parameter might support drug induced mitochondrial dysfunction.  There was a substantial 
increase in proton leak with all derivatives in both WiDr and MDA-MB-231 cell lines 
except for the directly attached TBS derivative 3.1b. Interestingly, the derivative 3.1a 
seemed to exhibit a greater degree of proton leak when compared to its extended derivatives 
but was very closely tied for second with the extended TBS derivative 3.5b. This enhanced 
proton leak could support silyl ethers’ improved lipophilicity resulting in greater membrane 
permeability and subsequent targeting of the mitochondria. To understand the effect of 
these derivatives, the derivative 3.1a was chosen for it exhibited one of the greatest levels 
of proton leak and subsequent increase in glycolytic dependence.  
3.5 Assessment of mitochondrial damage using epifluorescence microscopy 
The extracelluar flux assay via Seahourse XFe analyzer supports the hypothesis 
that these derivatives have the potential to damage the mitochondria resulting in proton 
leak. Mitotracker Red CMXROS is a fluorescent small molecule that binds and 
accumulates in the mitochondria as a function of mitochondrial membrane potential.  This 
fluorophore is widely utilized to study the location,  morphology, and vitality of the 
mitochondria. We utilized epifluorescent microscopy technique to investigate the effect of 
compound treatment on the mitochondria.  Derivative 3.1a and its corresponding extended 




to understand the importance of a spacer group in the silylated CHC derivatives (Figure 
3o).  
 WiDr 
 DIC MTR Merge 
DMSO 
   
3.1a 
   
3.5a 
   
Figure 3o: Results after 24 hours of exposure to test compounds. The bright field image 
of WiDr after exposure to test compounds 3.1a and 3.5a or the vehicle DMSO.  
 
The fluorescence of the MTR dye following exposure along with the overlay 
between the brightfield image and the MTR dye. The fluorescence and DIC images were 
recorded with similar exposure times and neutral density filters. These epifloruescent 




changes due to the exposure to the compound on the mitochondria can be observed using 
mitotracker red and the cells morphology using DIC was also imaged. In the control 
images, the WiDr cell line has tightly packed mitochondria with very distinct groups within 
each cell. Furthermore, cells are tightly packed together rather then being spread out. The 
exposure to the DPS derivative 3.1a resulted in observable cell stress like blebbing and in 
some cases significant lysing events. Interstingly, with exposure to the extended DPS 
derivative 3.5a the cells are no longer able to keep their tightly packed formation anymore 
and can be seen floating. After exposure to both derivatives, it is apparent that the 
mitochondria is significantly stressed. The mitochondria is much more diffused throughout 
the cell which is indicative of signifcant loss of function in the mitochondria.  
The next cell line evaluated was the more glycolytic MDA-MB-231 which is also 
known to predominantly express the MCT4 protein. Similar to the WiDr study, the cells 
are exposed to the compounds over a 24 hour period of time. Following exposure, the cells 
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Figure 3p: Results after 24 hours of exposure to test compounds. The bright field image 
of MDA-MB-231 after exposure to test compounds 3.1a and 3.5a or the vehicle DMSO.  
 
The fluorescence of the MTR dye following exposure to 3.1a and 3.5a along with 
the overlay between the brightfield image and the MTR dye. The fluorescence and DIC 
images were recorded with similar exposure times and neutral density filters.  After 24 
hours of exposure to the compounds,  the MDA-MB-231 cells DIC and epifluorescent 




defined shapes and no indication of much blebbing. The epfluorescence shows healthy 
mitochondria forming tightly packed structures centered within the cell. When compared 
to the DMSO treated cells, it was apparent that cells were extremely stressed with balling 
up and in some cases lysing. The linked derivative 3.5a seemed to have a significant impact 
on the viability of the MDA-MB-231 cells as most of the cells had allready balled up and 
were becoming detached from the dish. Similarly, exposure to 3.1a had signifcant rounding 
up of the cells and also many lysing events were observed in the attached cells. The 
epifluorcence further supported this conclusion as the mitochondria was now spread out 
with no discernable clusters. All of the above-mentioned results are indications of 
significant dysfunction in the mitochondria after exposure to our compounds. 
3.6 Evaluation of DNA damage and apoptosis with 3.1a 
Mitochondrial damage, glycolytic deregulation, and inhibition of metabolite 
shuttling with the synthesized compounds may cause cancer cells to trigger programmed 
cell death pathways. Hence, we investigated the ability of the test compounds to turn on 
apoptotic pathways via common molecular proteins involved in this pathway including 
PARP-1, p53 and γ-H2AX. The protein PARP1 and specifically, its cleaved product Cl. 
PARP1 are strong indicators of early apoptotic events being triggered within the cell. The 
other protein γ-H2AX is an indication of double stranded breaks and DNA damage. DNA 
damage is also a strong indicator of apoptosis being pursued in the cells after exposure. 
The wild type p53 (wt-p53) is a transcription factor that binds to specific sequences in the 
DNA activating the transcription of the gene. In cancer cells mutant type p53 (mut-p53) is 




deffective transcription regulator that has a loss of normal activity. In fact there is strong 
support that the mut-p53 activates pro-oncogenic proteins resulting in unregulated growth 
and lack of tumor suppressing activity.77,78 There is potential for activation of wt-p53 via 
γ-H2AX especially in the presence of ROS induced DNA damage. This regain of p53 
expression could result in downfield apoptotic effects like increased caspase expression 
and induce apoptosis in cancer cells. In evaluating the potential events that could be 
happening intracellularly and whether the derivatives are inducing apoptosis, 3.1a was 
chosen for it had consistently exhibited significant antiproliferation charactersitics against 
all the cell lines tested. Furthermore, this compound showed significant effect in metabolic 
phenotype in the Seahorse Flux Assay. A concentration study was conducted to evaluate 
the lowest concentraiton that could exhibit the activation of these markers. Compounds 
were compared to the parent derivative CHC which has similar inhibitory property but 
lacks the antiproliferative character when compared to the silylated CHC derivatives, and 






Figure 3q: The western blot analysis after exposure to 3.1a in WiDr and MDA-MB-231 
cell lines at three different concentrations. The proteins probed for were p53, γ-H2AX, and 
PARP1.  
The silylated CHC derivative resulted in an increase in the expression of PARP 
cleaved product. This result indicated that these derivatives were causing apoptosis in the 
cells. Interestingly there is also expression of γ-H2AX after exposure to 3.1a at 100 µM. 
These results showed that DNA damage was observed at this concentration. Both MDA-
MB-231 and WiDr cell lines express an oncogeneic mutant form of p53, 77,79 and 
expression levels may vary depeding on the degree that each cell line depends on p53 for 
prolifereation. In MDA-MB-231 cells, there was a substantial concentration dependent 
increase in mut-p53 expression. This could indicate that the γ-H2AX expression is a 
downstream effect of the increase in mut-p53 expression as a result of reactive oxygen 
species (ROS) from mitochondrial damage.  Interestingly, in WiDr cells which also express 
mut-p53, an increase in p53 expression was not observed. This cell line did exhibit a similar 
trend in Cl. PARP1 and γ-H2AX when compared to MDA-MB-231 cell line, indicating 
    3.1a 




that apoptosis is being induced following exposure to our compounds. Interested by the 
western blots results, the potential mechanism for DNA damage was investigated. 71 
3.7 Assessment of potential ROS induced DNA damage through mitochondrial 
dysfunction with 3.1a 
Previous literature reports indicate that accumulation of deprotected silyl 
derivatives induced mitochondrial damage and increased ROS that may result in 
heightened levels of DNA damage.4 Phosphorylation of histone H2AX is the result of DNA 
damage which can be caused by many kinds of cellular stress. One potential cause of 
cellular stress is ROS release from damage mitochondria. The ROS can freely diffuse into 
the nucleus causing DNA damage resulting in the increase in γ-H2AX expression. 
Bioaccumulation of silicon atoms could stimulate ROS via mitochondrial damage resutling 
in the DNA damge and subsequent γ-H2AX expression. To test this theory, WiDr cell line 
was treated with the test compound in the presence of a known antioxidant and ROS 
scavenging agent N-actyl cystine (NAC) which will quench free radicals reducing any 
potential DNA damge they might cause. If ROS is the main source of DNA damage and 
subsequently γ-H2AX expression, then NAC treatment should reverse the expression of γ-





Figure 3r: NAC reverses 3.1a induced H2AX phosphorylation (A) western blot analysis 
of WiDr after exposure to NAC with or without 3.1a and (B) analysis of protein expression 
when compared to GAPDH. 
NAC by itself did not seem to affect the expression of the various apoptotic proteins 
sampled in the western blot. Furthermore, we observed that exposure to just the compound 
3.1a at 100 µM resulted in a similar set of expression as seen in the previous western blot 
analysis. Interestingly, in the combined exposure of NAC with 3.1a, there was a significant 
decrease in γ-H2AX. Densitometric analysis with GAPDH as a control showed a 10 fold 
decrease in γ-H2AX. Remarkably, this reduction in expression did not seem to effect the 
Cl. PARP1 expression indicating that while ROS seems to be present and causing DNA 
damage, it is not the reason for induced apoptosis within the cell. This result supports the 
theory that there is a dual mode of action within our silylated CHC derivative where both 






3.8 Systemic toxicity evaluation of candidate compounds 10a-c in CD1 mice 
Considering the excellent antiproliferation activities, MCT1 inhibition activity, and 
disruption of both glycolysis and OxPhos, compound 3.1a and its sister two carbon spaced 
derivative 3.5a were elevated to candidate compounds to be translated to in vivo systems. 
Before translation to a xenograft model, initial toxicity studies were conducted in healthy 
CD1 mice to evaluate the maximum tolerated dose (Figure 3p). 
 
Figure 3s: Candidate compounds used for translation into in vivo models for evaluation of 
chemotherapeutic potential.  
For solubility purposes, the silylated derivatives were converted into their 
corresponding sodium salts using sodium bicarbonate. The derivatives 3.1a and 3.5c had 
some trouble with solubility at high concentrations in just 10% DMSO in saline, so a 
formulation was used. The commonly used formulation was as follows: 10% DMSO, 10% 
PEG-400, 7.5% HS-15, and 72.5% water to guarantee full solubility when the compound 
is injected into the mice. The healthy CD-1 mice were purchased from Charles River and 
allowed to acclimatize for one week before administration of candidate compounds. The 
mice were assigned into groups (n=6 mice). Selection was based on the average weight of 
the group and mice were selected to ensure the average was consistent amongst all 




3.1a and 3.5c were administered daily at a dosage of 20mg/kg and the body weights of the 
mice were monitored to ensure the dosage was not causing any significant stress on the 
mice. The control group was given vehicle (10% DMSO, 10% PEG-400, 7.5% HS-15, and 
72.5% water) daily along with the administration of derivatives 3.1a and 3.5c. 
 
Figure 3t: Systemic toxicity of (A) 3.1a and (B) 3.5a in CD-1 mice at a concentration of 
25 mg/kg given i.p daily indicate normal body weight gains in treated mice when compared 
to the vehicle control. 
The derivatives 3.1a and 3.5c did not exhibit any significant reduction in body 
weights or visibly toxic side effects at the end of the study (Figure 3t). Encouraged by 
these results, the next step was to evaluate the efficacy of these candidate compounds in in 








3.9 Tumor growth inhibition study of 3.1a and 3.5a in WiDr xenograft 
Selection of candidate compound 3.1a and 3.5a for further translation was based 
on its excellent selectivity towards cancerous cell lines and its potent metabolic inhibitory 
profile. Furthermore, the “silicon switch” of the atom should reduce their susceptibility to 
CYP450 oxidation and elimination allowing the metabolic inhibitors to persist longer 
within the system.  
 
Figure 3u. In vivo WiDr xenograft model indicated significant reduction in (A) tumor 
volume when compared to vehicle treated mice. At the end of the study, tumors were 
resected and (B) weighed. Statistical significance of tumor growth inhibition was 
calculated using the Mann-Whitney test (*** P <0.001). 
The WiDr xenograft model was chosen for it is an MCT1 expressing cell line and 
was previously evaluated against the lead candidate compound for transport inhibition, cell 




The tumor growth was monitored every 2-3 days and after the tumor had reached 100 mm3 
the compound was administered. The mice were treated with 3.1a and 3.5a at a dosage of 
25 mg/Kg, intraperitoneally (i.p), once daily and treatment was continued for 14 days. Each 
day before injection, the body weights of the mice were monitored to ensure that the mice 
were not being negatively impacted by the treatment. The tumor volume was measured 
every three days to evaluate tumor reduction via candidate compounds. After 14 days, the 
mice were euthanized, and tumor masses were isolated and weighed. 3.1a exhibited a 
significant tumor growth inhibition, 36% by volume (Figure 3r) and ~30% by tumor mass 
(Figure 3r), when compared to the control group.  
3.10 Discussion 
Previously synthesized N,N-dialkyl/aryl CHC based MCT1 and MCT4 inhibitors 
showed significant anticancer effects in vivo at high concentrations (50 mg/kg or higher) 
due to lower biological half-life and lack of potent cell proliferation inhibition 
properties.40,74 To improve the therapeutic potential of these MCT inhibitors, the 
integration of alkyl and aryl silyl groups into the para position of the aromatic ring of CHC 
was pursued. This substitution greatly improved cell proliferation inhibition properties 
with IC50 values in low µM concentration against numerous tumorigenic cell lines. 
Furthermore, all the synthesized derivatives 3.1a-b and 3.5a-b maintained their potent 
MCT1 inhibition similar to N,N-dialkyl/ aryl CHC derivatives. Interestingly, there was not 
a direct correlation between MCT1 inhibition activity and an increased antiproliferative 




To evaluate the mechanism of action, the XFe Seahorse flux instrument was used 
to study the glycolytic and mitochondrial stress parameters after exposure to the 
compounds. The MCT1 expressing WiDr cell line and MCT4 expressing cell line MDA-
MB-231 were utilized for these studies. In WiDr cell line, there is a significant increase in 
glycolysis when exposed to silylated CHC derivatives 3.1a (Figure 3c). Our studies 
indicated that WiDr cell line is more OxPhos for ATP generation as opposed to MDA-MB-
231 cell line which has more glycolytic phenotype. The changes in glycolysis of the MDA-
MB-231 cell line was not apparent after the addition test compounds. The glycolytic 
capacity was significantly reduced in WiDr cell line when exposed to the silylated 
derivatives but not as effective in MDA-MB-231 cells. This could be attributed to the 
potent MCT1 inhibition property of the derivatives. The inhibition of the transporter would 
ultimately influence the cells’ ability to pursue glycolysis as a source of ATP production. 
Without the ability to maintain cellular homeostasis, the rapid increase in glycolysis is no 
longer a viable option for ATP production. This would effectively reduce the glycolytic 
capacity and the glycolytic reserve of the cancer cells.  
In the mitochondrial stress test, most of the parameters were significantly affected 
by the silylated CHC derivatives 3.1a and 3.5a-c. These results indicated that the 
derivatives caused significant stress on the mitochondria resulting in reduction of ATP 
production from its respiratory capacity. Furthermore, there was a significant spike in 
proton leak in both WiDr and MDA-MB-231 cell lines, which indicated significant 
mitochondrial dysfunction upon treatment with candidate compounds. This could also 




dependent on both glycolysis and mitochondrial activity for ATP production and as 
mitochondrial activity is reduced, the cell line pursued more glycolysis to meet the deficit 
in ATP production. In MDA-MB-231 cell line, glycolysis was already being pursued for a 
majority of its ATP production. This more glycolytic phenotype could mean that the cell 
is not going to experience a major glycolytic shift should the mitochondrial ATP 
production be significantly reduced.  
To further evaluate whether these derivatives were causing mitochondria 
dysfunction, the florescence microscopy studies were carried out. The studies using MTR 
dye supported the hypothesis that these derivatives were in fact causing mitochondrial 
dysfunction (Figure 3m). Furthermore, this assay indicated that there was significant 
cellular stress and apoptotic events being triggered after exposure to the compounds. This 
was later confirmed using western blot analysis as PARP1 cleavage was being observed 
after exposure to the candidate compounds. One theory was the apoptotic events were 
triggered via ROS signaling from the silicon induced mitochondrial dysfunction which 
could also explain the increase in γ-H2AX expression and DNA damage.71 The 
introduction of ROS signaling from the mitochondria was not the primary trigger of 
apoptotic events. It was found after exposure to the ROS quencher NAC, there were no 
observed changes in PARP1 cleavage indicating that apoptosis was being induced through 
other means. Although, NAC did cause a significant reduction in γ-H2AX expression 
supporting the theory that ROS was being induced and causing DNA damage in the cells. 
All the mechanism studies indicate that the candidate compounds effectively arrest the 




We then conducted in vivo systemic toxicity studies in CD-1 mice with candidate 
compound 3.1a and 3.5a. Initial toxicity study indicated that the derivatives could be 
administered at 20 mg/kg I.P daily for 14 days with no apparent stress on the mice. The 
treatment with candidate compound in a WiDr xenograft model in mice exhibited 
significant tumor reduction, both in volume and weight of the tumor. This result supports 









CHAPTER 4: Synthesis and evaluation of o-silylated p-amino CHC derivatives as 
MCT inhibitors  
4.1 Introduction 
Previous SAR studies reported by us indicated that there was a strong correlation 
between lipophilic functional groups in the para position and increase in the MCT1 
inhibition activity. Furthermore, these SAR studies also highlighted the importance of the 
para N, N-dialkylamino substitution along with the placement of an ortho ether group for 
further enhancement of MCT1 inhibition to low nM potency. As discussed in the previous 
chapter 3, the “silicon switch” presented a way to enhance the lipophilic character of the 
synthesized silylated CHC derivatives with improved cell proliferation inhibition 
properties.  
 




Furthermore, these derivatives significantly inhibited glycolytic and mitochondrial 
parameters and induced apoptosis. In this regard, we combined p-N,N-dialkyl/aryl CHC 
derivatives with o-silyl substitution as a way to further improve MCT inhibition, 
mitochondrial disruption properties along with increased cell proliferation inhibition 
(Figure 4a).  
 
 
Scheme 4a: The synthetic route for the formation of the p-N,N-diethylamino CHC 






4.2 Synthesis of silylated amino CHC derivatives  
Synthesis of the proposed new p-N,N-diethylamino o-silylated CHC derivatives 
began by starting with commercially available 4-(diethylamino)salicylaldehyde and 
alkylating it with 1-bromopropanol in the presence of potassium carbonate and catalytic 
amount of potassium iodide to obtain the corresponding benzaldehyde 4.1. A negative 
control to evaluate the therapeutic benefit of silylated amino CHC derivative was 
synthesized by Knoevenagel condensation of aldehyde 4.1 with cyanoacetic acid in the 
presence of piperidine to provide non-silylated amino CHC derivative 4.2. To form the o-
silylated amino CHC derivatives, the benzaldehyde 4.1 was protected with various silyl 
chlorides in the presence of imidazole yielding the corresponding silylated benzaldehydes 
4.3a-c. These aldehydes were subjected to Knoevenagel condensation providing the 
desired o-silylated p-N,N-diethyl CHC derivatives 4.4a-c. 
4.3 Evaluation of compounds 4.2 and 4.4a-c for antiproliferation activity in cancer 
cells  
The synthesized silylated amino CHC derivatives 4.4a-c and their un-silylated 
amino CHC derivative 4.2 were evaluated for their antiproliferation ability against MCT4 
expressing triple negative breast cancer cell line MDA-MB-231. Furthermore, these 
derivatives were evaluated for their antiproliferation activity against two MCT1 expressing 
metastatic murine cell line 4T1 and human colorectal adenocarcinoma WiDr cell line. 
Finally, candidate compounds were also tested against a non-cancerous epithelial cell line 
MCF10A to evaluate the selective antiproliferative character (Table 4a). The MTT assay 




mitochondrial reductase to the corresponding formazan dye which can be measured at 570 
nm wavelength.76 The lipophilicity of the synthesized derivatives made it difficult to test 
past 1000 µM. Hence any derivative that did not exhibit any significant IC50 at that 
concentration was designated as >1000 µM. 
 
 
Table 4a Cell proliferation inhibition (IC50)* properties of compounds 4.2 and 4.4a-c 
against MDA-MB-231, 4T1, WiDr, and MCF10A.  
 MDA-MB-231 4T1 WiDr MCF10A 
4.4a 26 ± 6.1  13 ± 0.75 21 ± 1.7 38±5 
4.4b 128 ± 10 16 ± 1.4 15 ± 0.69 67±9 
4.4c 15 ± 0.02 5.7 ± 0.83 13 ± 0.59 24 ± 2 
4.2 >1000 >1000 >1000 >1000 






Figure 4b. Cell proliferation inhibition properties of compounds 4.2 and 4.4a-c. Values 
represent the average IC50 ± SEM (µM) of at least three independent experiments in (A) 





The antiproliferation study showed the significance of the silylated group. The 
unsilylated amino CHC 4.2 did not exhibit any cell proliferation inhibition even at 1000 
µM but the silylated amino CHC derivatives 4.2 exhibited excellent activity with a 
significant increase in potency ranging from 5 to 128 µM concentration. Similar to the 
previous chapter 3, these derivatives showed significant activity against MCT1 expressing 
cell lines 4T1 and WiDr when compared to MCT4 expressing cell line MDA-MB-231 
(Figure 4a). Interestingly in WiDr cell line, the DPS derivative 4.4a showed activity with 
an IC50 of ~21 µM which was lower when compared to the TBS and TIPS derivatives 4.4b-
c with IC50 values of ~15 and 13 µM, respectively. The TIPS silylated amino CHC 4.4c 
exhibited the best activity against all three cell lines and was especially effective in the 4T1 
cell line with the IC50 value of ~6 µM. This derivative also exhibited reduced 
antiproliferative activity against the non-cancerous MCF10A cell line with an IC50 at ~140 
µM concentration. Compared to the other silylated amino CHC derivatives 4.1a-b and 
4.4a-c (MCF10A IC50: 44-41 µM) the TIPS derivative 4.4c was observed to have ~28-fold 
reduction in activity.  
These derivatives were further evaluated for their broad-spectrum cell proliferation 
inhibition against three additional cell lines. The first cell line 67NR was isolated from the 
same malignance as 4T1 but lacks the aggressive metastatic character. The MCF-7 cell line 
is an estrogen receptor positive breast cancer cell line and MIAPaCa-2 is a pancreatic 






Table 4b. Cell proliferation inhibition (IC50)* properties of compounds 4.2 and 4.4a-c 
against 67NR, MCF7, and MIAPaCa-2.  
 67NR MCC-MCF-7 MiaPaCa 
4.4a 18 ± 2 6.2 ± 0.63 38±3 
4.4b 41 ± 1 34 ± 5.5 82±7 
4.4c 10 ± 1 4.2 ± 0.47 28 ± 2 
4.2 >1000 >1000 >1000 
 
Figure 4c. Cell proliferation inhibition properties of compounds 4.2 and 4.4a-c. Values 
represent the average IC50 ± SEM (µM) of at least three independent experiments in (A) 




The silylated amino CHC derivatives 4.4a-c exhibited excellent antiproliferation 
and enhanced activity when compared to the unsilylated amino CHC derivative 4.2. These 
derivatives exhibited a broad spectrum of activity especially against 67NR and MCF7. 
Interestingly, these derivatives were not as effective against MIAPaCa-2 cell line. This 
reduction in activity in all silylated amino CHC derivatives supports the cooperative effect 
of MCT1 inhibition and the mitochondrial disrupting silyl functional group.  
4.4 Evaluation of metabolic profile in WiDr and MDA-MB-231  
Silylated derivatives exhibited excellent antiproliferation ability against a broad 
spectrum of tumorigenic cell lines. Previously, silylated CHC derivatives 3.1a-b and 3.5a-
c exhibited excellent metabolic disruption within the cancer cells WiDr and MDA-MB-
231. To understand whether these properties are enhanced with the silylated amino CHC 
derivatives 4.4a-c, the glycolysis and mitochondrial stress tests were conducted in WiDr 
and MDA-MB-231 cell lines. In this regard, we evaluated the ability of compounds 4.2 and 
4.4a-c at disrupting both glycolysis ATP production and mitochondrial respiration. 
Utilizing the two stress assays, we evaluated the various metabolic parameters and 
compared their differences with control cells (Figure 4c). The differences in the parameters 
can help understand the effects on the cells after exposure to our compounds.  
Introduction of glucose into the media results in a spike in ECAR which is 
attributed to the cells glycolytic activity. The change in ECAR can be compared to the 






Figure 4d Comparison of the glycolytic parameters calculated from seahorse assay against 
(A) WiDr and (B) MDA-MB-231 cell lines. Comparison of the glycolysis parameters in 
(C) WiDr and (D) MDA-MB-231. Bar graphs represent the average ± SEM of at least three 
independent experiments. Statistical significance was calculated using one-way anova 
(****p<0.0001). 
The resulting area allows for the quantification of ATP production from glycolysis. 




exhibited apparent spikes in glycolysis after exposure to test compounds. Specifically, the 
4.4a and 4.4c derivatives had significant effect on the glycolysis parameter in WiDr cell 
line. Interestingly, these derivatives had a greater impact on the MDA-MB-231 cell line 
with spikes in ECAR reaching ~50 mpH/min. This increase in MDA-MB-231 glycolysis 
was exclusive to derivatives 4.4a and 4.4c.  
 The next parameter evaluated was the glycolytic capacity. Determination of this 
parameter follows addition of oligomycin. The result is a sharp increase in ECAR. The 
maximum of this response is the glycolytic capacity and represents the maximum rate of 
glycolysis the cell can achieve after exposure to test compounds (Figure 4e).  
 
Figure 4e: Comparison of the glycolytic capacity calculated from seahorse assay against 
(A) WiDr and (B) MDA-MB-231 cell lines. Bar graphs represent the average ± SEM of at 
least three independent experiments. Statistical significance was calculated using one-way 
anova (****p<0.0001). 
The glycolytic capacity was reduced significantly in the presence of test compounds 




derivative 4.4b but it was not statistically significant. Conversely, 4.4b exhibited a greater 
reduction in the glycolytic capacity when compared to the other silylated derivatives 4.4a 
and 4.4b. Interestingly, the MDA-MB-231 cell line seems to have greater susceptibility 
towards the silylated amino CHC derivatives 4.4a-c.  
 The final parameter that was calculated is the glycolytic reserve. The glycolytic 
reserve is the difference between basal glycolysis and the glycolytic capacity. This 
parameter represents cells’ metabolic plasticity and ability to switch ATP production from 
mitochondrial respiration to glycolysis. Inhibition of this parameter is indicative of a cell 
line that is more sensitive to metabolic disruption as response via glycolysis will be 
severely truncated.  
 
Figure 4f: Comparison of the glycolytic reserve calculated from Seahorse assay against 
(A) WiDr and (B) MDA-MB-231 cell lines. Bar graphs represent the average ± SEM of at 






In both cell lines WiDr and MDA-MB-231, there is significant reduction in the 
glycolytic reserve after exposure to the silylated amino CHC derivatives. The reduction 
and in some cases complete elimination of this property is closely related to the glycolytic 
capacity of the cell after exposure to the compounds. The parallels between these two 
properties highlight major glycolysis inhibitory effects of candidate inhibitors. The cells 
could no longer achieve their maximum glycolytic capacity. Furthermore, the glycolytic 
reserve property supports the theory that the cells are also pursuing most of their ATP 
production via glycolysis after exposure to the test compound. This dependency on 
glycolysis could be a result of mitochondrial dysfunction which can be examined using the 
mitochondrial stress test.  
We then conducted the mitochondrial stress test which evaluates the state of 
mitochondrial respiration after exposure to the test compounds. The mitochondrial stress 
test is conducted in glucose rich media. After initial exposure to the compound, the ATP 
synthase inhibitor oligomycin was added. The resulting inhibition causes a rapid build-up 
of protons in the intramembrane region of the mitochondria. The resulting gradient stalls 
the electron transport chain as the energetic requirements to shuttle protons against this 
gradient is no longer energetically favorable. The stalling of the electron transport chain 
results in a significant reduction in oxygen use and subsequently a reduction in the OCR. 
This reduction in OCR is used to evaluate how much ATP is produced via mitochondrial 





Figure 4g: Comparison of the ATP production parameter for (A) WiDr and (B) MDA-
MB-231 cell lines. Comparison of the ATP production in (C) WiDr and (D) MDA-MB-
231. Bar graphs represent the average ± SEM of at least three independent experiments. 
Statistical significance was calculated using one-way anova (****p<0.0001). 
 
In most of the silylated derivatives, there was a significant reduction in the ATP production 
via mitochondrial respiration in both WiDr and MDA-MB-231 cell lines. The derivatives 
4.4a and 4.4b exhibited significant reduction in ATP production in WiDr cell line. 




cell line. In MDA-MB-231 cell line, there was a significant reduction in the OCR after 
exposure to all silylated derivatives 4.4a-c. This result further supports the selectivity of 
these derivatives towards the MDA-MB-231 cell line.   
 The next step is the addition of FCCP. This derivative is an uncoupler effectively 
eliminating the proton gradient. This rapid reduction in the intramembrane potential results 
in increased electron transport chain activity. This activity subsequently increases the 
amount of oxygen the cell is using and causes a large spike in the OCR. This spike in OCR 
represent the maximum achievable mitochondrial respiration that the cell can pursue 
following exposure to the test compounds and is used to evaluate the relative efficiency of 
the mitochondria. 
 
Figure 4h: Comparison of the maximal respiration parameter for (A) WiDr and (B) MDA-
MB-231 cell lines. Bar graphs represent the average ± SEM of at least three independent 





The maximal respiration parameter supports effective disruption within the WiDr 
cell line after exposure to the candidate compounds. There is significant reduction in all 
silylated amino CHC derivatives 4.4a-c. Conversely, in the MDA-MB-231 cell line, the 
4.4b derivative had no apparent effects on the maximal respiration parameter. The TBDPS 
4.4a and TIPS 4.4c silylated amino CHC derivatives did exhibit significant reduction in 
the maximal respiration of MDA-MB-231. In fact, there was a 2-fold increase in efficacy 
of these two derivatives towards MDA-MB-231 cell line, again supporting the significance 
in selectivity towards this cell line when compared to WiDr.  
 
 
Figure 4i: Comparison of the spare respiratory capacity parameter for (A) WiDr and (B) 
MDA-MB-231 cell lines. Bar graphs represent the average ± SEM of at least three 
independent experiments. Statistical significance was calculated using one-way anova 
(****p<0.0001). 
The next parameter evaluated is the spare respiratory capacity which is similar to 




and the theoretical maximum respiration that the cells can pursue. As expected, derivatives 
that exhibited significant reduction in the maximum level of respiration and had a 
significant effect on the spare respiratory capacity. Some derivatives like 23c completely 
eliminated the cells’ spare respiratory capacity. These results indicated that the cancer cells 
had reached the maximum level OCR for ATP production.  
The final step in the mitochondrial stress test is the addition of rotenone and 
antimycin A. The combination of these two derivatives effectively shuts down any OCR 
related to the electron transport chain and mitochondrial respiration. Any remaining OCR 
is non-respiratory associated OCR. The difference between this and OCR following 
oligomycin addition allows for the determination of proton leak.  
 
Figure 4j: Comparison of the ATP production parameter for (A) WiDr and (B) MDA-MB-
231 cell lines. Bar graphs represent the average ± SEM of at least three independent 





Proton leak would be the main source of any OCR activity as electron transport activity 
would actively work to maintain the proton gradient resulting from the leaking protons. 
This parameter is directly associated with mitochondrial damage and effects the efficient 
production of ATP through mitochondrial respiration.  
There was a major increase in proton leak with all derivatives in WiDr cell line. 
The TIPS derivative 4.4c exhibited the greatest activity followed by TBS 4.4b and TBDPS 
4.4a. Contrary to WiDr cell line, only the TBDPS 4.4a and TIPS 4.4c exhibited significant 
proton leak in MDA-MB-231 cell line. Interestingly, the TBS derivative did not exhibit 
any significant or apparent activity in this cell line. Furthermore, these results support the 
antiproliferation results observed in the MTT assay of these derivatives. The TBS 
derivative 4.4b was the only derivative that had a significant reduction in activity towards 
the MDA-MB-231 cell line. Both these results support the selectivity of 4.4b towards cell 
lines that are still dependent on cellular respiration for a significant portion of ATP 
production.  
These studies also show how the silyl substitution could enhance the anti-cancer 
activity of these derivatives. In most of the parameters, the unsilylated amino CHC 
derivative 4.2 did not exhibit any enhanced activity towards both WiDr and MDA-MB-
231. This emphasizes the importance of incorporating the silyl derivative and supports the 







4.5 Assessment of mitochondrial damage using epifluorescence microscopy 
The Seahorse flux assay supports the theory that there exists mitochondrial damage. 
There was a significant increase in the proton leak of the cell’s mitochondria. To 
understand the effects on the cells after exposure to test compounds MTR dye was used. 
MTR is used to monitor the mitochondria intracellularly. It not only identifies the location 
of the mitochondria but can also help identify the relative health of the mitochondria. The 
intensity of the dye is associated to the relative health of the membrane polarization and is 
a strong indicator of health of mitochondria as well. Furthermore, the study helps to 
identify the morphological changes that the cell is undergoing. These morpholigical 
changes can be used to identify the relative health of the cell and whether the cell is 
undergoing apoptosis. All the candidate compounds 4.4a-c and 4.2 were imaged using this 
method. The concentration of 30 µM was chosen since this concentration was used for the 
Seahorse flux assays. This concentration is important for it allows for direct comparison of 
the metabolic parameters and the distribution and realative health of the mitochondria and 
cells. The silylated amino CHC derivatives 4.4a-b and the unsilyated derivative 4.2 were 
evaluated. The unsilylated derivative will provide a good comparison to see what type of 
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Figure 4k: Results after 24 hours of exposure to test compounds. The bright field image 
of WiDr after exposure to test compounds 4.4a-c and 4.2 or the vehicle DMSO. The 
fluorescence of the MTR dye following exposure along with the overlay between the 
brightfield image and the MTR dye. The fluorescence and DIC images were recorded with 




Following exposure to the compounds, the cells were imaged using DIC and 
fluorescence (Figure 4k). From these images, we can clearly observe that the mitotracker 
red for the DMSO control exhibits tight packing of the mitochondria. This is indicative of 
a healthy distribution of functional mitochondria within the cell. Following treatment with 
the silylated amino CHC derivatives 4.4a-c, the DIC images show much lower number of 
cells congregating together. Additionally, many of the cells were observed to lose their 
adherence and balling up. These are all classic signs of a cell that is significantly stressed 
and undergoing apoptosis. MTR fluorescence, images from Figure 4k  indicated that 
tightly packed pockets of mitochondria were absent. The dye was much more diffused and 
diminished in intensity. All these observations support the hypothesis that the silylated 
amino CHC derivatives 4.4a-c induce significant mitochondria damage. When compared 
to the unsilylated derivative 4.2, the importance of the silyl group for mitochondrial 
disfunction activity is apparent. Interestingly, the cell morphology was visibly changed as 
the cells congregation was in lower numbers when compared to the control DMSO 
treatment. This might indicate the importance of the transport inhibition property as the 
cells could not maintain cellular homeostasis of the surrounding microenvironment 
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Figure 4l: Results after 24 hours of exposure to test compounds. The bright field image of 
MDA-MB-231 after exposure to test compounds 4.4a-c and 4.2 or the vehicle DMSO. The 
fluorescence of the MTR dye following exposure along with the overlay between the 
brightfield image and the MTR dye. The fluorescence and DIC images were recorded with 




The images in Figure 4l are after MDA-MB-231 cell were exposed for 24 hours to 
silylated amino CHC derivatives 4.4a-b and the unsilylated amino CHC derivative 4.2. The 
DIC images of the MDA-MB-231 gave an indication of the overall health of the cells and 
any changes in cellular morphology. When compared to the DMSO images, it was apparent 
that cells were extremely stressed, and was a strong evidence of the cells undergoing 
apoptosis. The cells began to ball up and there was signficant blebbing events visible after 
exposure to the silylated derivatives 4.4a-c. Interestingly, the cells that were exposed to the 
unsilyalted derivative 4.2 had similar mophological properties to the control samples. 
These results support the importance of the silyl functional group in triggering apoptotic 
events within the tumorigenic cell lines as the cells started to ball up and in some cases, 
were being lyzed. The DPS 23a seems to also have a significant impact on the congregation 
of WiDr cells, completely eliminating the tightly packed structure seen in the control DIC 
images. The fluorescent images highlight the stressed state of the cells. When compared to 
the DMSO control group, the neatly packed mitochondrial structures were observed to be 
more diffused throughout the cells. Furthermore, the intensity of the mitotracker seemed 
to be reduced. All these results were indications of significant dysfunction in the 










Improvement on the p-silylated CHC template resulted in the integration of the p-
N,N-dialkyl/aryl CHC derivative with o-silylation. The silyl ether was integrated into the 
ortho position using an aklyl spacer which conserved the N,N-dialkyl substitution required 
for potent MCT inhibiton. Intial evaluation of the cytotoxic elements supported the 
increased efficacy of these derivatives as broad spectrum chemotherapeutics. The 
derivatives exhibited excellent proliferation inhibition activity towards most of the 
cancerous cell lines. The metabolic parameters evaluated using the seahorse extracellular 
flux assays highlight the effectiveness of reducing glycolytic activity as well as 
mitochondrial activity. The derivatives 4.4a and 4.4c seem to exhibit the greatest activity 
with the derivative 4.4c being slightly more effective. Future studies will involve systemic 






CHAPTER 5: Introduction to introduction to NOS and its potential therapeutic 
application 
5.1 Nitric Oxide Species (NOS) and Cancer Progression 
Nitric oxide (NO) exhibits numerous physiological roles in cancer biology and 
tumor progression. Specifically, it has been known that an increase in elevated NO 
signaling is linked to have anti apoptotic effects and promotes angiogenesis. Enhanced NO 
release is achieved by the over expression of the three isoforms of nitric acid synthase 
which have been linked to chemo resistance and poor clinical outcome leading to the theory 
that increased NO release is important for tumor progression.80–82 Thus NO release has to 
be carefully calibrated and controlled as NOS release is a double edged sword (Figure 6a). 
 
Figure 5a: The effects of NOS on the progression of tumors in patients. Low levels have 
been linked to tumor promoting events while high levels of induced NOS can lead to 
apoptosis.  
Conversely, increased levels of intracellular NOS via xenobiotics has a similar 
effect to other reactive oxygen species (ROS). Ultimately, micromolar concentrations of 











and cellular apoptosis.83 There have been numerous strategies employed to shift the balance 
of NO within the tumor cells between anti-NO and pro-NO effects for therapeutic 
intervention in cancer. The purpose of anti-NO strategy is to decrease the release of NO by 
inhibiting nitric oxide synthase. This method of therapeutic intervention requires chronic 
administration of the drug and can lead to serious side effects like hypertension.84 Pro-NO 
strategies pursue the selective induction of NO species within the tumor via NO-donors. 
This method is ideal as it does not require chronic systemic administration and can be 
tailored for selective induction of NO release. Selective delivery of NONOates have been 
classically studied as a model pro-NO strategy with excellent anti-proliferative effects.85 
Further expansion of the NONOates resulted in the development of  NO donors that were 
physiologically stable until activated by enzymatic activity like nucleophilic aromatic 
substitution by glutathione S-transferase or an external trigger like photo-labile NO 
releasing elements.86–90   
5.2 Literature known NO donors 
Development of more effective pro-NO structures have led to metabolically stable 
entities that require a trigger for the release of the reactive NOS. In most of the cases, these 





Figure 5b: Modern NO donors that have been used for selective release of NO. 
The development of heterocyclic pro-NO structures yielded a more stable 
molecular entity with increased biological half-life. The initial work was aimed at 
developing a pro-NO entity with enhanced pharmacological properties than nitroglycerine. 
Amyl nitrite is a clinically used antihypertensive medicine with well characterized NO 
donating properties but has little selectivity. The result of administration was a systemic 
effect leading to elevated blood flow and a decrease in vascular resistance.94 Melsidomine 
is a class of sydnonimines which are prodrug entities that are activated upon hydrolysis by 
the enzymes in the liver to yield the active 3-morpholinosydnonimine (SIN-1) (Figure 5b). 




very short biological half-life of only two hours and has been linked to peroxynitrite 
toxicity limiting the therapeutic potential of this molecular entity.95 Glycerol trinitrate 
(GTN) is an organic nitrite prodrug requiring denitration for activation of the pro-NO 
molecular entity. The denitration is facilitated by sulfhydryl groups, enzymes like 
glutathione S-transferase, and mitochondrial aldehyde dehydrogenase. The therapeutic 
potential of this derivative has been evaluated for its anti-cancer properties and it has been 
found to translate well into xenograft and murine models resulting in the reduction of 
metastatic events, increasing chemo-sensitization, and tumor reduction.96,97 Sodium 
nitroprusside (SNP) represents a special class of pro-NO based on metal-NO complexes 
(Figure 5b). NO has a high affinity to iron metals and this complex releases in a 1:1 ratio 
of SNP to NO. The mechanism of NO release is mediated via thiol reduction or with 
irradiation.92 Studies with this pro-NO metal complex have shown promise in its anticancer 
efficacy but suffers from toxic side effects including the formation of cyanide, 
peroxinitrite, and hydrogen peroxide.98  
Metronidazole represents a heterocyclic NO-donor and is commonly used for its 
antimicrobial properties via selective NO release (Figure 5b). Metronidazole has been the 
optimal drug for its selective targeting of anaerobic or microaerophilic microbes which 
incorporate the metronidazole molecular entity into its electron transport chain forming 
NO.99 Most recently, it has been incorporated into molecular entities for selective delivery 
of therapeutically important anti-cancer derivatives.100,101 
Phenylsulfonylfuroxan is another NO-donor heterocycle that has gained a lot of 




stability under physiological conditions and does not cause nitrate tolerance over chronic 
exposure in vivo. Two well-known furoxan derivatives CAS1609 and CHF2363 have been 
extensively evaluated for their cardiovascular properties (Figure 5c). Both the derivatives 
have been very attractive therapeutics due to their long term potency, oral bioavailability, 
and lack of tolerance development. 102,103 
 
Figure 5c: Commonly used furoxan derivatives for their treatment of various 
cardiovascular disease via vasodilatory effects.  
Evaluation of both compounds for their cytotoxic properties as potential anticancer 
treatment have shown that CHF 2363 is more effective at much lower concentrations when 
compared to CAS 1609. The specificity of CHF 2363 is largely attributed to the 
electronegative properties of the heterocyclic ring.104 This increased efficacy of CHF 2363 
has driven further development of the phenylsulfonylfuroxan group. The 
diphenylsulfonylfuroxan heterocyclic ring comprises of strong electron-withdrawing 
nature resulting in an activated electrophilic carbon atom. The widely accepted mechanism 
of NO release of substituted phenylsulfonylfuroxan begins with a nucleophilic attack on 
the electrophilic carbon C3 or C4 via thiols in glutathione S-transferase followed by 
intramolecular reaction resulting in a cleavage of the N-O bond. The resulting unstable 
anion decomposes to form isomeric nitrosoethylenes followed by release of the nitroxyl 





Figure 5d: The two glutathione S-transferase mediated release mechanisms of the 
phenylsulfonylfuroxan group leading to intracellular release of NO.  
The above mechanism makes use of the active site of glutathione S-transferase 
which has been found to selectively target the furoxan derivatives to cancer cells resulting 
in the release of NO intracellularly.105 The targeted release of NO via glutathione S-
transferase has been widely supported by other researchers as the main mechanism and 
have highlighted the therapeutic relevance of selectively exploiting them in the 
development of furoxan based chemotherapeutics.81,106,107  
 
5.3 Glutathione S-Transferase (GST) 
Cancer progression is marked by adoption of strategies to promote drug resistance. 
One approach that cancers commonly adopt is the overexpression of various enzymatic 
entities like GST. The GST family is a select group categorized as phase II detoxification 




macromolecules. This is achieved by conjugating the macromolecules with glutathione 
(GSH). Conjugation of GSH protects the macromolecules from intra/extracellular 
electrophilic compounds and oxidative stress. 108,109 
This protection properties of the GSH and GSTs have been exploited by cancer 
cells imparting resistance to therapeutic agents. The result of this overexpression is an ever-
decreasing benefit from chemotherapeutics. Recently, the overexpression of GST within 
late stage tumors represent a potential opportunity for selective therapeutic intervention. 
This over expression can be exploited by the pro-NO donor furoxan which is activated 





CHAPTER 6 Synthesis and Evaluation of NO Donor CHC Hybrid Derivatives as 
Anti-Cancer Agents 
6.1 MCT 1 and 4 inhibitor-NO donor conjugates 
The electrophilic carbons are liable to nucleophilic attacks allowing for easy 
substitutions and incorporation into novel molecular hybrids for various therapeutic 
effects.91 Recently, the molecular conjugation of novel phenylsulfonylfuroxans have 
produced interesting chemotherapeutics that were able to induce necrosis in vivo at a dose 
that exhibited no negative side effects in mice.110 This multifaceted design of coupling two 
pharmacologically privileged structures has led to many phenylsulphaforoxan derivatives 
with excellent chemotherapeutic potential demonstrated in vivo xenograft models.86,110–118 
In this regard, we envisioned to combine toxicity enhancing furoxan based NO donor with 
our previously studied MCT1 and 4 inhibitors to evaluate their efficacy as anticancer agents 
(Figure 6a).   
 
Figure 6a: Hypothesis and rationale of MCT1/4 NO donor hybrids as anticancer agents. 
The p-N,N-dialkylamino CHC inhibitors reported by us exhibited excellent MCT1 
and MCT4 inhibition and reduced growth in various tumor models. However due to the 




concentration (~50mg/kg or higher) to observe significant tumor growth inhibition. In this 
regard, we envisioned that conjugating metabolically stable NO donor 
phenylsulfonylfuroxan to p-N,N-dialkylamino CHC template would provide novel 
candidate compounds with potent MCT inhibition and higher cytotoxicity. We 
hypothesized that this molecular hybridization would produce novel candidate compounds 
with a higher therapeutic potential for cancer treatment. 
6.2 Synthesis of hybrid NO Donor N,N-dialkyl CHC Derivatives  
The NO Donor diphenylsulphafuroxan (Scheme 6a) was synthesized via literature 
known procedures by starting with thiophenol and reacting it with bromoacetic acid in the 
presence of potassium hydroxide as a base to yield 6.1. The desired product was formed 
by initial oxidation with hydrogen peroxide followed by nitration, dimerization, and 
cyclization using fuming nitric acid. The reaction mixture was then cooled, and the product 
was crystallized from the mixture at -20°C to yield a white to off white solid 62. 
 





Next, the N,N-dialkyl CHC-NO donor conjugates  40a and b were synthesized by 
starting from commercially available N-ethyl/benzyl anilines. Reaction of these amines 
with methyl acrylate in the presence of sodium bromide under acidic conditions resulted in 
Michael addition products 6.3a and b. The esters 6.3a and b were reduced to corresponding 
alcohols 6.4a and b with lithium aluminum hydride by refluxing in THF for two hours. 
The hydroxy group in hydroxydialkyl aniline 6.4a and b was protected with acetyl chloride 
to yield the corresponding acetate 6.5a and b. Next Vilsmeier-Haack formylation reaction 
was performed using POCl3 in DMF to obtain the corresponding aldehydes 6.6a and b. 
The acetate group in aldehydes 6.6a and b were deprotected with potassium carbonate to 
yield the monohydroxydialkyl benzaldehydes 6.7a and b. Knoevenagel condensation of 
the benzaldehyde 6.7a with cyanoacetic acid resulted in the hydroxycyanocinnamic acid 
6.8. The aldehydes 6.7 a and b were coupled to diphenylsulphafuroxan 6.2 to in the 
presence of DBU to provide the furoxan aldehydes 6.9a and b. Knoevenagel condensation 
of 6.9a and b with cyanoacetic acid gave the desired NO donor furoxan- N,N-dialkyl CHC 





Scheme 6b: Synthetic procedure for the preparation of the N,N-dialkyl amino CHC 6.8 




To test the effects of the size of the spacer between the furoxan and the CHC, we 
incorporated the butanol side chain to ethyl aniline (Scheme 6c). To synthesize this 
derivative 6.10c, N-ethylaniline was reacted with succinic anhydride yielding the amido 
acid 3c. Complete reduction of amido and carboxylic acid groups in 6.3c to amino alcohol 
with LiAlH4 lead to poor yields Hence, to improve the yield of this reaction, the acid group 
in 6.3c was esterified by treatment with thionyl chloride in methanol to yield the 
corresponding amido methyl ester 6.11. Complete reduction of amide and ester to the 
corresponding amino alcohol 6.4c was accomplished in good yields upon treatment with 
LiAlH4 in refluxing THF. The alcohol in 6.4c was then protected with acetyl chloride 
yielding the corresponding acetate 6.5c followed by Vilsmeier-Haack formylation with 
POCl3 in DMF to yield the aldehyde 6.6c. Deprotection of the acetate group in 6.6c was 
performed in the presence of potassium carbonate to yield the corresponding amino butanol 
aldehyde 6.7c. The alcohol group in 6.7c was coupled to diphenylsulphafuroxan 6.2 in the 
presence of DBU to get the NO donor conjugated product 6.9c. The aldehyde in 6.9c was 
subjected to Knoevenagel condensation with cyanoacetic acid to yield the desired furoxan 







Scheme 6c: The synthesis of the furoxan N,N-dialkylamino CHC with a butyl linker 




To help evaluate the importance of N,N-dialkyl groups in the CHC derivative, a 
novel furoxan ether CHC derivative 6.13 without N-alkyl groups was synthesized. In this 
case, the N,N-dialkyl subunit was replaced with hydroxyethoxy group of the furoxan to 
synthesize the hybrid derivative 6.13. 
 
Scheme 6d: The synthesis of furoxan ether CHC 6.13 derivative starting from 
commercial grade 4-hydroxybenzaldehyde.  
The synthesis of this derivative started with alkylation of commercially available 
4-hydroxybenzaldehyde with chloroethanol in the presence of potassium carbonate. This 
reaction is followed by coupling 4- hydroxyethoxy benzaldehyde 6.11 to furoxan 6.2 in the 
presence of DBU followed by Knoevenagel condensation to yield the desired furoxan 





6.3 Evaluation of compounds 6.10a-c, 6.13, and 6.8 for antiproliferation activity 
The synthesized NO donor-CHC derivatives 6.8, 6.10a-c, and 6.13 were evaluated 
for their antiproliferation ability against MDA-MB-231, which is an MCT4 expressing 
triple negative breast cancer cell line. These derivatives were also tested against 4T1, a 
metastatic murine model breast cancer cell line and WiDr, a human colorectal cancer cell 
line. Both 4T1 and WiDr predominantly express MCT1.40,74 The immortalized Non-
cancerous mammary epithelial cell line MCF10A was used to evluate the effectiveness of 
the compounds on a non-cancerous cell line. Cell proliferation inhibition was measured 
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric 
assay. The MTT is reduced by cellular mitochondrial reductase to the corresponding 
formazan dye which can be measured at 526 nm. The amount of MTT converted to 
formazan is an indication of the density and activity of the cells.76 
Table 6a: Cell proliferation inhibition (IC50) properties of compounds 6.10a-c, 6.13, and 
6.8.  
 MDA-MB-231 4T1 WiDr MCF10A 
6.10a 3.2±0.58 8.3±0.7 5.16±1.71 36.0±7.5 
6.10b 2.9±0.63 6.1±1.5 31.1±3.6 1.7±0.16 
6.10c 2.0±0.63 8.2± 0.4 9.3± 2.0 21.8±3.3 
6.13 168.0±7.2 131.2±13.2 8.3±0.7 15.1±0.7 
6.8 >250 >250 >250 >250 







Figure 6b: Cell proliferation inhibition properties of compounds 6.10a-c, 6.13, and 6.8. 
Values represent the average IC50 + SEM (µM) of at least three independent experiments 
in (A) MDA-MB-231, (B) 4T1, (C) WiDr, and (D) MCF10A cell lines. 
Compounds 6.10a-c exhibited cell proliferation inibition properties with IC50 
values in the  range of 2-36 µM against the cell lines tested (Table 6a). The derivatives 
6.10a-c were consistantly more effective against the cell line MDA-MB-231 (IC50 2 to 3 




a reduced activity against all of the cell lines except WiDr (IC50 ~8 µM). Interestingly, 
derivatives 6.10a and 6.10c were more effective on the cancerous cell lines (IC50
 ~2 to 9 
µM) but had diminished cell proliferation inhibition activity against MCF10A (IC50 ~20-
30 µM) (Table 6a, Figure 6b). 
Incorporation of the cell proliferation inhibition enhancing furoxan derivatives 
6.10a-c based on the pro-NO release were in general more cytotoxic. This was supported 
by the lack of any observed cell proliferation inhibition in non furoxan CHC derivative 6.8. 
When No donors were conjugated with the MCT1 and MCT4 inhibitors, there was an 
enhanced antiproliferative activity with compounds 6.10a and 6.10c in cancerous cell lines 
with apparently lower antiproliferative activity towards the MCF10A cell line. With these 
encouraging cell proliferation inhibition results, we then proceeded to evaluate these 
derivatives for MCT inhibition to see if they retain their MCT inhibition activities. 
6.4 Evaluation of test compounds for MCT inhibition using 14C-lactate uptake assay 
Incorporation of the furoxan subunit in 6.10a-c, 6.13 and 6.8 in place of the free 
alcohol 2.8 greatly enhanced the antiproliferation activity of these derivatives. Derivatives 
6.10a-c, 6.13 and 6.8 were evaluated for MCT1 and MCT4 inhibition using 14C-lactate 
uptake assay to determine whether there was a loss of inhibition activity due to the furoxan 
unit. The uptake assay is a radiometric assay that uses 14C-lactate. Plated cells were 
exposed to 14C-lactate in the presence of the test compounds. After lysing the cells, the β-
radiations from the 14C-lactate that were internalized in the cell were measured using a 
scintillation counter. The change in lactate uptake with varied concentrations of inhibitor 




the assay are the MCT1 expressing RBE4 for MCT1 inhibition and the MCT4 expressing 
MDA-MB-231 for MCT4 inhibition.30 
Table 6b: MCT1 and MCT4 IC50 values of compounds 6.10a-c, 6.13, and 6.8.  
Compound MCT1 IC50 (µM) MCT4 IC50 (µM) 
6.10a 0.057±0.016 0.116±0.002 
6.10b 0.114±0.014 0.161±0.019 
6.10c 0.229 0.106±0.005 
6.13 0.099±0.004 TBD 
6.8 >10  >10 






Figure 6c: MCT1 and MCT4 inhibition properties of compounds (A) 6.10a, (B) 6.10b, 
(C) 6.10c, (D) 6.13, (E) 6.8. Bar graphs represent the average IC50 ± SEM (µM) of at least 
three independent experiments. (E) Bar graph of the IC50 values of compounds. 
The results of the lactate uptake assay highlighted the importance of the lipophilic 




hybrids exhibited low nanomolar inhibitor activity against MCT1 and MCT4. 
Incorporation of the polar hydroxyl group on the side chain in 6.8 resulted in a loss of 
inhibition of MCT1 or MCT4 even up to 10 µM concentration. The derivative 6.10a 
exhibited the highest activity against MCT1 with an IC50 of ~0.065 µM. The same 
compound 6.10a had lower selectivity to MCT4 of ~0.11 µM. A similar trend in activity 
was seen for 6.10b derivative as well. Compound 6.10c was interesting as it showed great 
selectivity towards MCT4 (IC50 0.11 µM) but slightly lesser towards MCT1 (IC50 ~0.23 
µM). This could be explained by a potential threshold on the chain length and an impact 
on lipophilicty towards MCT1 or MCT4. Higher lipophilic molecules such as 6.10c had a 
slightly higher selectivity towards MCT4 activity and 6.10a with slightly lower 
lipophilicity was more selective towards MCT1 (Table 6b, Figure 6b).  
6.5 Evaluation of the glucose stress test of test compounds 
MCTs play a vital role in the cellular transport of glycolytic metabolites including 
lactate and pyruvate which are shuttled into the mitochondria for use in the TCA cycle for 
OxPhos. Hence, inhibition of this transport may result in perturbation of the processes 
involved in efficient glycolysis and/or OxPhos. In this regard, we evaluated the ability of 
compounds 6.10a-c, 6.13 and 6.8 at disrupting various metabolic parameters. These 
discrepancies in the metabolic parameters were evaluated using established glycolysis 
stress test and mitochondrial stress test.  
Prior to running the assay, cells were washed twice with glucose free assay media. 
This allows for the measurement of non-glycolytic ECAR followed by addition of the test 




ECAR can be used to determine the rate of glycolysis within the cells. The induction of the 
ATP synthase inhibitor oligomycin results in another spike in ECAR. This represents the 
cells’ maximum obtainable rate of glycolysis as most ATP production will be produced 
through glycolysis. Finally, 2-deoxyglucose was added to completely shut down the 
process of glycolysis which is required to interpret the glycolytic capacity. The glycolytic 
reserve is the difference between the glycolytic capacity and glycolysis.  
Previously our lab utilized MCT1 expressing WiDr and MCT4 expressing MDA-
MB-231 cell lines to study the glycolytic parameters. Metabolic profile of these two cell 
lines are markedly different since, WiDr uses greater amounts of OxPhos and MDA-MB-



















Figure 6f:  Comparison of the glycolytic parameters calculated from glycolytic stress test 
in (A) WiDr cell line for compounds 6.10a-c and (B) 6.13 and 6.8; (C) MDA-MB-231 cell 
line for compounds 6.10a-c and (D) 6.13 and 6.8. Bar graphs represent the average + SEM 
of at least three agreeing independent experiments. Statistical significance was calculated 




 In the presence of the test compounds, there was a significant increase in glycolysis 
in WiDr cell line (Figure 6c). The derivatives 6.10a and 6.10b did not affect glycolysis. 
The ethyl derivative 6.10c with a butyl spacer exhibited a significant increase in the 
glycolysis in WiDr cells. In MDA-MB-231 cell line, there was a significant reduction in 
glycolysis following exposure to compounds 6.10a-c. Both the ethyl derivatives 6.10a and 
6.10c had similar reduction in the glycolysis of MDA-MB-231. This supports that the 
length of the linker group by one carbon had little effect in changing the activity of the 
amino CHC derivatives. The disparity in activity between WiDr and MDA-MB-231 cell 
lines could be attributed to secondary effect of the furoxan amino CHC derivative resulting 
in a reduction of cellular glycolysis in MDA-MB-231 cell line. Furthermore, the ether 
linked furoxan CHC derivative 6.13 seemed to enhance glycolysis in WiDr cell line along 
with the non-furoxan derivative 6.8 when compared to the control. This could indicate a 
fundamental shift in the metabolic phenotype of the cells to a more glycolytic nature. These 
two derivatives did not have any effect on MDA-MB-231 cell line which had been shown 
to be more glycolytic in nature (Figure 6f A-D).  
The next parameter evaluated is after the addition of the ATP synthase inhibitor 
oligomycin. Inhibiting the source of ATP production from mitochondrial respiration results 
in a significant increase in ECAR as the cell approaches its maximum glycolytic activity 






Figure 6g:  Comparison of the glycolytic capacity calculated from glycolytic stress test in 
(A) WiDr cell line for compounds 6.10a-c and (B) 6.13 and 6.8; (C) MDA-MB-231 cell 
line for compounds 6.10a-c and (D) 6.13 and 6.8. Bar graphs represent the average + SEM 
of at least three independent experiments. Statistical significance was calculated using 





The glycolytic capacity was significantly affected following exposure to the 
compounds. The importance of the amino CHC structure in reduction of the glycolytic 
capacity through MCT1 inhibition had already been discussed previously.30,73 This 
reduction in the glycolytic capacity could be attributed to the significant MCT1 inhibition 
activity of 6.10a-c. The greatest activity was exhibited by the benzyl amino CHC derivative 
6.10b which almost eliminated the glycolytic capacity in WiDr cell line and had a 
significantly greater reductive activity in MDA-MB-231 when compared to the other 
derivatives. Both the ethyl derivatives 6.10a and 6.10c had similar activity again showing 
that linker length of the furoxan group does not significantly impact the activity of these 
derivatives. Furthermore, the derivatives 6.10a and 6.10c did not differ much in their 
activity between WiDr and MDA-MB-231 cell lines either. In the study of the furoxan 
ethoxy linker derivative 6.13, the activity was largely reduced in WiDr when compared to 
the amino furoxan CHC derivatives and no activity was found in the MDA-MB-231 cell 
line. Contrarily, the hydroxyl amino CHC derivative 6.8 was not effective in MDA-MB-
231 but exhibited some significant reduction in the glycolytic capacity in WiDr. These two 
studies highlight the importance of the furoxan amino CHC derivative at enhancing the 
activity towards both WiDr and MDA-MB-231 cell lines (Figure 6g A-D).  





Figure 6h:  Comparison of the glycolytic reserve calculated from glycolytic stress test in 
(A) WiDr cell line for compounds 6.10a-c and (B) 13 and 6.8; (C) MDA-MB-231 cell line 
for compounds 6.10a-c and (D) 6.13 and 6.8. Bar graphs represent the average + SEM of 
at least three independent experiments. Statistical significance was calculated using 




The next parameter that we calculated was the glycolytic reserve. This is simply the 
difference between the rate of glycolysis and the glycolytic capacity. This parameter is 
closely tied to the metabolic plasticity of the cell and its response to ATP deficiency using 
glycolysis. A reduction in this parameter means the cell is no longer able to respond as 
efficiently to microenvironmental metabolic changes, which could be due to inhibitory 
effects caused by exposure to the test derivatives (Figure 6h A-D).   
There was a direct correlation between the reduction in the glycolytic parameters 
and the glycolytic reserve with derivatives 10a-c. The derivatives that exhibited the highest 
reduction in the glycolytic capacity also had similar activity in the glycolytic reserve. 
Interestingly, in the second study, both derivatives 6.13 and 6.8 had a significant reduction 
in the glycolytic reserve of both cell lines. If glycolytic reserve was reduced significantly, 
the cell could no longer reach the maximal glycolysis that it could previously, and as a 
result the cells’ metabolic plasticity was reduced. With significant reduction in the 
glycolytic parameters supported by the glycolysis stress test, we planned to evaluate 
whether there was any significant mitochondrial stress after exposure to the compounds 
(Figure 6i A-B and Figure6j A-B) 
As previously discussed, the MCT inhibition activity could have a significant effect 
on reducing the glycolytic parameters of the cells. This inhibitory activity would eliminate 
a primary way to maintain cellular homeostasis which would reduce the cells’ ability to 






6.6 Evaluation of the mitochondrial stress test of 6.10a-c, 6.13, and 6.8 
Mitochondrial stress test measures the oxygen consumption rate (OCR) of the cell. The 
respiratory parameters were calculated using the changes in the OCR. This assay differs 
from the glycolysis stress test for the cells are washed with glucose enriched media so that 
normal metabolism is maintained at basal levels (Figure 6h and Figure 6i).  
 
Figure 6i: Mitochondrial stress test profile in WiDr cell line for compounds (A) 6.10a-c 





Figure 6j: Mitochondrial stress test profile in MDA-MB-231 cell line for compounds (A) 








The first addition for the stress test is oligomycin, an ATP synthase inhibitor. The 
initial result of ATP synthase inhibition is a subsequent reduction in the cells oxygen 
consumption rate. This is due to stalling of the mitochondrial transport chain as the 
oxidative potential is no longer greater than the steep energetic requirements to pump 
protons against the gradient. As a result, this reduction in oxygen consumption allows for 














Figure 6k: Comparison of the ATP production calculated from mitochondrial stress test 
in (A) WiDr cell line for compounds 6.10a-c and (B) 6.13 and 6.8; (C) MDA-MB-231 cell 
line for compounds 6.10a-c and (D) 6.13 and 6.8. Bar graphs represent the average + SEM 
of at least three independent experiments. Statistical significance was calculated using 




The ATP production was reduced in WiDr cell line after exposure to the derivatives 
6.10a-c. In this cell line, the benzyl derivative 10b exhibited the greatest activity, whereas 
the activity of 6.10a and 6.10c were similar in WiDr cell line. In MDA-MB-231 cell line, 
the ethyl derivative 10a exhibited the greatest activity. Interestingly, the other ethyl 
derivative 10c did not exhibit any activity in this cell line (Figure 6h A-D) 
 In the second study, there was no significant reduction in ATP production in either 
WiDr or MDA-MB-231 cell lines following exposure to the furoxan ethoxy CHC 
derivative 6.16. Interestingly, the derivative that did not contain the furoxan functional 
group 6.8 had significant reduction in ATP production from cellular respiration. This result 
combined with the previous study indicated that the inhibition of ATP production was 
largely dependent on the amino CHC template rather than the NO donor functional group. 
Furthermore, the benzyl derivative 10b was found to be very selective towards WiDr cell 
line in its ATP reducing activity (Figure 6h A-D) 
The next compound added is FCCP, a proton uncoupler. The mechanism of action 
is equivalent to perforating the mitochondrial membrane leading to an efflux of protons out 
of the transmembrane region down the gradient. The result of rapid efflux of protons drives 
the electron transport chain into overdrive as it tries to reestablish this gradient. This 
activity causes an artificial spike in oxygen consumption as the cell achieves the theoretical 





Figure 6l: Comparison of the maximal respiration calculated from mitochondrial stress 
test in (A) WiDr cell line for compounds 6.10a-c and (B) 6.13 and 6.8; (C) MDA-MB-231 
cell line for compounds 6.10a-c and (D) 6.13 and 6.8. Bar graphs represent the average + 
SEM of at least three independent experiments. Statistical significance was calculated 




 After exposure to the compounds, there was a significant reduction of the maximal 
respiration in WiDr cell line with 6.10a-c and the activities were comparably similar 
between the three derivatives. Contrarily, this activity was significantly reduced except 
with the derivative 6.10a, which had a complete reduction in the maximal respiration. The 
derivative 6.10b exhibited significant activity in MDA-MB-231 cell line, but the derivative 
6.10c had no activity.  In the second study, the furoxan ethoxy CHC d6jrivative 6.13 did 
not show any affect in either WiDr or MDA-MB-231 cell line. Again, the hydroxy amino 
CHC derivative 6.8 significantly reduced maximal respiration in both WiDr and MDA-
MB-231 cell lines (Figure 6l A-D). 
 These results indicated that the derivatives lacking a lipophilic character was more 
effective in disrupting mitochondrial activity in WiDr cell line. The mitochondrial 
parameters in MDA-MB-231 cell line were found to be significantly inhibited by exposure 
to the more polar derivative 6.8. As for the furoxan derivative, it did not significantly 
modify the activity of the amino CHC template.  
The next parameter that can be evaluated is the spare respiratory capacity. This is simply 
the ability of the cell to respond to stress that would result in increased ATP production 
from mitochondrial respiration. This parameter is obtained by the difference between basal 






Figure 6m: Comparison of the spare respiratory capacity calculated from mitochondrial 
stress test in (A) WiDr cell line for compounds 6.10a-c and (B) 6.13 and 6.8; (C) MDA-
MB-231 cell line for compounds 6.10a-c and (D) 6.13 and 6.8. Bar graphs represent the 
average + SEM of at least three independent experiments. Statistical significance was 




 The spare respiratory capacity is usually correlated with the maximal respiration. 
Any significant reduction in the maximal respiration parameter usually results in a 
significant reduction in the spare respiratory capacity. This could be seen in WiDr cell line 
where the most effective derivatives 6.10b exhibited a complete elimination and further 
reduction of the spare respiratory capacity. Furthermore, both the ethyl amino CHC 
derivatives 6.10a and 6.10c had comparable reduction in the spare respiratory capacity. 
Interestingly, in MDA-MB-231 cell line, the spare respiratory capacity was significantly 
reduced with derivative 6.10b. In the second study, 6.13 and 6.8 had no reduction in the 
spare respiratory capacity. In the derivative 6.8 there was a significant reduction in the 
spare respiratory capacity while the derivative 6.13 had no apparent activity in MDA-MB-
231 cell line (Figure 6k A-D).  
 The final metabolic inhibitors that we added were rotenone and antimycin A. 
Rotenone is an isoflavone that disrupts complex I in the electron transport chain. The 
metabolic inhibitor antimycin A effectively inhibits complex III. The result of these two 
derivatives is the complete shutdown of oxygen consumption via the electron transport 
chain and subsequently any mitochondrial respiration. This final step is important for it 
allows for the determination of the proton leak parameter. In short, proton leak is indicative 
to any destabilization in the mitochondrial membrane integrity. The result is small levels 
OCR from the activity of electron transport chain even after ATP synthase inhibition. This 
proton leak is a strong indicator of significant compound induced mitochondrial 





Figure 6n: Comparison of proton leak calculated from mitochondrial stress test in (A) 
WiDr cell line for compounds 6.10a-c and (B) 6.13 and 6.8; (C) MDA-MB-231 cell line 
for compounds 6.10a-c and (D) 6.13 and 6.8. Bar graphs represent the average + SEM of 
at least three independent experiments. Statistical significance was calculated using 





 There was a significant increase in the proton leak after exposure to the derivatives 
6.10b and 6.10c in both WiDr and MDA-MB-231 cell lines. Specifically, the benzyl 
derivative was the only compound with the greatest spike in proton leak. Interestingly, the 
ethyl derivative 10a did not exhibit any increase in proton leak in either WiDr or MDA-
MB-231 cell lines. Mostly, the effect on the mitochondrial respiratory activity was likely a 
combination of different effects that could potentially include the mitochondrial 
dysfunction activity of NO release intracellularly. In the second study, the furoxan ethoxy 
CHC derivative 6.13 did not exhibit any increase in the proton leak in both WiDr and 
MDA-MB-231 cell lines. Furthermore, the hydroxy ethyl CHC derivative 6.8 did not have 
any effect on the proton leak as well (Figure 6l A-D).  
6.7 Systemic toxicity evaluation of candidate compounds 6.10a-c in CD1 mice 
Considering the excellent activities of derivatives 6.10a-c at disrupting cellular 
energetic production via glycolysis and mitochondrial respiration, we decided to elevate 
them as candidate compounds for in vivo evaluation (Figure 6o). Initial systemic toxicity 
studies were conducted in healthy CD1 mice. 
 
Figure 6o: Candidate compounds used for translation into in vivo models for evaluation of 




For solubility purpose, derivatives 6.10a-c were converted into their corresponding 
sodium salts using sodium bicarbonate. The derivatives 6.10b and 6.10c even as sodium 
salts had some trouble with solubility at 1mg/ml in 10% DMSO in water. All the 
derivatives were soluble in the formulation consisting of 10% DMSO, 10% PEG-400, 7.5% 
HS-15, and 72.5% water. CD-1 mice were purchased from Charles River and allowed to 
acclimatize for one week before administration of candidate compounds. The mice were 
assigned into groups (n=6 mice). Selection was based on the average weight of the group 
and mice were selected to ensure the average was consistent amongst all test groups. 
Toxicity evaluation was conducted over a period of 14 days. Dosage of 6.10a-c was 
administered at 20mg/kg daily intraperitoneally. This dosage was chosen based on the 
relative maximum solubility at room temperature. The body weights of the mice along with 
behavior were monitored to ensure the dosage was not causing any significant stress on the 
mice. The control group was given vehicle (10% DMSO, 10% PEG-400, 7.5% HS-15, and 






Figure 6p: Systemic toxicity of (A) 6.10a, (B) 6.10b, and (C) 6.10c in CD-1 mice at a 
concentration of 20mg/kg i.p indicate normal body weight gains in treated mice when 
compared to controls. 
Mice treated with the derivatives 6.10a-c did not exhibit reduction in body weights 
and did not show any noticeable side effects at the end of the study (Figure 6n). 
Encouraged by these results, we then evaluated the efficacy of one of one lead derivative 







6.8 In vivo tumor growth inhibition study in MDA-MB-231 xenograft model 
Selection of the lead candidate compound 6.10a for further preclinical development 
was based on its high cell proliferation inhibition and MCT1/4 inhibition activity. 
Furthermore, derivative 6.10a has less vulnerable phenyl groups when compared to 6.10b 
that could be susceptible to CYP450 oxidation and elimination resulting in a decrease in 
therapeutic exposure. Additionally, the solubility of 6.10a was greater than that of 6.10b-
c making it a better candidate compound for further anticancer efficacy evaluation.  
 
Figure 6q. (A) In vivo MDA-MB-231 xenograft model indicated significant reduction in 
tumor volume when compared to vehicle treated mice. (B) At the end of the study, tumors 
were resected and weighed. Statistical significance of tumor growth inhibition was 




The MDA-MB-231 xenograft model was chosen as it is an MCT4 expressing cell 
line and was previously evaluated against the lead candidate compound for transport 
inhibition, cell proliferation, and metabolic disruption capabilities. Mice were inoculated 
with MDA-MB-231 cells in a 1:1 mixture with Matrigel and PBS. Treatment was started 
after the tumors reached an average volume of 100 mm3. Group 1 mice were treated with 
6.10a at a dosage of 20 mg/Kg, intraperitoneally, once daily and group 2 mice were given 
vehicle (10% DMSO, 10% PEG-400, 7.5% HS-15, and 72.5% water). The weights of the 
mice were monitored daily and tumor volume was measured every three days with calipers 
(Figure 6q). After 14 days of treatment, mice were euthanized, and tumor masses were 
isolated and weighed. Compound 6.10a exhibited a significant tumor growth inhibition, 
~50% by volume (Figure 2q, A) and ~30% by tumor mass (Figure 6q, B) when compared 




The integration of the NO donor furoxan into the p-N,N-dialkylamino CHC template 
resulted in a significant increase in the antiproliferative nature of the compounds. These 
results support the effectiveness of the pro-NO strategy as a potential therapeutic. There 
was some degree of selectivity between the cell lines with higher activity against the 
tumorigenic cell lines MDA-MB-231, 4T1, and WiDr. The degree of activity was lower 
against the immortalized epithelial cell line MCF10A. The candidate compounds exhibited 




derivatives are structurally similar to our previously reported p-N,N-dialkylamino CHC 
based dual MCT1and MCT4 inhibitors.119  
 To evaluate the effects on the metabolic profile, two cells lines were used. The first 
was an MCT1 expressing cell line WiDr and the second was an MCT4 expressing cell line 
MDA-MB-231. Evaluation of glycolytic parameters revealed that the NO donor CHC 
hybrids were more effective in the MCT1 expressing WiDr cell line when compared to the 
MDA-MB-231 cell line. Interestingly, the derivative that lacked the NO donor showed 
similar reduction in the glycolytic properties. These results support the hypothesis that the 
changes in the glycolytic parameters could be attributed largely to the amino CHC template 
rather than the NO donor activity.  
 The mitochondrial stress test parameters were more effective in the WiDr cell line 
that is more dependent on mitochondrial respiration for ATP production. The largely 
glycolytic dependent MDA-MB-231 cell line showed some indication of mitochondrial 
stress but was largely unaffected when compared to WiDr. Mitochondrial parameters such 
as maximal respiration and ATP production were also significantly reduced in the presence 
of candidate compounds. The amino CHC derivatives 6.10a-c specifically had the greatest 
effect on these parameters when compared to the furoxan ethoxy derivative 6.13. 
Furthermore, based on the increase in proton leak, the N,N-dialkylamino group and pro-
NO release strategy in the CHC derivative could influence mitochondrial dysfunction.  
 Excited by these studies the three NO donor amino CHC hybrids were selected as 
candidate compounds for further development. The systemic toxicity was conducted in 




xenograft model based on its in vitro activity and selectivity towards tumorigenic cell lines. 
This derivative translated well into the MDA-MB-231 xenograft model with significant 
reduction in the volume and tumor weight. The result of the study was a successful 
development of a small library of NO donor amino CHC hybrids with significant in vitro 





CHAPTER 7 Synthesis and Evaluation of NO Donor Aminocarboxy Coumarin 
Conjugates as Anticancer Agents 
7.1 Introduction 
Previous SAR study reported in chapter 1 highlighted the importance of the 
conjugation of two molecular entities N,N-dialkylamino CHC  and the NO donor furoxan. 
The current chapter focuses on the hybridization of the potent dibenzylcoumarin derivative 
1.16 with NO donor furoxan. Here we employed a pro-drug strategy where a bicyclic 
system of coumarincarboxylic acid which is a cyclic ester (a class of 6 membered lactone) 
was linked to furoxan unit. For this purpose, we employed two different linker groups to 
combine the coumarincarboxylic acid and furoxan derivatives. The linker groups that we 
utilized contain readily cleavable ester group 7.7a and more metabolically stable amide 
linkage 7.7b. Both these strategies had a terminal alcohol that would be coupled with the 
NO donor diphenylsulphafuroxan (Scheme 7a).  
The coumarin template is a pharmacologically privileged structural entity with 
excellent therapeutic activity and have been successfully utilized towards drug 
development for numerous indications.36,82,86,120 As mentioned in the previous chapter, 
coumarin carboxylic acids are structurally similar to the CHC. The coumarin derivative 
has similar electronic features with a two electron groups flanking the unsaturated region 
with a lipophilic electron donating aromatic system in the opposing side. Both these 
features enhance the electrophilic nature of the unsaturated carbon towards possibly 
reversible nucleophilic attack. The incorporation of the furoxan derivative has been linked 




towards the tumor microenvironment is based on the overexpression of GSTs in the late 
stage cancerous. We envision coupling this derivative to the pharmacologically privileged 
coumarin template will enhance the activity of this derivative, with limited off target 
toxicities. Our previous studies on dibenzyl couarmin carboxylic acid revealed that these 
are slightly selective towards MCT1 with an IC50 of 57nm as opposed to MCT4 which is 
~200nm.  Inclusion of this novel prodrug strategy would result in a probable cytotoxicity 
enhancing features with activity towards MCT1 and/or MCT4 expressing cell lines upon 
cleavage of the linker.40  
7.2 Synthesis of hybrid NO Donor N,N-dialkyl coumarin Derivatives 7.7a-b  
Initial synthesis of the diphenyl coumarin derivative started with the commercially 
available 3-aminophenol. The amine in was selectively alkylated under controlled 
conditions with benzyl bromide in the presence of potassium carbonate in DMSO as 
solvent. The resulting dibenzyl derivative 7.1 was formylated via Vilsmeier-Haack reaction 
using POCl3 and DMF mixture resulting in the phenolic aldehyde 7.2 followed by 
condensation of aldehyde with diethylmalonate in the presence of piperidine. Hydrolysis 
with 3M sodium hydroxide in ethanol under reflux conditions followed by acid mediated 









Acid catalyzed Fischer esterification of the dibenzylcarboxy coumarin 7.4 with 
excess ethylene glycol resulted in the corresponding selective mono ester 7.5a. The 
terminal alcohol of the ester was coupled with the diphenylsulphafuroxan in the presence 
of DBU yielded the desired furoxan dibenzyl coumarin conjugate 7.6a. The piperazine 
ethanol amide derivative was prepared by coupling 7.4 with ethanol piperazine using 
HBTU and triethylamine to give the corresponding amide 7.5b. The amide was similarly 
coupled with diphenylsulphafuroxan in the presence of DBU to yield the corresponding 


















7.3 Evaluation of compounds 7.6a-b and 7.8a-b for antiproliferation activity 
The synthesized dibenzyl coumarin prodrugs 7.5a-b and hybrids 7.6a-b were 
evaluated for their antiproliferation activity against various cancerous and non-cancerous 
cell lines.  Proliferation inhibition was measured using MTT. Cells that were tested were 
MDA-MB-231, a triple negative breast cancer, 4T1, a murine metastatic breast cancer cell 
line, and WiDr, a colorectal adenocarcinoma. For an evaluation of efficacy on non-
cancerous cells, MCF10A cell line was used (Table 7a). 
 
Table 7a: MTT IC50*(µM) values of functionalized coumarin derivatives 7.6a-b and 7.7a-
b in MDA-MB-231, 4T1, MCF7 and WiDr cell lines. 
 MDA-MB-231 4T1 WiDr MCF10A 
7.5a >250 >250 >250 >250 
7.5b >250 >250 >250 >250 
7.6a 0.02 ± 0.00 0.13 ± 0.05 0.03 ± 0.01 34.0 ± 4.6 
7.6b 0.46 ± 0.02 0.96 ± 0.1 10.0 ± 0.02 8.6 ± 0.9 





Figure 7a: MTT based IC50 values of coumarin NO hybrids (A) MDA-MB-231, (B) 4T1 
(C) WiDr and (D) MCF10A. MTT assay was used to evaluate cell proliferation inhibition 
of the test compounds 7.6a and 7.6b. All the experiments were done in duplicate wells and 
the final average+sem of minimum three separate experimental values were calculated and 
the graphs were generated using GraphPad 7.0. 
 
The coumarin-NO conjugates 7.6a and 7.6b were very effective in inhibiting the 
proliferation of all the cancerous cell lines MDA-MB-231, 4T1 and WiDr (Figure 7a). 
This was a significant improvement when compared to their non-hybrid derivatives which 




enhancing conjugates 7.6a and 7.6b exhibited moderate activity towards MCF10A. 
Specifically, 7.6a was effective at very low concentrations ranging from 0.02 - 0.13 µM 
against the cancerous cell lines. Comparatively, this derivative 7.6a had a significantly 
lower activity towards the non-cancerous cell line MCF10A (IC50 of 34 µM). The amide 
derivative (7.6b) was comparatively less effective in its antiproliferative properties (0.46 - 
10 µM) against all the cell lines. The parent compounds 7.5a and 7.5b did not have any 
significant inhibition of proliferation even at the maximum tested concentration of 250 
micromolar (Figure 3.2a). The 7.6a derivative had outstanding selectivity between the 
cancerous and non-cancerous cell lines with a 10-fold reduction in activity against the two 
types of cell lines. Based on the nM antiproliferation activity, the two derivatives were 
immediately designated to lead derivative status and evaluated for their in vivo toxicity and 
anticancer efficacy.  
7.4 Systemic toxicity study of the NO donor-carboxy coumarin conjugates 7.6a-b 
 Based on in vitro cell proliferation inhibition, the candidate compounds 7.6a-b 
were evaluated for their translatability as a cancer chemotherapeutic. Both derivatives were 
insoluble in water and required formulations (10% (v/v) DMSO, 10% (v/v) PEG-400, 40% 
(v/v) HS-15 (18.8%w/v), 40%H2O) to be injected successfully intraperitoneally (i.p.). 
Initially, we evaluated the systemic toxicity of each derivative in ICR mice (n=6). Mice 
were injected daily with 7.6a and 7.6b at a dosage of 20 mg/kg, i.p. which was chosen 





Figure 7b: The toxicity study of (A) molecular hybrid 7.6a administered at 20mg/kg daily 
and (B) molecular hybrid 7.6b administered 20mg/kg daily in ICR mice showed no 
significant weight loss over a 14 -day period. 
The results of this study showed that the candidate compounds 7.6a and 7.6b did 
not exhibit body weight loss when compared to control groups (Figures 2m). Based on 
this toxicity study and the previous near nm in vitro results against MDA-MB-231 cell line, 
lead candidate compound 7.6a was chosen and evaluated for anticancer efficacy in an 
MDA-MB-231 tumor xenograft model. 
7.5 In vivo efficacy study in MDA-MB-231 xenograft model:  
MDA-MB-231 based tumor xenograft model was chosen to evaluate the 
translatability of candidate compound 7.6a in female SCID mice. This derivative was 
chosen for its excellent antiproliferation activity and tolerability in CD-1 mice. After 
tumors reached ~100 cm3, mice were randomly divided into two groups based on average 
tumor volume. The mice were injected with 20mg/kg (i.p.) of compound 7.6a and the 
control group was given an injection of vehicle. Treatment was continued for 14 days and 





Figure 7c: In vivo MDA-MB-231 xenograft model: (A) Treatment with 7.6a resulted in a 
reduction of tumor volume when compared to vehicle treated mice. (B) Tumor weight 
indicated a reduction in tumor growth in 7.6a treated mice compared to vehicle. 
The hybrid derivative 7.6a exhibited significant suppression in tumor volume 
(Figure 7c) compared to the control group. At the end of the study, all the tumors were 
resected, and the tumor mass was weighed. Although, there was an apparent reduction in 
tumor volume and weight there was no statistical significance compared to the control 
(Figures 3.2c A and B). 
 
7.6 Discussion 
The coupling of coumarin carboxylic acid to the NO donor via an ester 7.6a or an 
amide 7.6b bond resulted in significant increase in the antiproliferative property of the 
parent structure. In fact, in the derivative 7.6a the activity was 20 nM in the MDA-MB-




antiproliferative activity towards the MDA-MB-231 cell line lead to further preclinical 
evaluation of the candidate compound in vivo xenograft studies. 
Both the ester and amide derivatives 7.6a-b were well tolerated in mice up to a 
dosage of 20 mg/kg ip. A xenograft study was carried out using MDA-MB-231 tumor 
model and the administration of compound 7.6a was conducted over a 14-day period. The 
reduction in tumor volume showed that this derivative had similar activity to the known 
chemotherapeutic drug doxorubicin. The derivative 7.6a exhibited reduction in tumor 
volume this was reflected in the tumor weight of the after resection. The project yielded a 
very selective in vitro cell proliferation inhibition and moderate anticancer efficacy in in 







We synthesized novel metabolic plasticity inhibitors for treatment of cancer. 
The chemical structure of lead candidate compounds and their biological 






Co-treatment with NAC reveals decrease in γ-H2AX, apoptotic protein 
GST and MST study conclude that metabolic functions are compromised  





















Candidate compounds 1 and 3: Future studies would include further preclinical 
development of the candidate compounds. First studies will involve in vivo evaluation of 
the PK/PD of the candidate compounds including CACO-2 permeability and liver 
microsomal stability study. Further studies would evaluate the anticancer efficacy studies 
in combination with other glycolytic inhibitors or chemotherapeutics to see if the 















Candidate compounds 5 and 7: The future studies of these derivatives would involve in 
vivo evaluation in a tumor xenograft of an MCT1 and MCT4 cell line. Furthermore, 
western blot analysis to evaluate the mechanism of action. Furthermore, the derivatives 
will be evaluated for various PK/PD parameters like CACO-2 permability and liver 
microsomal stability study.    
 
 
    
 
    



















Candidate compounds 8 and 11: The future studies of the candidate compounds will 
involve in vivo metabolic stability evaluation using CACO-2 permability and liver 
microsomal enzyme stability studies. Further tumor efficacy studies would involve an 
MCT1 expressing cell line like WiDr and also combination studies with toxic 
chemotherapeutics. Furthermore, western blot analysis to understand the mechanism of 











Candidate compounds 13: Although in vitro studies are encouraging with compound 12 
due to the presence of more labile ester group this compound could metabolize resulting 
faster elimination rates in vivo. Future studies will involve in vivo metabolic stability 
evaluation studies with candidate compound 13. Further anticancer efficacy studies in 
MCT1 and MCT4 expressing tumor studies as single agents and in combination with 






CHAPTER 9: Experimental Procedures and Chemical Analysis 
Cell lines and culture conditions:  
MDA-MB-231 cells (ATCC) were grown in DMEM supplemented with 10% 
FBS (Atlanta Biologicals) and penicillin-streptomycin (50U/ml, 
50µg/ml, Invitrogen). WiDr cells (ATCC) were cultured in MEM medium 
supplemented with 10% FBS and penicillin-streptomycin. 4T1 and 67NR cells 
were grown in RPMI-1640 supplemented with 10% FBS and penicillin-
streptomycin. MCF7 cells (Masonic Cancer Center, University of Minnesota) 
were grown in MEM supplemented with 6% FBS, EGF (0.01 µg/ml), NEAA 
(1X), HDC (1 µg/ml), insulin (10 µg/ml), HEPES (12 mM) and sodium pyruvate 
(1 mM). The RBE4 cell line was obtained from Dr. Drewes’s lab and were 
cultivated in 1:1 mixture of α-MEM and Ham’s F-10 nutrient mix with HEPES 
(Gibco), 10% heat inactivated FBS (Atlanta Biologicals), basic fibroblast growth 
factor (1 ng/mL, US Biologicals), geneticin G418 (0.3 mg/mL, VWR 
International), and antibiotic-antimycotic (10,000 U/mL of penicillin, 10,000 
µg/mL of streptomycin, and 25 µg/mL of Fungizone, Gibco) 
MTT based cell proliferation inhibition assay:  
Cell proliferation inhibition was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT). This colorimetric assay measures the amount of MTT reduced 




compounds were added in serial dilution to the wells in replicates and incubated for 72 
hours. 10 µL of MTT (12µM) was added to each well and incubated for 4 hours before 
adding 100µL of SDS (1g/10mL 0.01M HCl) and incubated for another 4 hours. The 
absorbance for each well was recorded at 570 nm. The percent viability was calculated by 
comparing the absorbance value of treated wells to the control (% viability = (Abstest 
compound/Abscontrol) x 100). IC50 was obtained using GraphPad by plotting log[concentration] 
on x-axis and percent of viable cells on y-axis.  
MCT1 inhibition using 14C-lactate uptake assay 
For MCT1 RBE4 cell lines were used. The cells were seeded at a concentration of 2 x 
105 cells/mL in a collagen coated 24-well plate (500 µL in each well) and incubated for 20 
hours prior to the addition of the test compounds. Prior to experiment the growth media 
was removed and the cells were washed twice with HEPES buffer at pH 7.43 (140 mM 
NaCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, and 10 mM HEPES). The cells were 
equilibrated at 37°C for 15 minutes. Test compounds were diluted in a solution containing 
3 µM 14C-lactic acid sodium salt, 2 µM lactic acid sodium salt, and HEPES buffer. Test 
compounds were added to the wells and incubated for 20 minutes. This solution was then 
replaced with ice-cold cold buffer containing 100 µM CHC and placed on ice. The wells 
were washed three times with cold buffer and 250 µL of 0.1 M NaOH in 5% triton X-100 
was added to solubilize the cells. Next 150 µL of this solution was transferred to a 
scintillation vial that contained 4 mL of ecolite (+). The intracellular 14C-lactate uptake was 
measured using a Beckman scintillation counter and the readings were obtained as dpm. 








The IC50 value of a test compound can be calculated using GraphPad Prism and analyzed 
by interpolation of sigmoidal curve. 
MCT4 inhibition using 14C-lactate uptake assay:  
For MCT4 MDA-MB-231 cell lines were used. The cells were seeded at a concentration 
of 4 x 105 cells/mL in a 24-well plate (500 µL in each well) and incubated for 20 hours 
prior to the addition of the test compounds. Prior to experiment the growth media was 
removed and the cells were washed twice with HEPES buffer at pH 7.0 (140 mM NaCl, 5 
mM KCl, 2 mM CaCl2, 2 mM MgCl2, and 10 mM HEPES). The cells were equilibrated at 
37°C for 15 minutes. Test compounds were diluted in a solution containing 3 µM 14C-lactic 
acid sodium salt, 2 µM lactic acid sodium salt, and HEPES buffer. Test compounds were 
added to the wells and incubated for 20 minutes. This solution was then replaced with ice-
cold cold buffer containing 100 µM CHC and placed on ice. The wells were washed three 
times with cold buffer and 250 µL of 0.1 M NaOH in 5% triton X-100 was added to 
solubilize the cells. Next 150 µL of this solution was transferred to a scintillation vial that 
contained 4 mL of ecolite (+). The intracellular 14C-lactate uptake was measured using a 
Beckman scintillation counter and the readings were obtained as dpm. The % inhibition of 
lactate were calculated by  







The IC50 value of a test compound can be calculated using GraphPad Prism and analyzed 
by interpolation of sigmoidal curve. 
Western blot analysis:  
Cells were plated at 25000 cells/ml in petri dishes and allowed to grow for 48 hours. Next, 
cells were treated with test compounds for 24 hours, and then were washed twice with 1X 
PBS and solubilized in 200 μL SDS boiling buffer (5% w/v SDS, 10% v/v glycerol, and 
60mM Tris pH 6.8), and sonicated. The resultant cell lysate was diluted 1:5 with deionized 
H2O and assayed for protein using the Pierce BCA protocol. A volume of test sample 
containing 10 μg protein was loaded on SDS PAGE gel for electrophoresis according to 
manufacturer’s instructions. Proteins were transferred from the gel to nitrocellulose 
membrane according to the manufacturer’s instructions. The PARP (rabbit polyclonal IgG, 
Origene, TA321555), P53 (rabbit polyclonal IgG, Santa Cruz, sc50329), and γ-H2AX 
(mouse monoclonal, Upstate 05-636, 0.5μg/mL) were detected and visualized using HRP 
chemiluminescence. For relative quantitation, β-actin (mouse monoclonal IgG C4, 
Millipore, MAB1501) was detected and measured as a control protein. 
Seahorse XFe96® assessment of glycolysis and mitochondrial respiration:  
Cells were plated at a concentration of 20,000 cells/well in a Seahorse XFe96 culture 
microplate (Agilent, part no. 101085-004) and incubated for 24 hours at 37⁰C at 5% CO2. 
Sensor cartridge (Agilent, part no. 102416-100) was hydrated with XF calibrant (Agilent, 
part no. 100840-000) overnight at 37⁰C in an incubator without CO2. The assay media was 
prepared from Seahorse base medium (Agilent, part no. 102353-100) and enriched with 




maintained at 7.4, and prewarmed to 37oC before usage.  For glycolysis stress test, the 
assay media was used without glucose. For the mitochondrial stress test the assay media 
was enriched with glucose (10mM). For both stress tests an 8X stock concentration of test 
compounds in their respective media was prepared for microplate injections in port A. 
Stock solutions of glucose (90mM or 9X), oligomycin (100 μM or 10X), and 2-
deoxyglucose (Chem Impex) (550mM or 11X) were prepared such that their final working 
concentrations are 10mM, 1μM and 50mM, respectively, for glycolysis stress test. For 
mitochondrial stress test, stock solutions of oligomycin (9 µM or 9X), FCCP (2.5-10 µM 
or 10X), rotenone+antimycin A (5.5 µM or 11X) were prepared such that their final 
concentrations were 1 µM, 0.25-1 µM, and 0.5µM, respectively in the glucose enriched 
assay media. Under glycolytic stress test, the cells were treated with test compounds after 
14.29 minutes, and glucose, oligomycin and 2-deoxyglucose were added after 33.8, 53.35, 
and 72.87 minutes, respectively. For mitochondrial stress test, port A was injected with test 
compoundsbat 14.29 minutes, and oligomycin, FCCP, and rotenone+antimycin A were 
added after 33.8, 53.35, 72.87 minutes, respectively. ECAR and OCR were measured for 
glycolysis and mitochondrial stress tests, respectively, via Seahorse XFe96® analyzer 
(Agilent). The glycolysis and mitochondrial parameters for GST and MST were calculated 
utilizing the Wave 2.4.0 software (Agilent). 
Fluorescent microscopy studies:  
MDA-MB-231 or WiDr cells (5x104 cells/mL) were seeded in glass-bottom dishes 
(MatTek Corp, part no. P35G010C) and incubated for 48 hours.  Test compound (30μM) 




imaging. In some cultures, MitoTracker Red CMXROS (Invitrogen, M7512, 100 nM) was 
added 15 min prior to imaging. The growth media was removed and replaced with 5% FBS 
in 1X PBS for imaging. Cells were then examined and photographed using a Nikon TE2000 
epifluorescent microscope and camera. The images shown are representative of at least 3 
fields of view of three separate experiments. 
Ethical statement:  
The experimental procedures involving animals that were conducted at the University of 
Minnesota Duluth were in compliance with the U.S. National Institutes of Health Guide 
for Care and Use of Laboratory Animals and approved by the Institutional Animal Care 
and Use Committee at the University of Minnesota (UMN). 1307-30773A, 1311-31063A, 
and 1612-34444A 
General procedure for systemic toxicity evaluation:  
Healthy CD-1 mice were ordered from Charles River. Upon arrival the mice were housed 
two mice per cage and acclimatized at room temperature for 7 days. Prior to the study the 
mice were weighed and placed into groups (n = 6 mice per group) so the standard deviation 
between each group was minimal. In each cage of two mice, one mouse was identified 
from the either with a black mark on its tail. Treatment with candidate compounds was 
started via i.p. The body weights were monitored very day before injections for a period of 
14-21 days. At the end of the study, mice were euthanized using CO2. 
Tumor growth inhibition studies:  
WiDr cells (5 x 106 cells) were suspended in 1:1 mixture of matrigel (Corning, cat. no. 




mice (Charles River). The mice were randomly assigned into 3 groups (n=6 mice per 
group). Vertical and horizontal diameters of tumors were measured every two or three days 
using calipers. The tumor volumes were calculated assuming a perfect sphere using the 
formula V = ab2/2 where ‘a’ is the longer diameter of the tumor and ‘b’ is the shorter 
diameter of the tumor. Treatment was initiated when the tumor volume reached 100mm3. 
The study was terminated after sixteen days and tumors were then resected and weighed.  
Statistical analysis:  
Statistics were computed using GraphPad Prism version 7.0. Repeated measures one-way 
ANOVA was used for in vitro studies and Mann-Whitney test was used for in vivo studies. 
A P-value of < 0.05 was considered significant where *, P < 0.05; **, P < 0.01; ***, P < 






Synthesis of (E)-3-(4-((tert-butyldiphenylsilyl)oxy)phenyl)-2-cyanoacrylic acid (3.1a): 
Commercially available α-cyano-4-hydroxycinnamic acid (10.6 mmol) was dissolved in 
DMF followed by the addition DIPEA (31.7 mmol) to the solution. After stirring for one 
hour, TBDPSCl (42.3 mmol) was added dropwise to the reaction on ice and was stirred 
overnight. The completion of the reaction was monitored with TLC (70% EA/Hexanes). 
Upon completion of the reaction, the solution was quenched with HCl and ice. The 
precipitate was then filtered and washed with hexanes. The product was purified using 
column chromatography (triethyl amine treated silica gel, EA and Hexanes 1:3) giving the 













(E)-3-(4-((tert-butyldiphenylsilyl)oxy)phenyl)-2-cyanoacrylic acid (3.1a) 
 1H NMR (500 MHz, CDCl3):  
δ ppm 8.15 (s, 1H), 7.84 (d, J = 9 Hz, 2H), 7.67 - 7.72 (m, 4H), 7.43 - 7.50 (m, 2H), 7.37 - 
7.43 (m, 4H), 6.86 (d, J = 9 Hz, 2H), 1.12 (s, 9H)  
13C NMR (126 MHz, CDCl3):  
δ ppm 168.0, 161.1, 156.1, 135.3, 133.9, 131.7, 130.4, 128.0, 124.4, 120.8, 115.6, 98.2, 
26.4, 19.5  
HRMS (ESI) m/z:  
calc’d for C17H22N2O3 [M+Na]
+: 428.168  
found 428.146  
Elemental Analysis C, H, N, O  
Anal. Calcd for C26H25NO3Si (427.16): C 73.04, H 5.89, N 3.28.  









Synthesis of E)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-cyanoacrylic acid (3.1b): 
Commercially available α-cyano-4-hydroxycinnamic acid (10.6 mmol) was dissolved in 
DMF followed by the addition DIPEA (31.7 mmol) to the solution. After reacting for one 
hour, TBSCl (42.3 mmol) in 5 ml of DCM was added dropwise to the reaction on ice. The 
reaction was stirred overnight. The completion of the reaction was monitored with TLC 
(70% EA/Hexanes). Upon completion of the reaction, the solution was poured over ice and 
worked up with ether. The organic layer was dried with magnesium sulphate and the 
organic layer was evaporated. The product was purified using column chromatography 















(E)-3-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-cyanoacrylic acid (3.1b):  
1H NMR (500 MHz, CDCL3-d)  
δ 8.25 (s, 1H), 8.00 (d, J = 9 Hz, 2H), 6.96 (d, J = 9 Hz, 2H), 1.00 (s, 9H), 0.27 (s, 6H)  
13C NMR (126 MHz, CDCl3):  
δ 168.5, 161.5, 156.2, 134.2, 124.5, 121.0, 115.6, 98.4, 25.5, 18.3, -4.3 
HRMS (ESI) m/z:  
calc’d for C16H21NO3Si [M+H]
+: 304.12  
found: 304.12.  
Elemental Analysis C, H, N, O 
Anal. Calcd for C16H21NO3Si (303.43): C 63.33, H 6.98, N 4.62.  












The synthesis of 4-(2-hydroxyethoxy)benzaldehyde (11) 4-hydroxybenaldehyde (81.8 
mmol) was dissolved in 80 ml of EtOH. Potassium carbonate (163 mmol) was added to the 
reaction flask followed by 2-chloroethanol (327 mmol). The reaction mixture was refluxed 
for 10 hours, potassium carbonate was filtered and ethanol was partially evaporated. The 
slurry was extracted 3x with 100 ml of ethyl acetate in water and washed with 100 ml of 
0.01M NaOH solution. The organic layer was separated and dried on anhydrous MgSO4 
and the organic layer was evaporated using a rotatory evaporator. The resulting white solid 
was used for the next reaction without further purification. 
 
The synthesis of (E)-2-cyano-3-(4-(2-hydroxyethoxy)phenyl)acrylic acid (3.3): The 
benzaldehyde 11 (12 mmol) was dissolved in 40 ml of acetonitrile (0.2M). Cyanoacetic 
acid (18.1 mmol) was added followed by the addition of piperidine (24.1 mmol). The 
reaction was then allowed to reflux overnight. Upon completion of the reaction (monitored 
via TLC), the solution was poured over ice and 10 ml 3M HCl. The resulting precipitate 




column chromatography (silica gel, EA) to yield the final cream colored solid (Yield: 
78%). 
 
E)-2-cyano-3-(4-(2-hydroxyethoxy)phenyl)acrylic acid (3.3):  
1H NMR (500 MHz, MeOH-d6):  
δ 8.09 (s, 1H), 7.98 (d, J = 9 Hz, 2H), 7.12 (d, 2H), 4.20 (t, 2H), 3.97 (t, J = 5 Hz, 2H)  
13C NMR (126MHz, MeOH-d6):  
δ 167.5, 161.8, 149.7, 131.8, 125.4, 118.4, 114.6, 107.0, 69.4, 60.1.  
 
 
74-(2-((tert-butyldiphenylsilyl)oxy)ethoxy)benzaldehyde (3.4a): 4-(2-hydroxyethoxy) 
benzaldehyde (3.2) (12 mmol) was dissolved in 90 ml of DCM (0.1M) and imidazole 
(36mmol) was added to the reaction at room temperature. After 10 minutes, a solution of 
TBDPSCl (14.4 mmol) in DCM was added to the reaction at 0oC. Reaction completion was 
monitored with TLC (10% EA/Hexanes) which was then extracted with DCM and washed 
twice with water followed by brine. The organic layer was dried with MgSO4 and the 
solvent was removed. The resulting brown oil was then carried on to the next reaction 





4-(2-((tert-butyldimethyllsilyl)oxy)ethoxy)benzaldehyde (3.4b): 4-(2-hydroxyethoxy) 
benzaldehyde (11) (12 mmol) was dissolved in 90 ml of DCM and imidazole (36mmol) 
was added at room temperature. After 10 minutes a solution of TBSCl (14.4 mmol) in 
DCM was added to the reaction at 0oC. Reaction completion was monitored with TLC 
(10% EA/Hexanes) which was then extracted with DCM and washed twice with water 
followed by brine. The organic was dried on MgSO4 and the solvent was removed. The 
resulting brown oil was then carried on to the next reaction without further purification. 
 
4-(2-((triisopropylsilyl)oxy)ethoxy)benzaldehyde (3.4c): 4-(2-hydroxyethoxy) 
benzaldehyde (11) (12 mmol) was dissolved in 90 ml of DCM and imidazole (36mmol) 
was added to the reaction room temperature. After 10 minutes a solution of TIPSCl (14.4m 
ml) in DCM was added to the reaction at 0oC. Reaction completion was monitored with 
TLC (10% EA/Hexanes). The reaction was extracted with ethyl acetate then washed twice 








 (E)-3-(4-(2-((tert-butyldiphenylsilyl)oxy)ethoxy)phenyl)-2-cyanoacrylic acid (3.5a): The 
silylated benzaldehyde 3.4a (12 mmol) were dissolved in 40 ml of acetonitrile. Cyanoacetic 
acid (18.1 mmol) was added followed by the addition of piperidine (24.1 mmol). The 
reaction was then allowed to reflux for 10 hours. Reaction completion was monitored with 
TLC (10% EA/Hexanes). Upon completion the solution was poured over ice and 10 ml of 
3M HCl. The resulting precipitate was then filtered and washed with 50 ml of ether to 
obtain the crude product 3.5a. The crude product was purified using column 








 1H NMR (500 MHz, CDCl3) δ ppm 8.24 (br. s., 1H), 8.01 (d, J = 8 Hz, 2H), 7.67 - 7.74 
(m, 4H), 7.36 - 7.48 (m, 6H), 6.94 (d, J = 8 Hz, 2H), 4.16 (t, J = 5 Hz, 2H), 4.02 (t, J = 5 
Hz, 2H), 1.07 (s, 9H).  
13C NMR (126 MHz, CDCl3) δ ppm 168.8, 163.8, 156.1, 135.6, 134.2, 133.3, 129.9, 127.8, 
124.1, 115.4, 98.4, 69.4, 62.3, 26.8, 19.2  
Elemental Analysis C, H, N, O 
Anal. Calcd for C28H29NO4Si Na
+ (494.18): C 67.99, H 5.91, N 2.83.  
Found: C 69.06, H 5.98, N 2.90. 
 
(E)-3-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenyl)-2-cyanoacrylic acid (3.5b): The 
silylated benzaldehyde 2.4b (12 mmol) was dissolved in 40 ml of acetonitrile. Cyanoacetic 
acid (18.1 mmol) was added followed by piperidine (24.1 mmol) and refluxed for 10 hours. 
Reaction completion was monitored with TLC (10% EA/Hexanes). Upon completion the 
solution was poured over ice and 10 ml of 3 M HCl. The resulting precipitate was then 
filtered and washed with 50 ml of ether to obtain the crude product 3.5b. The crude product 
was purified using column chromatography (silica gel, EA and hexanes 1:5) yielding the 






(E)-3-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenyl)-2-cyanoacrylic acid (3.5b): 
1H NMR (500 MHz, CDCl3-d):  
δ 8.22 (s, 1H), 8.03 (d, J = 9 Hz, 2H), 7.03 (d, J = 9 Hz, 2H), 4.15 (t, 5Hz, 2H), 4.01 (t, 
5Hz, 2H), 0.91 (s, 9H), 0.11 (s, 6H) 
13C NMR (126 MHz, CDCl3-d):  
δ 167.9, 163.8, 156.0, 134.2, 124.1, 115.7, 115.5, 98.1, 69.8, 61.7, 25.9, 18.4, -5.2 
HRMS (ESI) m/z:  
calc’d for C18H25NO4Si [M+H]
+: 348.16 
found: 348.14;  
Elemental Analysis C, H, N, O 
Anal. Calcd for C18H25NO4Si (347.48): C 73.04, H 5.89, N 3.28.  
Found: C 72.34, H 5.96, N 3.20.  
 
and (E)-3-(4-(2-((tri-isopropylsilyl)oxy)ethoxy)phenyl)-2-cyanoacrylic acid (3.5c) : The 




acid (18.1 mmol) was added followed by the addition of piperidine (24.1 mmol). The 
reaction was then allowed to reflux for 10 hours. Reaction completion was monitored with 
TLC (10% EA/Hexanes). Upon completion the solution was poured over ice and 10 ml of 
3 M HCl. The resulting precipitate was then filtered and washed three times with 50 ml of 
ether to obtain the crude product 3.5a. The crude product was purified using column 
chromatography (silica gel, EA and hexanes 1:5) yielding the pure product (Yield: 86%). 
 
 
(E)-3-(4-(2-((tri-isopropylsilyl)oxy)ethoxy)phenyl)-2-cyanoacrylic acid (3.5c):  
1H NMR (500 MHz, CDCl3-d):  
δ 8.10 (s, 1 H), 7.93 (d, J = 9 Hz, 2H), 6.95 (d, J = 9 Hz, 2H), 4.10 (t, J = 5 Hz, 2 H), 4.02 
(t, J = 5 Hz, 2 H), 0.98 - 1.12 (m, 21H)  
 13C NMR (126 MHz, CDCl3-d): δ 164.8, 163.0, 153.9, 133.4, 124.4, 116.6, 115.2, 100.2, 
69.7, 62.0, 17.9, 11.9;  
HRMS (ESI) m/z:  
calc’d for C21H31NO4Si [M+H]
+: 390.21  
found: 390.19  
Elemental Analysis C, H, N, O 
Anal. Calcd for C21H31NO4Si (389.57): C 64.75, H 8.02, N 3.60.  







4-(diethylamino)-2-(3-hydroxypropoxy)benzaldehyde (4.1): Commercially available 4-
(diethylamino)-salicylaldehyde (26 mmol) was dissolved in 100ml of acetonitrile. Next 
potassium carbonate was added to the reaction. The reaction reacted at room temperature 
for 30 minutes before bromopropanol (31 mmol) was added to the reaction slowly. Next 
catalytic amounts of potassium iodide (0.26 mmol) was added to the reaction. The reaction 
was heated to reflux and left to react for 16 hours. A TLC was checked (30% EA/Hexanes) 
to ensure completion. The potassium carbonate was filtered off and the acetonitrile was 
evaporated via rotoevaporation. The resulting product was washed with hexanes twice to 










4-(diethylamino)-2-(3-hydroxypropoxy)benzaldehyde (4.1):  
1H NMR (500 MHz, CDCl3):   
δ 9.95 (s, 1H), 7.60 (d, J = 9 Hz, 1H), 6.29 (d, J = 9 Hz, 1H), 6.06 (s, 1H), 4.19 (t, J = 6 Hz, 
2H), 3.89 (t, J = 6 Hz, 2H), 3.43 (q, J = 7 Hz, 4H), 2.11 (quin, J = 6 Hz, 2H), 1.22 (t, J = 7 
Hz, 6H)  d 
13C NMR (126 MHz, CDCl3):  
δ ppm 187.5, 162.8, 153.8, 133.3, 114.1, 104.1, 93.3, 66.2, 60.3, 44.8, 32.0, 12.6 
 
2-(3-((tert-butyldiphenylsilyl)oxy)propoxy)-4-(diethylamino)benzaldehyde (4.3a): The 
benzaldehyde (4.2) (12 mmol) was dissolved in 90 ml of DCM and imidazole (36 mmol) 
was added to the reaction room temperature. After 10 minutes a solution of TBDPSCl (14.4 
mmol) in DCM was added to the reaction at 0oC. Completion of the reaction was monitored 
by TLC (20% EA/Hexanes) over 3 hours as the reaction warmed to room temperature. 




organic was dried on MgSO4 and the solvent was removed. The resulting brown oil was 
then carried on to the next reaction without further purification. 
 
2-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-(diethylamino)benzaldehyde (4.3b): The 
benzaldehyde (4.2) (12 mmol) was dissolved in 90 ml of DCM and imidazole (36 mmol) 
was added to the reaction room temperature. After 10 minutes a solution of TBSCl (14.4 
mmol) in DCM was added to the reaction at 0oC. Completion of the reaction was monitored 
by TLC (20% EA/Hexanes) over 3 hours as the reaction warmed to room temperature. 
Upon completion the reaction was worked up twice with water followed by brine. The 
organic was dried on MgSO4 and the solvent was removed. The resulting brown oil was 
then carried on to the next reaction without further purification. 
 
4-(diethylamino)-2-(3-((triisopropylsilyl)oxy)propoxy)benzaldehyde (4.3c): The 
benzaldehyde (4.2) (12 mmol) was dissolved in 90 ml of DCM and imidazole (36 mmol) 
was added to the reaction room temperature. After 10 minutes a solution of TIPSCl (14.4 




by TLC (20% EA/Hexanes) over 3 hours as the reaction warmed to room temperature. 
Upon completion the reaction was worked up twice with water followed by brine. The 
organic was dried on MgSO4 and the solvent was removed. The resulting brown oil was 
then carried on to the next reaction without further purification. 
 
(E)-3-(2-(3-((tert-butyldiphenylsilyl)oxy)propoxy)-4-(diethylamino)phenyl)-2-
cyanoacrylic acid (4.4a): The silylated benzaldehyde 4.3a (12 mmol) were dissolved in 40 
mL of acetonitrile. Cyanoacetic acid (18.1 mmol) was added followed by piperidine (24.1 
mmol). The reaction was then refluxed for 10 hours. Completion of the reaction was 
monitored using TLC (30% EA/Hexanes) Upon completion of the reaction, the solution 
was poured over ice and 10 mL of 3 M HCl. The resulting precipitate was then filtered and 
washed with 50 mL of ether to obtain the crude product 4.4a. The crude product was 
purified using column chromatography (triethyl amine treated silica, EA and hexanes 2:5) 







cyanoacrylic acid (4.4a):  
1H NMR (500 MHz, CDCl3):  
δ 8.85 (s, 1H), 8.74 (d, J = 9 Hz, 1H), 7.89 (d, J = 7 Hz, 4H), 7.64 - 7.70 (m, 2H), 7.56 - 
7.62 (m, 4H), 6.64 (d, J = 9 Hz, 1H), 6.31 (s, 1H), 4.46 (t, J = 6 Hz, 2H), 4.17 (t, J = 6 Hz, 
2H), 3.73 (q, J = 7 Hz, 4H), 2.36 (quin, J = 6 Hz, 2H), 1.51 (t, J = 7.1 Hz, 6H), 1.32 (s, 
9H)    
13C NMR (126 MHz, CDCl3):  
δ 170.4, 162.1, 154.1, 148.9, 135.4, 133.5, 131.6, 129.7, 127.7, 118.2, 109.3, 105.3, 93.1, 











cyanoacrylic acid (4.4b): The silylated benzaldehyde 4.3b (12 mmol) were dissolved in 40 
mL of acetonitrile. Cyanoacetic acid (18.1 mmol) was added followed by piperidine (24.1 
mmol). The reaction was then refluxed for 10 hours. Completion of the reaction was 
monitored using TLC (30% EA/Hexanes) Upon completion of the reaction, the solution 
was poured over ice and 10 mL of 3 M HCl. The resulting precipitate was then filtered and 
washed with 50 mL of ether to obtain the crude product 4.4b. The crude product was 
purified using column chromatography (triethyl amine treated silica, EA and hexanes 2:5) 












cyanoacrylic acid (4.4b):  
1H NMR (500 MHz, CDCl3-d):  
δ 8.71 (s, 1H), 8.47 (d, J = 9 Hz, 1H), 6.36 (d, J = 9 Hz, 1H), 6.06 (s, 1H), 4.14 (t, J = 6 Hz, 
2H), 3.87 (t, J = 6 Hz, 2H), 3.47 (q, J = 7 Hz, 4H), 2.08 (quin, J = 6 Hz, 2H), 1.26 (t, J = 7 
Hz, 6H), 0.90 (s, 9H), 0.07 (s, 6H);  
13C NMR (126 MHz, CDCl3-d):  
δ 170.6, 162.1, 154.1, 148.8, 131.7, 118.2, 109.2, 105.3, 93.2, 89.9, 64.9, 59.3, 45.0, 32.1, 











(E)-2-cyano-3-(4-(diethylamino)-2-(3-((triisopropylsilyl)oxy)propoxy)phenyl)acrylic acid  
(4.4c):  The silylated benzaldehyde 4.3c (12 mmol) were dissolved in 40 mL of acetonitrile. 
Cyanoacetic acid (18.1 mmol) was added followed by piperidine (24.1 mmol). The reaction 
was then refluxed for 10 hours. Completion of the reaction was monitored using TLC (30% 
EA/Hexanes) Upon completion of the reaction, the solution was poured over ice and 10 
mL of 3 M HCl. The resulting precipitate was then filtered and washed with 50 mL of ether 
to obtain the crude product 4.4c. The crude product was purified using column 
chromatography (triethyl amine treated silica, EA and hexanes 2:5) yielding the final pure 












(4.4c): 1H NMR (500 MHz, CDCl3-d):  
δ 8.71 (s, 1H), 8.47 (d, J = 9 Hz, 1H), 6.36 (d, J = 9 Hz, 1H), 6.07 (s, 1H), 4.18 (t, J = 6 Hz, 
2H), 3.94 (t, J = 6 Hz, 2H), 3.47 (q, J = 7 Hz, 4H), 2.10 (quin, J = 6 Hz, 2H), 1.25 (t, J = 7 
Hz, 6H), 1.05-1.15 (m, 21H);  
13C NMR (126 MHz, CDCl3-d):  
δ 170.8, 162.2, 154.1, 148.9, 131.6, 118.2, 109.3, 105.3, 93.2, 89.9, 65.2, 59.6, 45.0, 32.2, 







Synthesis of 2-(phenylthio)acetic acid (6.1): Synthesis of the precursor 3.1 was 
conducted by taking commercially available thiophenol (0.908 mol) and suspending it in a 
solution of 150 ml of water. potassium hydroxide (1.083 mol) dissolved in 300 ml of water 
was added slowly to the cooled solution to ensure that the temperature did not exceed 20° 
C. The solution was allowed to react for ten minutes while another solution of bromoacetic 
acid (1.082 mol) in 450 ml of water was made. This solution of bromoacetic acid was added 
to the chilled reaction solution of thiophenol and potassium hydroxide slowly. Following 
the final addition of the bromoacetic acid solution the reaction was heated to 90° C for 3 
hours. After cooling the pH of the solution was adjusted with concentrated HCl and worked 
up with dichloromethane in three 200 ml aliquots. The organic layer was dried with 
magnesium sulfate and concentrated via roto evaporation. The resulting white solid (1) was 
used for the next reaction without any further purification.  
 
Synthesis of diphenylsulphafuroxan (6.2): The synthesis of the (6.2) was conducted by 
initially dissolving 6.1 (59 mmol) in 48 ml of glacial acetic acid. 12 ml of aqueous H2O2 




of the white solid confirms the complete oxidation of sulphur in 6.1. The solution was 
cooled on ice for ten minutes followed by the addition of 25 ml of fuming nitric acid. The 
reaction was taken off ice and slowly heated to 90° C over a period of 1 hour. Immediately 
a few small blocks of ice were added and the solution was allowed to recrystallize for at 
least a day at -20°C. The resulting white solid was filtered and washed with hexanes to 
yield the pure diphenylsulphafuroxan 6.2 as a white solid.  
 
 
Synthesis of (methyl 3-(ethyl (phenyl)amino)propanoate (6.3a): N-Ethyl aniline (185 
mmol) was mixed with acetic acid (20 ml) and methyl acrylate (30 ml). Sodium bromide 
(4.25 mmol) was added to the reaction and the reaction was refluxed for 16 hours. The 
completion of the reaction was monitored by TLC (10% EA/Hexanes) until all the 
corresponding aniline had been converted to 6.3a. The reaction was initially worked up 
with ether and water. The aqueous layer was then quenched with bicarbonate followed by 
another workup with ethyl acetate to yield product as a brown oil. No additional 
purification was performed to remove the remaining extra methyl acrylate and was used 





Synthesis of (methyl 3-(ethyl (phenyl)amino)propanoate (6.3b): N-benzyl aniline (185 
mmol) was mixed with acetic acid (20 ml) and methyl acrylate (30 ml). Sodium bromide 
(4.25 mmol) was added to the reaction and the reaction was refluxed for 16 hours. The 
completion of the reaction was monitored by TLC (10% EA/Hexanes) until all the 
corresponding aniline had been converted to 6.3a. The reaction was initially worked up 
with ether and water. The aqueous layer was then quenched with bicarbonate followed by 
another workup with ethyl acetate to yield product as a brown oil. No additional 
purification was performed to remove the remaining extra methyl acrylate and was used 
for next step. 
 
Synthesis of 4-(ethyl(phenyl)amino)-4-oxobutanoic acid (6.3c): Succinic anhydride (165 
mmol) was dissolved in 100 ml of THF followed by the addition of N-ethylaniline (198 
mmol). The reaction was stirred at room temperature for one hour and completion of the 




reaction worked up with ethyl acetate and water. The organic layer was dried and 
evaporated yielding a white solid. 
 
Synthesis of methyl 4-(ethyl(phenyl)amino)-4-oxobutanoate (6.11): 200 ml of MeOH 
was cooled on ice followed by slow addition of thionyl chloride (158 mmol). The reaction 
was stirred on ice for 10 minutes. The carboxylic acid 6.3c was added slowly over a period 
of 30 minutes. After one hour, a TLC (30% EA/Hexanes) of the reaction was checked for 
completion. The solution was then the reaction was worked up using brine and ether. The 
organic layer was evaporated and the crude product was utilized for the next step without 
any purification. 
 
Synthesis of 3-(ethyl(phenyl)amino)propan-1-ol (6.4a): The ester 6.3a (42.5 mmol) was 
dissolved in 200 ml of THF and the reaction was cooled on ice followed by the slow 
addition of lithium aluminum hydride (128 mmol). The reaction was taken off ice and 




checking a TLC (30% EA/Hexanes) for completion, ethyl acetate was slowly added to the 
reaction followed by completely quenching LiAlH4 with 50 ml of ice cold water and 
sufficient amounts of 2.5M NaOH. The white solid was filtered off and worked up with the 
ethyl acetate and water. The organic layer was then dried and evaporated off to yield a 
brown oil. The pure product was then isolated using column chromatography (silica gel, 
EA and Hexanes 3:10) to yield the final product as a brown oil.  
 
3-(ethyl(phenyl)amino)propan-1-ol (6.4a) 
1H NMR (500 MHz, CDCl3):  
δ 7.20 - 7.27 (m, 2H), 6.77 (d, J = 8 Hz, 2H), 6.71 (t, J = 7 Hz, 1H), 3.76 (t, J = 6 Hz, 2H), 
3.34 - 3.44 (m, 4H), 1.80-2.0 (m, 3H), 1.15 (t, J = 7 Hz, 3H) 
13C NMR (125 MHz, CDCl3): δ 148.1, 129.3, 116.4, 113.1, 61.2, 47.7, 45.4, 30.2, 12.0 
 
Synthesis of 3-(benzyl(phenyl)amino)propan-1-ol (6.4b): Procedures for the synthesis and 
isolation of the derivative were replicated from the reduction of the derivative 4a. 







1H NMR (500 MHz, CDCl3):  
δ 7.17 - 7.34 (m, 7H), 6.76 (d, J = 8 Hz, 2H), 6.70 (t, J = 7 Hz, 1H), 4.56 (s, 2H), 3.74 (t, J 
= 6 Hz, 2H), 3.51 - 3.58 (m, 2H), 1.86 - 1.96 (m, 2H), 1.44 (br. s., 1H) 
13C NMR (125 MHz, CDCl3): δ 148.6, 138.9, 129.2, 128.6, 126.8, 126.7, 116.6, 112.8, 
60.8, 54.9, 48.0, 30.1 
 
Synthesis of 3-(ethyl(phenyl)amino)butan-1-ol (6.4c): Procedures for the synthesis and 
isolation of the derivative were replicated from the reduction of the derivative 6.4a. 
Purification of the derivative was done via column chromatography (silica gel, EA and 








Synthesis of 3-(ethyl(phenyl)amino)propyl acetate (6.5a): The alcohol 6.4a (15.52 mmol) 
was dissolved in 30 ml of DCM and pyridine (31.0 mmol) was added to the reaction. The 
reaction was stirred at room temperature for 10 minutes before addition of acetic anhydride 
slowly. After one hour, a TLC (20% EA/Hexanes) of the reaction was checked for 
completion. The reaction was then worked up with water followed by brine solution. The 
organic layer was dried with magnesium sulfate and evaporated to yield the crude product 
as dark colored oil. 
 
3-(ethyl(phenyl)amino)propyl acetate (6.5a) 
1H NMR (500 MHz, CDCl3):  
δ 7.21 (t, J = 8 Hz, 2H), 6.63 - 6.71 (m, 3H), 4.12 (t, J = 6 Hz, 2H), 3.32 - 3.38 (m, 4H), 
2.07 (s, 3H), 1.92 (quin, J = 7 Hz, 2H), 1.14 (t, J = 7 Hz, 3H) 
 13C NMR (125 MHz, CDCl3):  






Synthesis of 3-(benzyl(phenyl)amino)propyl acetate (6.5b): The synthesis of derivative 
6.5b was conducted under the exact same conditions as those for 6.5a. The purification 
also followed the same workflow for isolation of the product. 
 
3-(benzyl(phenyl)amino)propyl acetate (6.5b) 
1H NMR (500 MHz, CDCl3):  
δ 7.17 - 7.35 (m, 7H), 6.67 - 6.74 (m, 3H), 4.55 (s, 2H), 4.14 (t, J = 6 Hz, 2H), 3.47 - 3.54 
(m, 2H), 2.06 (s, 3H), 1.94 - 2.03 (m, 2H) 
 13C NMR (125 MHz, CDCl3):  








Synthesis of 4-(ethyl(phenyl)amino)butyl acetate (6.5c): The synthesis of derivative 6.5c 
was conducted under the exact same conditions as those for 6.5a. The purification also 
followed the same workflow for isolation of the product. 
 
 
Synthesis of 3-(ethyl(4-formylphenyl)amino)propyl acetate (6.6a),: The dialkyl aniline 
6.5a (9.35 mmol) derivative was dissolved in DMF (8.69 ml). The flask was cooled on ice 
for 10 minutes and then POCl3 (14 mmol) was added to the reaction dropwise. The reaction 
was warmed to room temperature and a TLC (30% EA/Hexanes) was checked for 
completion. The reaction was quenched on 50 ml of cooled 0.3 M potassium carbonate 
solution. The reaction was then worked up with ether. The organic layer was dried with 






3-(ethyl(4-formylphenyl)amino)propyl acetate (6.6a) 
1H NMR (500 MHz, CDCl3):  
δ 9.69 (s, 1H), 7.69 (d, J = 9 Hz, 2H), 6.67 (d, J = 9 Hz, 2H), 4.09 - 4.14 (m, 2H), 3.40 - 
3.48 (m, 4H), 2.07 (s, 3H), 1.95 (quin, J = 6 Hz, 2H), 1.19 (t, J = 7 Hz, 3H) 
13C NMR (125 MHz, CDCl3):  
δ 190.0, 170.9, 152.2, 132.2, 125.0, 110.8, 61.9, 47.1, 45.3, 26.6, 20.9, 12.2 
 
 
Synthesis of 3-(ethyl(4-formylphenyl)amino)propyl acetate (6.6b): Conversion of 6.5b into 







3-(ethyl(4-formylphenyl)amino)propyl acetate (6.6b) 
1H NMR (500 MHz, CDCl3):  
δ 9.74 (s, 1H), 7.71 (d, J = 9 Hz, 2H), 7.24 - 7.38 (m, 3H), 7.18 (d, J = 8 Hz, 2H), 6.75 (d, 
J = 9 Hz, 2H), 4.66 (s, 2H), 4.16 (t, J = 6 Hz, 2H), 3.56 - 3.65 (m, 2H), 2.08 (s, 3H), 2.01 - 
2.07 (m, 2H) 
 13C NMR (125 MHz, CDCl3):  
δ 190.1, 170.9, 152.9, 137.0, 132.2, 128.9, 127.4, 126.2, 125.8, 111.4, 61.9, 54.3, 48.1, 
26.4, 20.9 
 
Synthesis of 4-(ethyl(4-formylphenyl)amino)butyl acetate (6.6c): Conversion of 6.5c into 






Synthesis of 4-(ethyl(3-hydroxypropyl)amino)benzaldehyde (6.7a): Deprotection of the 
acetate 6.7a was conducted by dissolving 6.6a (38 mmol) in ethanol (53.2 ml). Potassium 
carbonate (114 mmol) dissolved in 5 ml of water was added to the reaction. The reaction 
was slightly heated to 70°C and allowed to react for three hours. A TLC (40% EA/Hexanes) 
was checked to ensure the reaction had gone to completion. The reaction was poured over 
6 ml of 6M HCl on ice followed by workup with ethyl acetate. The organic layer was dried 
with magnesium sulfate and the solvent was evaporated. The resulting oily product was 
purified using column chromatography (silica gel, EA and Hexanes 3:1) to yield the final 












1H NMR (500 MHz, CDCl3):  
δ 9.71 (s, 1H), 7.71 (d, J = 9 Hz, 2H), 6.73 (d, J = 9 Hz, 2H), 3.76 (t, J = 6 Hz, 2H), 3.44 - 
3.56 (m, 4H), 1.84 - 1.94 (m, 2H), 1.54 (br., 1H), 1.22 (t, J = 7 Hz, 3H) 
 13C NMR (125 MHz, CDCl3):  
δ 190.1, 152.5, 132.3, 124.8, 110.8, 60.1, 47.0, 45.2, 30.2, 12.1 
 
 
Synthesis of 4-(benzyl(3-hydroxypropyl)amino)benzaldehyde (6.7b): The deprotection of 
the acetate group on 6.6b to form the corresponding alcohol derivative 6.7b was 







1H NMR (500 MHz, CDCl3):  
δ 9.72 (s, 1H), 7.70 (d, J = 9 Hz, 2H), 7.18 - 7.33 (m, 5H), 6.77 (d, J = 9 Hz, 2H), 4.69 (s, 
2H), 3.76 (t, J = 6 Hz, 2H), 3.66 - 3.70 (m, 2H), 1.92 - 1.99 (m, 2H)  
13C NMR (125 MHz, CDCl3):  
δ 190.2, 153.2, 137.2, 132.2, 128.8, 127.3, 126.3, 125.5, 111.4, 60.1, 54.2, 48.0, 30.0. 
 
Synthesis of 4-(ethyl(4-hydroxybutyl)amino)benzaldehyde (6.7c): The deprotection of the 
acetate group on 6.6c to form the corresponding alcohol derivative 6.7c was conducted 







oxadiazole 2-oxide (6.9a): Coupling of the furoxan 6.2 with the corresponding alcohol 
(6.7a) was performed by dissolving 6.7a (6.78 mmol) in 30 ml of DCM. DBU (13.56 
mmol) was added to the reaction. The reaction was stirred at room temperature for 20 
minutes before cooling on ice. The furoxan 6.2 (13.56 mmol) dissolved in 30 ml of DCM 
was added slowly over a 30-minute period. An hour later, the reaction was monitored using 
TLC (30% EA/Hex) for completion. Upon completion the reaction was initially worked up 
with water followed by brine. The organic layer was dried with magnesium sulfate and the 










oxadiazole 2-oxide (6.9b): The coupling of the furoxan (6.2) to the derivative 6.7b was 
conducted under the exact same conditions as 6.9a and purified under similar conditions 
to yield 6.9b. 
 
Synthesis of 4-(4-(ethyl(4-formylphenyl)amino)butoxy)-3-(phenylsulfonyl)-1,2,5-
oxadiazole 2-oxide (6.9c): The coupling of the furoxan (6.2) to the derivative 6.7c was 
conducted under the exact same conditions as 6.9a and purified under similar conditions 






Synthesis of (E)-2-cyano-3-(4-(ethyl(3-hydroxypropyl)amino)phenyl)acrylic acid (6.8) : 
The corresponding aldehyde 6.7a (3.14 mmol) was dissolved in 15 ml of acetonitrile and 
piperidine (6.29 mmol) was added to the reaction. The solution was stirred for 10 minutes 
at room temperature followed by the addition of cyanoacetic acid (4.71 mmol). The 
reaction was then heated to reflux for 18 hours. A TLC (10% MeOH/EA) was checked to 
confirm completion of the reaction. The product was then poured over ice and quenched 
with 1 ml of 6M HCl. The reaction was worked up with ethyl acetate and brine. The organic 
layer was dried with magnesium sulfate and volatiles were concentrated. The resulting 
yellow oil was then purified using column chromatography (silica gel, EA) to yield a pale 











(E)-2-cyano-3-(4-(ethyl(3-hydroxypropyl)amino)phenyl)acrylic acid (6.8) 
1H NMR (500 MHz, DMSO-d6):  
δ 7.93 (s, 1H), 7.80 (d, J = 9.3 Hz, 2H), 6.64 (d, J = 8.8 Hz, 2H), 3.59 (t, J = 5.9 Hz, 2H), 
3.34 - 3.47 (m, 4H), 1.72 - 1.81 (m, 2H), 1.12 (t, J = 7.1 Hz, 3H)  
13C NMR (125 MHz, DMSO-d6):  
δ 166.0, 154.0, 151.7, 134.1, 118.7, 118.0, 111.3, 93.9, 59.3, 47.1, 45.1, 30.2, 12.2. 
 
Synthesis of (E)-4-(3-((4-(2-carboxy-2-cyanovinyl)phenyl)(ethyl)amino)propoxy)-3-
(phenylsulfo nyl)-1,2,5-oxadiazole 2-oxide (6.10a) : The aldehyde 6.9a was reacted with 
cyanoacetic acid using Knoevenagel condensation to yield 6.10a under the same conditions 






1,2,5-oxadiazole 2-oxide ( 6.10a) 
1H NMR (500 MHz, DMSO-d6): 
δ 8.02 - 8.05 (m, 3H), 7.73 - 7.93 (m, 5H), 6.86 (d, J = 10 Hz, 2H), 4.46 (t, J = 5 Hz, 2H), 
3.48-3.57 (m, 4H), 2.05 - 2.09 (m, 2H), 1.14 (t, J = 5 Hz, 3H).  
13C NMR (126 MHz, DMSO-d6): 
δ 165.3, 159.3, 154.1, 151.9, 137.7, 136.6, 134.3, 130.5, 128.7, 118.8, 118.4, 112.0, 111.0, 
93.8, 69.6, 46.4, 45.0, 26.6, 12.6 
Elemental Analysis C, H, N, O 
Anal. Calcd for C23H21N4O7S Na
+ (520.49): C 53.08, H 4.07, N 10.76.  









(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide (6.9b): The aldehyde 6.9b was reacted with 
cyanoacetic acid using Knoevenagel condensation to yield 6.10b under the same conditions 




1,2,5-oxadiazole 2-oxide (6.9b) 
1H NMR (500 MHz, DMSO-d6+CDCl3):  
δ 7.89 (s, 1H), 7.82 (d, J = 5 Hz, 2H), 7.70 (d, J = 5 Hz, 2H), 7.58 (t, J = 8, 1H), 7.41 (t, J 
= 8 Hz, 2H), 7.02 - 7.17 (m, 5H), 6.63 (d, J = 9 Hz, 2H), 4.52 (s, 2H), 4.30 (t, J = 4.5 2H), 
3.58-3.59 (m, 2H), 2.05-2.06 (m, 2H)  




δ 166.5, 158.5, 153.3, 151.4, 137.7, 136.9, 135.8, 133.6, 129.7, 128.8, 128.2, 127.3, 126.3, 
120.3, 118.1, 111.8, 110.3, 97.5, 68.6, 54.3, 47.4, 40.4, 40.3, 26.3. 
Elemental Analysis C, H, N, O 
Anal. Calcd for C28H24N4O7S H2O (560.59): C 58.12, H 4.43, N 9.68.  
Found: C 58.88, H 4.44, N 10.06. 
 
Synthesis of (E)-4-(4-((4-(2-carboxy-2-cyanovinyl)phenyl)(ethyl)amino)butoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide (6.9c): The aldehyde 6.9c was reacted with 
cyanoacetic acid using Knoevenagel condensation to yield 6.10c under the same conditions 













1,2,5-oxadiazole 2-oxide 6.9c:  
1H NMR (500 MHz, DMSO-d6):  
δ 7.90 - 7.93 (m, 3H), 7.81 (d, J = 10 Hz, 2H), 7.68 (t, J = 7 Hz, 1H), 7.51 (t, J = 7 Hz, 2H), 
6.63 (d, J = 9 Hz, 2H), 4.40 (t, J = 7 Hz, 2H), 3.40 - 3.45 (m, 4H), 1.73 - 1.88 (m, 4H), 1.16 
(t, J = 7 Hz, 3H)  
13C NMR (126 MHz, DMSO-d6):  
δ 165.7, 158.8, 153.9, 151.5, 137.8, 135.8, 134.1, 129.8, 128.3, 119.0, 117.9, 111.3, 110.4, 
94.4, 71.2, 49.8, 45.2, 25.9, 23.8, 12.3 
Elemental Analysis C, H, N, O 
Anal. Calcd for C24H24N4O7S (512.54): C 56.24, H 4.72, N 10.93.  








Synthesis of 4-(2-hydroxyethoxy)benzaldehyde (6.11) 4-hydroxybenaldehyde (81.8 mmol) 
was dissolved in 80 ml of EtOH (1M). Potassium carbonate (163 mmol) was added to the 
reaction flask followed by the addition of 2-chloroethanol (327 mmol). The reaction 
mixture was refluxed for 10 hours, followed by filteration of potassium carbonate, and 
subsequent evaporation of ethanol. The remaining contents were extracted 3x with 100 ml 
of ethyl acetate in water and washed with 100 ml of 0.01M NaOH solution. The organic 
layer was separated and dried on anhydrous MgSO4 and the organic layer was evaporated 
using a rotatory evaporator. The resulting white solid was used for the reaction without 
further purification. 
 
Synthesis of 4-(2-(4-formylphenoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 
(6.12): Coupling of the furoxan 6.2 with the alcohol (6.11) was conducted by dissolving 
6.11 (6.78 mmol) in 30 ml of DCM followed by the addition of  DBU (13.56 mmol). The 
reaction was stirred at room temperature for 20 minutes before cooling on ice. The furoxan 
2 (13.56 mmol) dissolved in 30 ml of DCM was added slowly to the above mixture over a 
30-minute period. An hour later the reaction was checked via TLC (20% EA/Hexanes) for 




brine. The organic layer was dried with magnesium sulfate, filtered and then evaporated to 





1,2,5-oxadiazole 2-oxide (6.13): The corresponding aldehyde 6.13 (3.14 mmol) was 
dissolved in 30 ml of acetonitrile and piperidine (6.29 mmol) was added to the reaction. 
The two reagents were stirred for 10 minutes are room temperature before cyanoacetic acid 
(4.71 mmol) was added. The reaction was then heated to reflux for 18 hours. A TLC (10% 
MeOH/EA) was checked to confirm completion of the reaction. The product was then 
poured over ice and quenched with 1 ml of 6 M HCl. The reaction was worked up with 
ethyl acetate. The organic layer was dried with magnesium sulfate followed by filtration 
and evaporation. The resulting white oil was then purified using column chromatography 










oxadiazole 2-oxide (6.13):  
1H NMR (500 MHz, DMSO-d6)  
δ 8.28 (s, 1H), 8.09 (d, J = 8 Hz, 2H), 7.96 (d, J = 7 Hz, 2H), 7.82 (t, J = 7 Hz, 1H), 7.63 - 
7.66 (m, 2H), 7.20 (d, J = 8 Hz, 2H), 4.76 (m, 2H), 4.49 (m, 2H).  
13C NMR (DMSO-d6 ,126MHz):  
δ 164.2, 162.4, 159.2, 154.3, 137.6, 136.6, 133.8, 130.4, 128.7, 125.0, 117.1, 115.9, 
111.0, 100.7, 70.1, 66.3 
 
Synthesis of 3-(dibenzylamino)phenol (7.1): Commercially available 3-aminophenol (5 g, 
45.8 mmol) was dissolved in 25 ml of DMSO. The reaction was slightly cooled on ice 
followed by addition of benzyl bromide (10.90 ml, 92 mmol) over a 2-hour period. Finally, 
K2CO3 (15.83 g, 115 mmol) was added in portions. The reaction was stirred for 12 hours 
at room temperature. A TLC in 30% EA/Hexanes was checked to ensure complete 
formation of dialkylated product. The reaction mixture was poured over ice water and 3 M 
HCl. The resulting dark brown precipitate was then filtered and washed with hexanes to 





Synthesis of 4-(dibenzylamino)-2-hydroxybenzaldehyde (7.2) The aldehyde was 
synthesized by dissolving 3-(dibenzylamino)phenol (7.1) (13.25 g, 45.8 mmol) in 125 ml 
of DMF. The contents were cooled on ice followed by the slow addition of POCl3 (6.40 
ml, 68.7 mmol) to the mixture. The reaction was then allowed to warm to room temperature 
and react for additional one hour. A TLC (10% EA/Hexanes) was monitored to ensure the 
complete conversion to aldehyde. The reaction mixture was poured over aqueous saturated 
K2CO3. The precipitate was filtered and washed twice with hexanes to yield 72% of the 
crude 7.1 as a yellow solid.  
 
Synthesis of ethyl (Z)-3-(4-(dibenzylamino)-2-hydroxyphenyl)-2-ethoxyacrylate (7.3) 
Knoevenagel condensation was conducted by dissolving aldehyde (7.2) (5 g, 15.75 mmol) 
in 50 ml of EtOH followed by diethyl malonate (3.78 g, 3.60 mmol). The reaction was 
cooled and piperidine (3.12 ml, 31.5 mmol) was added. This was then heated to 90°C for 
12 hours. Upon completion of the reaction the contents were quenched with 15 ml of 3M 




MgSO4 and the volatiles were concentrated to give 7.3 as a clear yellow oil which was used 
for the next reaction without any further purification.  
 
Synthesis of 7-(dibenzylamino)-2-oxo-2H-chromene-3-carboxylic acid (7.4) The 
condensation product 7.3 (5 g, 10.9 mmol) was dissolved in 100 ml of ethanol followed by 
addition of NaOH (2.18 g, 54.4 mmol) dissolved in 5 ml of water slowly. The reaction was 
then refluxed for 12 hours. Upon completion of the reaction the contents were quenched 
with 5 ml of 12 M HCl on ice. The resulting orange precipitate was then filtered and washed 
with water and hexanes. The product was purified via column chromatography (silica gel, 




Synthesis of 2-hydroxyethyl 7-(dibenzylamino)-2-oxo-2H-chromene-3-carboxylate (7.5a) 
The coumarin acid 7.4 (5 g, 12.97 mmol) was dissolved in 200 ml of ethylene glycol 
followed by sulphuric acid (0.346 ml, 6.49 mmol). The reaction was refluxed for 12 hours. 
Upon completion of the reaction the contents were worked up with brine and DCM twice. 




chromatography (silica gel EA and hexanes 1:1) the final pure product (7.5a) as a yellow 
paste was obtained with a yield of 32%.  
 
Synthesis of 7-(dibenzylamino)-3-(4-(2-hydroxyethyl)piperazine-1-carbonyl)-2H-
chromen-2-one (7.5b) The coumarin carboxylic acid 7.4 (1.5 g, 3.89 mmol) was dissolved 
in a 35 ml DCM and THF mixture with a ratio of 5:3. After complete dissolution of 7.4 
HBTU (2.96 g, 7.78 mmol) was added and allowed to react for 10 min at room temperature. 
The reaction mixture was placed on ice and a solution of ethanolpiperazine (0.716 ml, 5.84 
mmol) and triethylamine (2.17 ml, 15.57 mmol) in 10 ml of THF was added dropwise. The 
reaction was then allowed to warm to room temperature followed by catalytic addition of 
BOP-Cl. After reacting for 1 hour a TLC (50% EA/Hexanes) was checked for completion. 
The THF was evaporated off and the brow oil was extracted with brine and ethyl acetate. 
The resulting product was washed with small amounts of ether twice followed by 
recrystallization in ether to yield a yellow solid.  
 
Synthesis of 4-(2-((7-(dibenzylamino)-2-oxo-2H-chromene-3-carbonyl)oxy)ethoxy)-3-




with the free hydroxy group of 7.5a was completed by dissolving 7.5a (1 g, 2  mmol) in 
32 ml of DCM followed by the addition of DBU (0.606 ml, 4 mmol). The reaction was 
cooled and furoxan (6.2) (0.810 g, 2.2 mmol) dissolved in 24 ml of DCM was added drop 
wise. The reaction was removed from ice and allowed to warm to room temperature and 
stirred for additional 1 hour. A TLC (30% EA/Hexanes) was checked for completion. 
The product was poured over 3 M HCl in ice and worked up. The organic layer was dried 
using MgSO4 and concentrated. The crude product was then purified using column 
chromatography (triethylamine quenched silica gel, EA and Hexane 1:5). The resulting 
yellow solid was isolated with a yield of 56%. 
 
4-(2-((7-(dibenzylamino)-2-oxo-2H-chromene-3-carbonyl)oxy)ethoxy)-3-
(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide (7.6a) 
1H NMR (500 MHz, CDCL3-d):  
δ 8.32 (s, 1H), 7.89 (d, J= 7 Hz, 2H), 7.39-7.51 (m, 3H), 7.04-7.22 (m, 11H), 6.56 (d, 
J=10, 1H), 6.42 (s, 1H), 4.61-4.53 (m, 8H).  
13C NMR (126 MHz, CDCL3-d):  
δ 163.4, 158.8, 158.2, 157.7, 154.7, 149.8, 138.0, 136.0, 135.6, 131.4, 129.7, 129.2, 129.1 
128.6, 127.7, 126.3, 110.6, 110.5, 109.1, 108.7, 98.2, 68.9, 61.7, 54.7 
Elemental Analysis C, H, N, O 








Coupling of the furoxan 2 to the amide 7.6b was conducted in similar conditions as 
formation of 7.6ba. The resulting yellow solid was isolated with a yield of 43%. 
 
3-(4-(3-((5-(l1-oxidaneyl)-4-(phenylsulfonyl)-1,2,5l4-oxadiazol-3-
yl)oxy)propyl)piperazine-1-carbonyl)-7-(dibenzylamino)-2H-chromen-2-one (7.6b):  
1H NMR (500 MHz, CDCL3-d): 
δ 8.05 (d, J = 10 Hz, 2H), 7.83 (s, 1H), 7.75 (t, J=7 Hz, 1H), 7.63 (t, J=7.5 Hz, 2H), 7.37 - 
7.21-7.37 (m, 11H), 6.70 (d, J = 10 Hz, 1H), 6.59 (s, 1H), 4.76 (s, 4H), 4.55 (t, J = 5 Hz, 
2H), 3.75 (br., 2H), 3.39 (br., 2H), 2.90 (t, J = 5 Hz, 2H), 2.64 (br., 4H) 
 13C NMR (126 MHz, CDCL3-d): 
δ 164.6, 158.9, 156.8, 153.1, 144.6, 138.1, 136.5, 135.7, 129.8, 129.7, 129.0, 128.5, 127.6, 
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